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Abstract
Increasingly sophisticated new treatments such as trastuzumab (Herceptin®) and 
Bevacizumab (Avastin®) have contributed to reduced mortality from breast cancer 
over recent years, nevertheless 40-60 % of those affected still die from metastatic 
disease. Thus there remains an urgent need for novel therapies for breast cancer. As 
PLA2 (crotoxin) has proven anticancer activity but its use is limited by non-specific 
toxicity, and polymer-drug and polymer-protein conjugates are finding growing use 
as anticancer agents, the aim of this thesis was to explore the potential of polymer- 
PLA2 conjugates as a new treatment for breast cancer. Polymer conjugation has 
previously been shown to reduce systemic toxicity of proteins, prolong their plasma 
half-life and promote tumour-specific targeting by the enhanced permeability and 
retention (EPR) effect.
First, the synthesis and characterisation methods were optimised using trypsin as 
a model. After these studies highlighted dextrin as the best polymer for conjugation, 
dextrin-PLA2 {Apis mellifera venom) conjugates were prepared. Dextrin was chosen 
for conjugation as it can be used to mask protein activity in the protein masked- 
unmasked polymer therapy (PUMPT) concept. Such conjugates retained 36 % 
enzyme activity compared to free PLA2, and moreover, unmasking by a-amylase 
degradation of dextrin regenerated full enzyme activity. However, while free PLA2 
was found to be very haemolytic, dextrin-PLA2 displayed no haemolytic activity, and 
unmasking by a-amylase degradation of dextrin did not reinstate this activity. The 
conjugate displayed significant toxicity towards several tumour cell lines, including 
human breast cancer. Indirect evidence that epidermal growth factor receptor 
(EGFR) status and tyrosine kinase activity of the receptor influences PLA2-induced 
anti-proliferative activity were shown. Uptake studies have revealed that conjugation 
of dextrin to PLA2 reduces non-specific binding to breast cancer cells. In a further 
study, dextrin-PLA2’s ability to burst DaunoXome® using the polymer-enzyme 
liposome therapy (PELT) concept was assessed. Here, it was seen that the conjugate 
released liposomally encapsulated drug and the combination caused enhanced 
cytotoxicity in MCF-7 cells.
These studies confirm the potential of dextrin-PLA2 as a novel anticancer agent 
and/or as trigger for liposomal drug release and highlight the feasibility of 
developing a candidate for further in vivo pharmacokinetic and activity studies.
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Chapter 1 General Introduction
Chapter One
General Introduction
l
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1.1 Introduction
Cancer is defined as a collection of life-threatening diseases, which are 
characterised by uncontrolled division of abnormal cells (National Cancer Institute, 
2005). It currently affects one in three British people, and one in four people die 
from it. While mortality associated with other major diseases, such as heart disease 
and infections, has improved since 1950, cancer mortality has shown little such 
progress and became the most common cause of death in Britain since 1969 in 
women, and 1995 in men (Office for National Statistics, 2004). Meanwhile, recent 
research has shown that 50 % of cancers could be prevented by lifestyle changes 
such as smoking cessation, sensible eating and drinking, and increased exercise 
(Cancer Research UK, 2005).
Therefore, the aim of this study was to synthesise dextrin-phospholipase A2 
(PLA2) conjugates to investigate the potential of a polymer-PLA2 conjugate, either as 
an anti-cancer agent or for use as a trigger to promote release of liposome- 
encapsulated drug, in the context of Polymer Enzyme Liposome Therapy (PELT).
The traditional options available for the management of cancers include surgery, 
radiotherapy, cytotoxic drugs, immunotherapy and hormonal agents. The aims of 
treatment vary from curative to prolonging life or palliating symptoms. It has 
become an increasingly common practice to combine two or more treatments for 
cancer therapy, as they can be selected to achieve a synergistic action by, for 
example, targeting different points in the cell cycle, or blocking different growth 
factor receptors (reviewed in Moore, 2007). Most current drugs act by preventing 
nucleic acid synthesis or mitosis.
Unfortunately, conventional cancer treatments are often restricted by adverse 
systemic effects. Due to the mechanism of action of many chemotherapeutics, 
rapidly dividing cells, such as bone marrow, ovaries and testes are particularly 
sensitive to cytotoxic drugs. Further common adverse effects of chemotherapeutics 
include hair loss, nausea and vomiting and anaemia. These adverse effects have a 
limiting effect on the dose, frequency of administration and total cumulative dose, as 
well as prolonging the patient’s stay in hospital and decreasing their quality of life.
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Another unfortunate consequence of chemotherapy is the development of 
resistant tumour cells. Cells exhibit various mechanisms of resistance, including 
upregulation of p-glycoprotein (p-gp), a membrane transport protein, increased levels 
of target, for example dihydrofolate reductase, and decreased influx of drug.
Novel approaches to cancer treatment
The search for better cancer treatments is ongoing and research largely falls into 
two categories; the design of novel tumour-specific molecular targets using genomics 
and proteomics research and improving drug delivery and tumour targeting. One 
approach currently showing promise in the fight against cancer is ‘nanomedicine’, 
defined by the European Science Foundation (ESF) as ‘the science and technology of 
diagnosing, treating and preventing disease and traumatic injury, of relieving pain, 
and of preserving and improving human health, using molecular tools and molecular 
knowledge of the human body’ (European Science Foundation, 2005). 
Nanomedicines have also been defined by the ESF as ‘nanometer size scale complex 
systems, consisting of at least two components, one of which being the active 
ingredient’.
Polymer therapeutics are nanomedicines that are designed to deliver drug(s) 
specifically to tumours via the enhanced permeability and retention (EPR) effect, 
while reducing the exposure of normal tissue, and consequently reducing systemic 
toxicity, and prolonging drug half-life (reviewed in Duncan, 2006). The term 
‘polymer therapeutic’ was coined by Duncan and describes a class of therapeutic 
agents comprising of at least two components, including a water soluble polymer 
covalently attached to an active constituent, such as a drug, protein, gene or peptide 
(reviewed in Duncan, 2003). Over the past decade, several polymer-protein 
conjugates have been in routine clinical use, while 11 polymer-drug conjugates have 
entered clinical development. Of these, N-(2-hydroxypropyl)methacrylamide 
(HPMA) copolymer-doxorubicin has shown clinical activity in breast cancer (Vasey 
et al, 1999) and HPMA copolymer conjugates containing a combination of 
chemotherapy and aromatase inhibitors are already showing exciting synergistic 
activity (Vicent et al, 2004).
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Concurrently, PLA2 from snake venom (Crotalus durissus terrificus) has 
demonstrated promising activity in Phase I clinical trials (including breast cancer 
patients) and is already undergoing Phase II clinical trials as a cancer treatment. 
PLA2 is an enzyme that specifically hydrolyses the sn-2 acyl bond of phospholipids 
releasing fatty acid and lysophospholipid. In Phase I clinical trials crotoxin was 
administered intramuscularly for 30 consecutive days at doses ranging from 0.03 to 
0.22 mg/m2. Patients with histologically confirmed solid tumours deemed unbeatable 
by surgery, radiation therapy or conventional chemotherapy were selected. Four 
patients had breast cancer, and the cohort also included patients with gastrointestinal 
cancer, non-small cell lung cancer, prostate cancer and squamous cervix carcinoma. 
Results from these studies observing the anti-cancer properties of crotoxin look 
promising. Of 23 patients, 2 showed greater than 50 % tumour mass reduction, and 1 
patient had a complete response to the treatment. However, 13 out of the 23 patients 
tested displayed some reversible, non-limiting neurotoxicity, including diplopia, 
palpebral ptosis, nystagmus and anxiety (Costa etal, 1998; Cura et aly 2002).
Hypothesis of PLA2 conjugates as novel cancer therapeutics
Therefore, in this project, it is proposed that, by conjugating PLA2 to a polymer, 
not only will the neurotoxicity be reduced, but it will also be possible to target the 
protein specifically to tumours actively, by targeting residues, and passively, by the 
EPR effect, thus prolonging the plasma circulation (described in more detail in 
section 1.2).
The two hypotheses for the use of a PLA2 conjugate are depicted in Figure 1.1. It 
was postulated that the polymer-protein conjugate would localise in the tumour 
through the EPR effect and as a result of its selectivity towards cells that over­
express the epidermal growth factor receptor (EGFR). Subsequently, the PLA2 would 
adhere to the lipid membrane of cancer cells, to exert its enzymatic activity (Figure 
1.1a). Figure 1.1b depicts the PELT model, where the liposome-encapsulated drug 
would accumulate in the tumour interstitium as a result of the EPR. Polymer-PLA2 
would next be administered and would accumulate in the tumour interstitum by the 
same mechanism, where it can hydrolyse the phospholipid bilayer of the liposomes, 
resulting in rapid release of the drug load to the cancerous cells.
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Figure 1.1 Schematic of hypothesised mechanism of action of dextrin-PLA2. Panel 
(a) shows dextrin-PLA2 acting as an active entity, and panel (b) depicts the PELT model.
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1.2 Polymer Therapeutics as Novel Cancer Therapies
The term ‘polymer therapeutic’ encompasses many structures including 
polymeric drugs, polymer-drug conjugates, polyplexes, polymer-protein conjugates 
and polymeric micelles. Figure 1.2 shows schematics of each of these polymer 
therapeutics.
Polymeric drugs are entities, which are biologically active in their own right. In 
this context, polymeric micelles are micelles in which a drug is covalently bound to 
the core of the micelle. Polymer-drug conjugates consist of a bioactive drug 
covalently attached to a water-soluble polymer, through a spacer group. In order to 
target specific locations in the body, it is also possible to attach a targeting residue, 
which enhances receptor-mediated pinocytosis of the conjugate. Similarly, polymer- 
protein conjugates consist of a protein conjugated to one or more water-soluble 
polymeric structure, through a spacer group. As these form the basis of this project, 
they are described in more detail shortly.
Rationale for designing nanomedicines: the EPR effect
The underlying principle for attaching a drug or protein to a polymer is that 
conjugation can reduce toxicity, extend the plasma half life, reduce immunogenicity 
and mask protein charge, and can also allow passive targeting of the entity to 
tumours by the EPR effect (Maeda et al, 1988; Matsumara and Maeda, 1986). 
Conjugation of a drug or protein to a polymer alters its pharmacokinetic profile, 
which can be exploited to promote passive tumour targeting. This arises as a result of 
greater vascular permeability of the tumour’s blood vessels, which favours the 
extravasation of drugs. Additionally, tumours tend to have an extensive and 
disorganised vasculature, compared to normal tissues. The pathophysiology 
responsible for this increased permeability can be attributed to an increase in 
fenestrae, a discontinuous basement membrane, enlarged inter-endothelial junctions 
and an increased number of vesicles (Hashizume et al, 2000; reviewed in McDonald 
and Foss, 2000). Furthermore, the lymphatic drainage of the tumour is reduced, 
resulting in the pooling of circulating polymer-protein conjugates in the tumour 
interstitium. Thus, the EPR effect can be exploited in the delivery of polymer 
therapeutics. While conventional, low molecular weight drugs can pass readily
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Figure 1.2 Categories of polymer therapeutics including polymeric drugs, 
polyplexes, polymer-drug conjugates, polymeric micelles and polymer-protein 
conjugates. (Adapted from Duncan, 2003)
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through the bloodstream, into the tissue or to be excreted, polymer therapeutics can 
accumulate in tumour tissues due to the EPR (reviewed in Reddy, 2005; Seymour et 
aly 2002). A diagram of the EPR effect is shown in Figure 1.3.
Research has been ongoing for suitable polymeric carriers, since the idea of 
using a water soluble polymer to carry a drug bound to the polymer backbone via a 
biodegradable spacer for release at the target site was first proposed in 1975 by 
Ringsdorf (Ringsdorf, 1975). Although the original idea focused on drug delivery, 
this model can also be applied to proteins and peptides. Ringsdorf also suggested that 
a targeting moiety could be incorporated into the polymer to enhance uptake by 
receptor-mediated endocytosis. This was shown by the polymer therapeutic PK2, 
which is composed of HPMA copolymer-Gly-Phe-Leu-Gly-doxorubicin 
incorporating galactosamine (Pimm et al, 1993). The galactosamine residue 
enhances uptake of the conjugate by the liver by targeting the hepatocyte 
asialoglycoprotein receptor, thus it was investigated as a treatment for liver cancer. 
Results from the trials were positive, showing that, of the 23 participants in the trial, 
two had measurable partial response and a further 11 displayed stable disease. 
Gamma camera imaging confirmed liver targeting of 15-20 % of the dose as a result 
of the galactosamine moiety (Seymour et al, 2002)- a 12-50-fold increase compared 
to free drug (reviewed in Duncan, 2003). More recently, star-shaped 
immunoglobulin-HPMA copolymer-doxorubicin conjugates have been described 
having significantly greater antitumour activity in vivo than the non-targeted 
conjugates (Etrych et a l, 2007).
1.2.1 Polymer-protein conjugates
Since polymer conjugation was to be used to deliver PLA2 to tumours in these 
studies, it was interesting to first reflect on the current clinical application of 
polymer-protein conjugates. Ever since dextran-streptokinase (Streptodekase) was 
first used clinically (Torchilin et al, 1982) polymer therapeutics have become 
increasingly popular for delivering proteins, peptides and antibody-based 
therapeutics, with polymer-protein conjugates being the first polymer therapeutics to 
be used in practice. An ideal polymer-protein conjugate should be stable and usually
8
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pharmacologically inactive in the circulation. If required, it could then be specifically 
taken up by the tumour cells, internalised by endocytosis, and activated by enzymatic 
or hydrolytic cleavage in the lysosomes. Finally, the polymer needs to be excreted 
safely after delivering the drug load.
Polyethylene glycol (PEG)-protein conjugates
In parallel to the development of Streptodekase, Davis and Abuchowski also 
conducted pioneering research into polymer-protein conjugation for drug 
development (reviewed in Davis, 2002). PEGylation was first proposed by Davis and 
Abuchowski in the 1970s (Abuchowski et al, 1977) and has since been used to 
deliver an extensive range of therapeutic proteins, enzymes, cytokines and 
monoclonal antibody (mAb) fragments. PEG is a pharmaceutical excipient that has 
been extensively studied as a protein conjugate. It is a linear, semitelechelic polymer 
with a molecular weight (MW) range of 5,000 -  40,000 g/mol. It is a flexible, water- 
soluble chain that can extend to give a hydrodynamic radius many times greater than 
a globular protein of equal molecular weight, which can conceal the protein to which 
it is bound. PEGylation has many advantages, including its ability to increase protein 
solubility and stability, reduce protein immunogenicity, prevent rapid renal clearance 
by the reticuloendothelial system (RES), and prolong plasma half-life. Finally, from 
a clinical perspective, the less frequent dosing of PEGylated proteins encourages 
patient compliance (reviewed in Pasut et al, 2008). Initially, the first generation of 
PEGylated proteins displayed protein cross-linking and protein charge modification 
due to consumption of the charged surface groups during conjugation and unstable 
PEG-protein bonds. Since then, conjugation techniques have been improved to allow 
for site-specific conjugation, and reduce contamination of PEG with PEG-diol 
(Brocchini et al, 2007).
In 1990, PEG-adenosine deaminase (Adagen®) became the first polymer-protein 
conjugate to receive US Food and Drug Administration (FDA) approval for the 
treatment of severe combined immunodeficiency disease (SCID). It acts by 
replenishing levels of adenosine deaminase which are missing in this disease. Studies 
have demonstrated improved efficacy and reduced immunogenicity of Adagen®, than
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previous therapies involving blood transfusion or administration of native enzyme 
(Chaffee et al, 1992; Hershfield et al, 1987). Attempts to use gene therapy for 
adenosine deaminase replacement in SCID have also shown impressive levels of 
immune reconstitution, however, vector-related leukaemias have overshadowed this 
success (Kohn et a l, 2003).
Shortly after, in 1994, a PEG-L-asparaginase conjugate (Oncaspar®) received 
approval by the FDA for the treatment of acute lymphoblastic leukaemia (ALL). It is 
useful in the treatment of leukaemia as leukaemic cells must rely on an external 
source of asparagine as a result of a defect in asparagine synthetase. The 
administration of asparaginase degrades asparagine, thus depriving leukaemic cells 
of asparagine, and hence inhibiting protein biosynthesis (reviewed in Duncan, 2006; 
reviewed in Pasut et a l, 2008). Asparaginase is also available in a non-conjugated 
formulation, but Oncaspar® demonstrates longer retention time in the plasma, 
reduced immunogenicity and requires only a weekly administration, while 
unconjugated L-asparaginase requires daily administration and can induce 
anaphylaxis and other hypersensitivity reactions (reviewed in Duncan, 2006; 
reviewed in Pasut et al, 2008).
PEG has also been used to deliver cytokines, such as interleukin-2 (IL2), 
recombinant granulocyte colony-stimulating factor (GCSF) and interferon-a (INFa). 
GCSF is used to promote re-growth of white blood cells following chemotherapy, 
thereby preventing chemotherapy-induced neutropenia. The PEGylated form of 
GCSF need only be administered as a single subcutaneous injection while native 
GCSF requires daily dosing by injection for two weeks to obtain equivalent 
prevention of neutropenia.
Other polymer-protein conjugates currently used as therapeutics
Maeda and colleagues synthesised SMANCS by covalently linking two styrene 
maleic anhydride chains (SMA) to neocarzinostatin (NCS), an anti-tumour protein 
(Maeda and Matsumara, 1989). Previously, NCS had proved to be too toxic for 
clinical use. However, following conjugation to SMA and subsequent dispersion in 
Lipiodol, a phase contrast agent, it was possible to administer it specifically to
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tumour tissue using visualisation by x-ray, through the hepatic artery for the 
treatment of liver cancer. SMANCS has shown best results when given as ‘patient- 
individualised treatment’, where in a clinical trial 95 % of patients showed a decrease 
in tumour size, and 86 % of patients had decreased concentration of the biomarker 
for liver cancer, a-fetoprotein.
1.3 Rationale for design of polymer-PLA2 conjugates
1.3.1 Choice of polymer model
It was important to select the most appropriate polymer for conjugation to PLA2, 
in order to fully achieve the therapeutic aim. Polymers are high molecular weight 
substances made from one or more small repeating units (monomers). There are 
many structures of polymers; and size, 3-D shape (including crosslinking) and 
asymmetry determine the properties of them. Homopolymers are chains of polymers 
containing one type of repeating monomer. Copolymers contain more than one 
monomer, and may be an alternating copolymer chain, a block copolymer or a graft 
copolymer. The structure of the polymer also varies. It may be linear, star, branched 
or dendrimers.
A number of polymers have been used to prepare polymer-protein conjugates. 
These are summarised in Table 1.1, including examples of polymer-enzyme 
conjugates which have previously been described in the literature. An important 
factor in selecting a suitable polymer for protein conjugation is its ability to produce 
a conjugate whilst retaining enzymatic activity of the protein. PEG appears to be a 
very favourable choice for protein conjugation due to its extensive use in many 
regulatory authority-approved pharmaceutical products, its wide range of molecular 
weights and its potential for surface modification of proteins (reviewed in Harris and 
Chess, 2003; reviewed in Pasut et al, 2008). However, PEG is not suitable for use in 
these studies due to its potential for steric hindrance, which could interfere with the 
enzyme’s access to its substrate. In contrast, HPMA copolymers have shown little 
such effect on substrate specificity and enzyme activity against low molecular weight 
substrates (Satchi-Fainaro et al, 2002). Here, a novel catalytic antibody-polymer 
conjugate for selective prodrug activation was prepared, which retained 75-81 % of 
its catalytic activity compared to the free antibody.
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Table 1.1 Examples of polymer-protein conjugates in clinical use or development.
Polymer-protein combination Indication FDA
approval/
status
Manufacturer
Streptodekase® Dextran-streptokinase Anti-thrombolytic 1982 -
Adagen® PEG-adenosine deaminase Enzyme replacement therapy 
for SCID
1990 Enzon
SMANCS® Polystyrene-co-maleic acid- 
neocarzinostatin
Hepatocellular carcinoma 1993 -
Oncaspar® PEG-asparaginase Acute lymphoblastic leukaemia 1994 Enzon
Neulasta® PEG-filgrastim/
PEG-GCSF
Chemotherapy-induced
neutropenia
2006 Amgen
PEG Intron® PEG-interferon alfa-2b Hepatitis C
Renal cell carcinoma 
Advanced melanoma
Chronic myeloid leukaemia 
Gastrointestinal carcinoid 
tumour
Brain and CNS tumour
2004 
P III
PII
Schering
Somavert® Pegvisomant/ PEG-recombinant DNA 
protein (HGH analogue)
Acromegaly 2003 Pfizer
Table 1.1 Examples of polymer-protein conjugates in clinical use or development, (cont.)
Polymer-protein combination Indication FDA
approval/
status
Manufacturer
Pegasys® PEG-interferon alfa-2a Hepatitis C
Non-melanomatous skin cancer 
Chronic hepatitis B and C
2002 
P I 
P III
Roche
Macugen® Pegapanib (PEG-oligonucleotide) Age-related macular 
degeneration
2004 Eyetech
Pharmaceuticals/
Pfizer
CDP870 PEG- anti-TNF Fab’ fragment Rheumatoid arthritis PHI Celltech
CERA
(continuous
erythropoiesis
receptor
activator)
PEG-epoetin Renal anaemia P III Roche
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The aim was to prepare polymer-enzyme conjugates with one enzyme bound to 
each polymer chain (1:1). This should create a molecule of sufficient size that it will 
concentrate efficiently in tumour cells by the EPR effect, but avoid uptake by the 
reticuloendothelial system (RES). Therefore, two polymers were selected as models 
for protein conjugation.
HPMA copolymers
The first of these was HPMA copolymer-Gly-Gly-p-nitrophenol (ONp) (5 mol 
%; ~ 30,000 g/mol) (Figure 1.4a), which has a linear, random coil structure. HPMA 
copolymers are commonly prepared by a polymer analogous reaction, based on free 
radical precipitation co-polymerisation of HPMA monomer and methacryloylated 
(MA) peptides containing a reactive ONp group. This reaction produces the 
polymeric intermediate to which drugs, proteins or targeting moieties may be 
attached either by aminolysis or following further modification to the side chain to 
obtain the desired functionality (reviewed in Duncan, 2005).
HPMA-Gly-Gly-ONp is available commercially with a monomer feed ratio of 
HPMA:MA-peptide-ONp (95:5), as used for PK1, and (90:10), as used for PK2. 
Increasing the content of pendant side chains facilitates incorporation of more than 
one active agent or targeting group, as well as providing for higher drug loading 
(reviewed in Duncan, 2005). By selecting a HPMA copolymer with 5 mol % 
substitution, the possibility of multiple attachments to a single enzyme molecule is 
minimised, thus reducing the risk of cross-linking and interference with its active 
site, leading to inactivation of the enzyme. Determining the optimum reaction 
conditions for the conjugation can further control this.
HPMA copolymer was chosen for this study because it is a water-soluble, non- 
biodegradable polymer, which is accepted by the FDA for drug use. Furthermore, 
HPMA copolymers are already undergoing clinical trials, for example PK1 (Vasey et 
al, 1999). HPMA copolymers were originally designed as plasma expanders by 
Kopecek in the early seventies (Kopecek et al, 1973), but were later developed as 
anti-cancer drug carriers by linking the drug to the polymer to the polymer backbone 
through a pendant peptide spacer (Kopecek et al, 1985a). The -Gly-Gly- linker is a
15
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Figure 1.4 Chemical structure of a) HMPA copolymer-Gly-Gly-ONp, and b) 
dextrin.
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short and stable, selectively degradable linker. The ONp group is used as marker of 
hydrolysis/ aminolysis as it produces a yellow colour when it is released from the 
polymer as the free p-nitroanilide (NAp), which is detectable quantitatively in the 
UV spectrophotometer.
Dextrin
The second polymer chosen as a model for this work was dextrin (MW: 51,000 
g/mol) (Figure 1.4b), a biodegradable polysaccharide that is produced from the 
enzymatic hydrolysis of corn starch. Dextrin is a a - 1,4 polymer of D-glucose with 
less than 5 % a - 1,6 links, resulting in minimal branching of the polymer. It is rapidly 
degraded by a-amylase to yield the disaccharides maltose and iso-maltose, in just a 
few minutes (Hreczuk-Hirst et al, 2001a; Hreczuk-Hirst et al, 2001b). Studies on a- 
amylase-mediated degradation of dextrin have revealed that altering the degree of 
modification to the backbone by succinoylation can control the rate of enzymatic 
degradation (Hreczuk-Hirst et al, 2001a). Interestingly, several cases of elevated a- 
amylase concentrations in tumours have been reported (Inaji et al, 1991; Weitzel et 
al, 1988), where levels up to 85-fold normal have been observed, and this could be 
exploited for the delivery of anti-cancer proteins.
Dextrin was chosen as a model for these studies because it has been used 
clinically for many years and is FDA approved, proving it to be non-toxic and non- 
immunogenic. Caloreen is composed of maltodextrin, and has been used as a dietary 
supplement in patients with renal and hepatic failure. Following successful clinical 
safety trials, Icodextrin, a dextrin with a MW of ~ 20,000 g/mol, was approved for 
routine use as an intraperitoneal dialysis solution for chronic renal failure and is 
undergoing clinical trials for Kaposi’s sarcoma treatment (Thornton et al, 1999). 
Moreover, dextrin has also been used as a carrier for the delivery of 5-fluorouracil to 
the intraperitoneal cavity (McArdle et al, 1994), and recent papers describe its 
conjugation to various drugs, including doxorubicin, tyrosinamide and biotin 
(Hreczuk-Hirst et al, 2001b).
The main advantages supporting the use of dextrin are its multifunctionality and 
biodegradability. Multifunctionality allows the polymer to surround the protein and
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mask the protein’s activity. Furthermore, since it has been shown that succinoylation 
delays the break down of dextrin, it is possible to tailor the rate of degradation, and 
consequently the unmasking of protein activity. This concept has recently been 
coined ‘Polymer masking-UnMasking Protein Therapy’ (PUMPT) using dextrin as a 
model polymer (Duncan et al, 2008). The hypothesis is that conjugation of a 
biodegradable polymer to a biologically active protein can mask activity and enhance 
stability in the bloodstream, while subsequent regeneration of activity can be 
achieved by triggered degradation of the polymer at the target site.
Biodegradable polymers for masking/unmasking of PLA2 activity
Over recent years the concept of using biodegradable polymers for delivery of 
therapeutic proteins has become increasingly attractive. The use of non- or slowly 
biodegradable polymers in macromolecular therapeutics for an extended length of 
time have the potential to cause long term vacuolisation (Bendele et al, 1998), 
development of lysosomal storage disease (Chi et a l, 2006), and, at high 
concentrations, could lead to other pathological metabolic changes (Miyasaki, 1975). 
In response to this, a number of polymers have been investigated as biodegradable 
carriers, including naturally occurring polysaccharides such as chitosan, dextran, 
dextrin (Schacht et a l, 1987), and synthetic polymers including polyals and 
polyglutamic acid (PGA) (Singer et al, 2003). Additionally, biodegradable linkers, 
such as the peptide Gly-Phe-Leu-Gly found in PK1, have been described to enable 
drug to be released by enzymatic cleavage inside the lysosomes (Vasey et al, 1999).
The aim of coupling a biodegradable polymer to PLA2 was to create a conjugate, 
not only able to benefit from the advantages of PEGylation, but also render PLA2 
inactive during transit, yet enable activity to be reinstated at an appropriate rate by 
triggered polymer degradation.
The ideal biodegradable polymer should be completely degraded at the target 
site, resulting in the formation of non-toxic, readily clearable or metabolisable 
products. The advantages of these polymers include the ability to mask the 
immunogenicity and minimise enzyme activity prior to ‘unmasking’ of the protein 
by degradation of the polymer at the site of action. Furthermore, since historically
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polymers for protein delivery were usually required to have a molecular weight of < 
40,000 g/mol to permit excretion by the kidneys, biodegradable polymers allow the 
selection of much larger polymers. Altering the type of polymer-protein linkage or 
degree of modification can additionally be used to vary the degradation profile of the 
conjugate and its biological properties (Hreczuk-Hirst et al, 2001a).
1.4 Rationale for choice of PLA2 and trypsin models
p l a 2
The active enzyme selected for conjugation was PLA2. PLA2s are enzymes that 
catalyse the hydrolysis of phospholipids at the sn-2 fatty acyl bond to release free 
fatty acid and lysophospholipid (Kudo and Murakami, 2002). Phospholipids are 
polar structures composed of three main portions; a phosphorylated head group, 
linked to a glycerol moiety, to which two fatty acid chains are linked. There are 
several known phospholipids occurring in nature, and their abundance varies 
between the inner and outer layer of the cell membrane. The outer membrane is 
composed predominantly of phosphatidylcholine (PC), phosphatidylethanolamine 
(PE) and sphingomyelin (SM), while the inner membrane contains mostly 
phosphatidylinositol (PI) and phosphatidylserine (PS) (Punnonen et al, 1989). The 
catalysis of phospholipids has many toxic and pharmacological biological functions 
including lipid digestion, homeostasis of cell membranes, signal transduction and 
production of eicosanoids (Valentin and Lambeau,2000).
Many PLA2s have been characterised, and classified as either secretory (sPLA2) 
or cytoplasmic (cPLA2) types, based on their cellular localisation. sPLA2s typically 
have a molecular weight of around 14,000 g/mol while cytoplasmic types are bigger 
(typically 85,000 g/mol) (Dennis, 1997). To date, 10 distinct groups of mammalian 
sPLA2s have been identified, based on their primary structure. Phospholipase’s 
selectivity is affected by the nature of the water-soluble head group, and length and 
extent of saturation of hydrocarbon tail of the phospholipid. They are classified 
according to their target bond, as shown in Figure 1.5.
Crotoxin, a PLA2 currently undergoing clinical testing as an anti-cancer agent, is 
a dimeric sPLA2. Its native form consists of two subunits; where subunit A is non-
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Figure 1.5 Phospholipase classification according to target bond at the 
phospholipid. Where PLA = phospholipase A, PLC = phospholipase C, and 
phospholipase D. (Adapted from Invitrogen Molecular Technologies, 2004)
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toxic, and displays no enzymatic activity, while subunit B is toxic and is responsible 
for the enzymatic activity of the PLA2 (Cura et al, 2002; Hanley, 1979). As Figure 
1.6 demonstrates, crotoxin is activated by the dissociation of subunits A and B, and 
subsequent binding of subunit B to the cell membrane. Cura et al (2002) propose that 
subunit A acts as a ‘chaperone’ to prevent non-specific binding of the active 
component, as well as having a role in target recognition.
PLA2, whose isoelectric point is 10.5 ±1.0 (Shipolini et al, 1971), displays a 
preference for organised lipids. In fact, its enzymatic activity is further enhanced as 
the size of the target lipid vesicle decreases, demonstrating a preference for 
increasing curvature (reviewed in Jorgensen et al, 2002). Extensive studies have 
identified several specific membrane properties which determine how susceptible or 
resistant to hydrolysis they will be. Susceptibility is enhanced by negatively charged 
surfaces, high curvature of the bilayer, and ordering and heterogeneity of membrane 
lipids (Best et al, 2002). The adsorption of PLA2 was originally thought to be 
mediated by two lysine residues located independent of the active site. Enzymatic 
activity was then thought to be triggered by electrostatic interactions, resulting in the 
hydrolysis of the substrate molecules present on the outer monolayer of the target 
vesicle (Scott et al, 1990). More recently however, it has been shown that, in fact, ~ 
10-20 amino acid residues of PLA2 interact with tens of phospholipids, so that the 
hydrophobic amino acid side chains penetrate the bilayer just below the polar 
headgroups and enable hydrolysis of phospholipids at the interface (Bollinger et al, 
2004).
Polymer-PLA2 conjugates have previously been synthesised using PLA2 from 
Naja naja naja (cobra snake) venom, Bothrops Neuwiedii (crotalid snake) venom 
and from bee venom, conjugated to tresilated monomethoxy PEG (TMPEG) (Bianco 
et al, 2002). PLA2 was conjugated to activated TMPEG via a secondary amine. They 
performed the reaction in phosphate buffered saline (PBS) at room temperature over 
2 h, with a yield of 60 %. Studies found the conjugates retained enzymatic activity 
toward phospholipid monolayers, though with a reduced specific activity and a 
greater lag time than the free PLA2. Bianco et al (2002) found that different PLA2s
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Figure 1.6 Proposed mechanism of action of crotoxin. (Adapted from Ventech 
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displayed varying degrees of retention of enzyme activity (10 - 60 % native PLA2). 
This was considered to be a consequence of the different isoenzymes having varied 
distribution of lysine residues on their surface, which are affected to varying extents 
by conjugation to PEG, and thus affecting the ability of the enzyme to 
partition/adsorb with the target cell membrane.
PLA2 is a good candidate as a novel breast cancer agent for several reasons. 
Firstly, research has revealed that a number of human cancers, including breast 
cancer, overexpress EGFR. In the case of breast cancer, studies reveal approximately 
48 % of human breast cancers overexpress this receptor. This over-expression is 
considered to be a diagnostic marker for tumours due to its involvement in cell 
growth and proliferation and is associated poor clinical prognosis (Kumar et al, 
2001). The activity of these receptors is dependent on the phospholipid environment 
of the membrane. In particular, they are surrounded by high levels of PE (Kano- 
Sueoka et al, 1990). Moreover, further investigations have shown that PLA2 can bind 
to epidermal growth factor (EGF), and this could be used as a means of targeting 
PLA2 to breast cancer cells (Hack et al, 1991; Kano-Sueoka et al, 1990). Further, 
some PLA2s need Ca2+ for enzymatic action, while a feature of breast cancer is 
elevated levels of Ca2+(Journe et al, 2004). Finally, cancer cells contain higher levels 
of PC, SM, and particularly PE (Sterin et al, 2004); these are all degraded 
preferentially by PLA2 (Diez et al, 1994; Monteggia et al, 2000). These findings 
support the development of an anti-cancer agent of dextrin-PLA2 in this study.
Selection of trypsin as a model for conjugation optimisation
Before beginning investigative work using PLA2 it was first necessary to select 
the most suitable polymer for conjugation to the enzyme, and optimise the synthesis 
and characterisation methods.
Trypsin is a serine protease that is produced in the pancreas as an inactive 
zymogen and activated by the cleavage of trypsinogen at the Lys6-Ile7 peptide bond. 
Trypsin has an isoelectric point of 10.2-10.8 (Malamud and Drysdale, 1978). 
Enzymatic activity is optimum at pH 7-9 and is dependent on millimolar 
concentrations of Ca2+ and Na+ as cofactors (ExPASy, 2004). Trypsin catalyses the
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hydrolysis of peptides at the C-terminal end of lysine and arginine residues, for 
example in milk. Trypsin can also hydrolyse the ester and amide bonds of synthetic 
substances, such as benzoyl L-arginine ethyl ester (BAEE) and Na-benzoyl-L- 
arginine p-nitroanilide (L-BAPNA), forming the basis of the enzyme activity assay 
described later. A number of polymer-trypsin conjugates have been described in the 
literature (summarised in Table 1.2). Porcine pancreatic trypsin was used in this 
project.
Porcine trypsin (23,400 g/mol) consists of a single chain polypeptide of 223 
amino acids, of which 10 are lysine residues (European Bioinformatics Institute). It 
is these lysine amino acids that are commonly used for conjugation to polymeric 
carboxyl functional groups. The number of lysines in a protein’s structure can 
therefore be regarded as an indicator of the number of potential binding sites. While 
extensive characterisation of trypsin’s crystal structure and amino acid sequence has 
been described, the number of accessible lysines may differ from those calculated. 
This is due to the tertiary folding of the amino acid chain, leaving some lysine 
residues buried within the structure, and ultimately inaccessible for polymer 
conjugation.
Trypsin was chosen as an initial model to synthesise the first conjugates because 
it is a readily available enzyme that has previously been conjugated to polymers, 
including HPMA copolymer (Chytry and Kopecek, 1982) and dextrin (Duncan et al, 
2008), making it an ideal choice for optimisation of synthesis and characterisation 
methods. Also, since trypsin is inexpensive and has similar molecular weight, 
isoelectric point and number of lysine groups as PLA2, it was considered to be a 
good model enzyme for optimisation of synthesis and characterisation methods.
1.5 Enzyme-prodrug combinations
Since polymer PLA2 conjugates were also to be investigated as an enzyme- 
prodrug combination in the PELT model it was useful to explore other existing such 
combinations. There are several existing enzyme-prodrug combinations currently 
being explored for delivery of therapeutics to tumours, including Gene-Directed 
Enzyme Prodrug Therapy (GDEPT), Antibody-Directed Enzyme Prodrug Therapy
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(ADEPT), Virus-Directed Enzyme Prodrug Therapy (VDEPT), Polymer-Directed 
Enzyme Prodrug Therapy (PDEPT), and Lectin-Directed Enzyme Prodrug Therapy 
(LEAPT); these are summarised in Table 1.3. These systems, as well as the PELT 
model, use a similar mechanism whereby a drug-activating enzyme, gene or 
functional protein is delivered to tumour tissues using polymers or other 
macromolecules as carriers, and is accompanied by systemic administration of the 
prodrug. A general schematic of some enzyme-prodrug combinations are depicted in 
Figure 1.7.
Since PDEPT and PELT both utilise a polymer as delivery vector, more 
detail on the PDEPT approach will be discussed.
1.5.1 PDEPT: Polymer Directed Enzyme Prodrug Therapy
During the development of polymer-drug conjugates as anti-cancer agents, 
several mechanisms of inherent and acquired tumour resistance to the therapeutics 
were observed. It was noted that if the rate of internalisation of conjugate was 
reduced, intracellular trafficking of the conjugate to the lysosomes was diminished, 
or concentrations of activating enzymes (e.g. cathepsin B) are low, the anti-tumour 
effect of the conjugate would be greatly affected. Consequently, Duncan and Satchi 
resolved to formulate a polymeric combination to enable the delivery of a cytotoxic 
drug by an externally delivered enzymatic trigger (Satchi et al> 2001). Polymer- 
protein conjugates were subsequently used as part of anti-tumour combinations with 
a polymer-drug. PDEPT is a novel anti-tumour model, which utilises a two-step 
approach to quickly and selectively release a cytotoxic drug in tumour interstitium. A 
schematic of the concept is seen in Figure 1.8. PDEPT uses a combination of 
polymeric prodrug and polymer-enzyme conjugate to minimise immunogenicity, 
extend plasma circulation time and enhance passive tumour targeting by the EPR.
Duncan and Satchi were the first to develop the PDEPT concept (Satchi, 1999; 
Satchi et al, 2001; Satchi-Fainaro et al, 2003). The first model was a combination of 
HPMA copolymer-cathepsin B and PK1 (HPMA copolymer-Gly-Phe-Leu-Gly- 
doxorubicin (6-8 %) conjugate), where the cathepsin B enzymatically cleaves the 
peptide linker, thus releasing the doxorubicin. The rationale behind this idea stems 
from the fact that, after endocytosis, lysosomal enzymes, including cathepsin B,
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Table 12  Examples of polymer-trypsin conjugates from literature.
Polymer Polymer: trypsin 
(molar ratio)
Activity 
(% native enzyme)
Reference
P-cyclodextrin-carboxymethylcellulose 2:1 95-110 (Villalonga et aly 2003a)
mono-6-ethylenediamino-6-deoxy-P-cyclodextrin 4:1 104-121 (Villalonga et al, 2003c)
mono-6-propylenediamino-6-deoxy-(3-cyclodextrin 4:1
mono-6-butylenediamino-6-deoxy-p-cyclodextrin 4:1
mono-6-hexylenediamino-6-deoxy-P-cyclodextrin 4:1
mono-6-amino-6-deoxy-a-cyclodextrin 3:1 96-108 (Villalonga et al, 2003b)
mono-6-amino-6-deoxy-P-cyclodextrin 3:1 96-128
mono-6-amino-6-deoxy-Y-cyclodextrin 3:1 103-124
0-carboxymethyl-poly-p-cyclodextrin+ 1:1 >100 (Villalonga et aly 2005)
Succinoylated mPEG* 20:1 65.2 (Treethammathurot et al, 2008)
Cyanurate mPEG* 20:1 92.9
T osylate-mPEG* 20:1 67.6
+ = MW was 13,000 g/mol; * = MW was 5,000 g/mol (remaining MW not stated)
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normally slowly degrade PK1 intracellularly. This release of free doxorubicin can be 
considerably accelerated by the PDEPT concept (Satchi-Fainaro et al, 2003). 
Experiments have confirmed the viability of the PDEPT concept, by demonstrating 
that the bound enzyme retains ~ 20-25 % of its activity in vitro, as well as a 
significantly prolonged plasma half-life and a 4.2 fold increase in tumour 
accumulation than the free enzyme. Furthermore, it was also shown that when PK1 
was administered IV to C57 mice bearing palpable B16F10 tumours, followed 5 h 
later by administration of HPMA copolymer-cathepsin B, there was a marked 
increase in doxorubicin release at the tumour site, compared to PK1 alone (Satchi et 
al, 2001). It is also of interest to note that Satchi reported a relatively high yield from 
polymer-enzyme conjugation (30-35 % protein conjugation), compared to other 
conjugates. This was attributed to the semi-random aminolysis reaction used to 
conjugate the two starting materials.
Following from the success of the HPMA copolymer-cathepsin B/ PK1 
combination, the group moved on to develop a combination containing HPMA 
copolymer-methacryloyl-cephalosporin-doxorubicin (5.85 %) (HPMA-co-MA-Gly- 
Gly-C-dox) and HPMA copolymer-P-lactamase (HPMA-co-MA-Gly-Gly-(3-L) 
(Satchi-Fainaro et a l, 2003). Cephalosporin cytotoxic drug derivatives have 
previously been used successfully in the antibody-directed enzyme prodrug 
(ADEPT) approach (Grant and Smyth, 2004). These derivatives are advantageous as 
they do not contain a mammalian enzyme, and should, therefore, not interfere with 
other mammalian systems. In Satchi-Fainaro’s PDEPT studies, the HPMA-co-MA- 
Gly-Gly-p-L conjugate retained 70-80 % of its activity; depending on whether it was 
acting on free cephalosporin C or HPMA-co-MA-Gly-Gly-C-dox. In vivo 
experiments showed prolonged plasma half-life and accumulation of the conjugates 
in tumours, compared to free (3-lactamase. Moreover, the group established a 
substantial decrease in tumour growth (treatment/control ratio (T/C) 132 %), with no 
measurable toxicity at the doses used in the study (Satchi-Fainaro et al, 2003).
1.5.2 PELT: Polymer Enzyme Liposome Therapy
Following on from the development of PDEPT, a similar concept was then 
considered as a means of enhancing drug release from liposomes as a method of
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overcoming toxicity and enhancing tumour targeting.
Liposomes were first described by Bangham in 1965 (Bangham et al, 1965). 
They are microscopic spherical vesicles (0.03 -  10 pm diameter) that are formed 
when phospholipids are dispersed in excess water. They are characterised by the 
presence of a lipid bilayer (able to incorporate lipophilic drugs) surrounding an 
aqueous core (able to incorporate hydrophilic drugs) (Kirby and Gregoriadis, 1999; 
Talsma, 1991; Van Winden, 1996). Liposomes have the capacity to carry a high drug 
loading, and the incorporation of cholesterol and PEGylation can improve their 
stability and reduce immunogenicity (Andresen et al, 2005). There are four key 
features that are responsible for the behaviour of liposomes; vesicle size, morphology 
and number of bilayers, fluidity of bilayers, and surface characteristics, such as 
charge and hydrophobicity (Van Winden, 1996).
Two liposomal anti-cancer formulations are already approved in the UK for 
routine clinical use for the treatment of breast cancer: Caelyx® and Myocet®. Caelyx® 
is an 85-100 nm liposome formulation consisting of doxorubicin hydrochloride (2 
mg/mL) encapsulated in fully hydrogenated soy phosphatidylcholine: cholesterol: 
PEG-distearoylphosphatidylethanolamine (molar ratio 1.5:1:0.15) liposomes. 
Inclusion of PEG chains at the liposome surface (known as PEGylation) protects 
liposomes from detection by the RES thus increasing blood circulation time. 
Conversely, Myocet® is a 180 nm in diameter liposome composed of egg 
distearoylphosphatidylcholine: cholesterol (molar ratio 1:1), containing doxorubicin 
hydrochloride.
Although these formulations contain the same active drug, they have 
significantly different lipid composition, size and loading method, which results in 
dramatically different plasma pharmacokinetics and tissue distribution profiles. 
Consequently, the side effects seen with the two drug formulations vary too. The 
main dose limiting toxicity associated with Myocet® is myelosuppression, in 
particular, neutropenia, while, due to its altered lipid composition, Caelyx® has the 
propensity to cause mucositis, stomatitis and palmar-plantar erythrodysesthesia 
(commonly known as hand-foot syndrome). Liposomal formulations of anti-cancer 
drugs have numerous advantages over their parent drugs, including reduced toxicity
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and side effects resulting from improved tumour targeting. In particular, liposomal 
formulations of doxorubicin have successfully reduced the cardiomyopathy 
commonly associated with doxorubicin therapy.
Unfortunately however, liposomes are not without their disadvantages, including 
an inability to control drug release rate, insufficient drug loading, difficulty in 
overcoming biological barriers (such as skin, blood-brain barrier), and problems of 
active targeting within the body. Consequently, while liposomes significantly reduce 
the toxicity of otherwise cytotoxic drugs by containing them inside the liposome, 
they are not able to rapidly release the drugload into the tumour interstitium. This 
obstacle led to the PELT concept. Following the development of PDEPT, Satchi- 
Fainaro and Duncan (unpublished) examined the feasibility of designing a polymer- 
enzyme/ liposome combination as a means to rapidly release drug payload from 
liposomes after accumulation in the tumour interstitium by the EPR effect. PELT 
utilises a polymer-bound enzyme to trigger the release of drug encapsulated within a 
liposome (Figure 1.9). Satchi-Fainaro and Duncan (unpublished) used HPMA 
copolymer-Gly-Gly-phospholipase C (PLC) (60 wt. % PLC, MW = 75-150,000 
g/mol) to trigger doxorubicin or daunorubicin release from Doxil® or DaunoXome®, 
respectively. Incubation of HPMA copolymer-Gly-Gly-PLC with Doxil® resulted in 
partial release of doxorubicin, while complete daunorubicin release was seen from 
DaunoXome®. In both cases, polymer-conjugated PLC retained the enzyme activity 
of the free PLC.
The advantages of PELT include the ability to modulate the release of drugs 
from the liposomes, and cause them to burst locally in the tumour interstitium. It is 
hoped that PELT will reduce systemic toxicity of the drug by delivery of the 
liposome to the tumour, thereby protecting normal tissue by limiting exposure of 
normal tissue to the cytotoxic drug.
1.6 Aims of project
The overall aims of this project were to investigate the potentials of polymer- 
PLA2 conjugates as anti-cancer agents; both acting as therapeutic entities themselves, 
and as a means of triggering the release of liposome-encapsulated drug, in the
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Table 13  Examples of enzyme-prodrug combinations undergoing investigations.
Application Enzyme Prodrug Viral vector/ antibody/ 
Polymer
Reference
GDEPT Thymidine phosphorylase 5’-fluorouracil - (Evrard et al, 1999)
E. Coli P-galactosidase Anthracycline - (Bakina and Farquhar, 1999)
VDEPT Yeast cytosine reductase 5-fluorocytosine Retrovirus (Weedon et al, 2000)
E. coli nitroreductase CB1954 (5-(aziridin-l- 
yi)-2,4-
dinitrobenzamide)
Adenovirus (Hamstra et al, 1999)
ADEPT (3-glucosidase Amygdalin Bladder cancer-associated 
monoclonal antibody
(Syrigos et al, 1998)
Human p-glucoronidase Doxorubicin Single chain anti-CD20 
antibody
(Syrigos et al, 1998)
PDEPT Cathepsin B Doxorubicin HPMA copolymer (Satchi et al, 2001)
P-lactamase Doxorubicin HPMA copolymer (Satchi-Fainaro et al, 2003)
PELT Phospholipase C Doxorubicin Liposome (Satchi-Fainaro and Duncan, 
Unpublished)
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context of PELT.
Specifically, the focus of the work initially centred on the synthesis of dextrin- 
trypsin and HPMA copolymer-trypsin conjugates (Chapter 3). The conjugation 
method was optimised to produce the best reaction efficiency while retaining 
maximum enzyme activity. Activity of free and bound trypsin was tested using L- 
BAPNA a colourless chromogenic substance.
Once dextrin had been selected as the most suitable polymer, bee venom PLA2 
was chosen to synthesise dextrin-PLA2 conjugates using the previously optimised 
reaction method (Chapter 4). A library of dextrin-PLA2 conjugates was prepared and 
the PLA2 activity was tested using an egg yolk emulsion. This assay was 
subsequently used to test the PUMPT hypothesis. Finally, to assess whether the 
conjugate would cause non-specific toxicity following IV administration, haemolysis 
of red blood cells by free and conjugated PLA2 was measured, a-Amylase was used 
to unmask dextrin-PLA2 conjugates for haemolysis testing.
Given the success in these primary studies, the next studies were intended to 
determine the ability of the conjugate to kill various cancer cell lines (Chapter 5). In 
order to better understand the mechanism by which PLA2 exerts its cytotoxic 
activity, three different cancer cell lines were studied (HT29, MCF-7, B16F10), each 
expressing varying levels of EGFR. Cytotoxicity to these cells with dextrin-PLA2, 
co-incubated with EGF and a tyrosine kinase inhibitor, was measured using the MTT 
assay. Further studies investigating the potential of using dextrin-PLA2 in 
combination with conventional chemotherapeutics (doxorubicin and daunorubicin) 
were also performed.
Having established the involvement of the EGFR in PLA2 cytotoxicity, it was 
considered important to perform preliminary studies using Oregon Green-labelled 
conjugates to follow the cellular uptake of native and dextrin-conjugated PLA2 
(Chapter 6). Analysis of the cellular uptake of free and dextrin-conjugated PLA2 was 
measured using flow cytometry and confocal microscopy.
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It was also intended that this work would examine the feasibility of the PELT 
concept using a well-characterised dextrin-PLA2 conjugate as a model polymer- 
enzyme combination (Chapter 7). The overall objectives of the study were to provide 
proof of concept data. This was achieved by monitoring the ability of dextrin-PLA2 
conjugates to rupture liposomal daunorubicin (DaunoXome®), thus enhancing the 
release of drug.
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2.1 Chemicals
2.1.1 General chemicals
HPMA copolymer-Gly-Gly-ONp (5 mol %) was supplied by Polymer 
Laboratories (Church Stretton, UK). Type 1 dextrin from corn was supplied by ML 
laboratories (Keele, UK). Gefitinib was provided by AstraZeneca (Macclesfield, 
UK). Trypsin from porcine pancreas, PLA2 from honey bee venom, PLA2 from 
porcine pancreas, anhydrous dimethyl sulfoxide (DMSO), calcium chloride, sodium 
tetraborate (N a^O y), lithium acetate dihydrate, 98 % sodium hydroxide (NaOH), 1- 
Ethyl-3-(3-dimethylaminopropyl carbodiimide hydrochloride) (EDC), copper (II) 
sulphate pentahydrate 4 % w/v solution, bovine serum albumin (BSA), bicinchoninic 
acid solution (BCA), TRIZMA base, sodium dodecyl sulfate (SDS), TRIZMA 
hydrochloride (Tris HC1), triton X-100, glycerol, ammonium persulfate, 
acrylamide/bis-acrylamide, hydrindantin, ninhydrin, 2,4,6-trinitrobenzene 1- 
sulphonic acid (TNBS) boric acid (H3B 03) and L-BAPNA were all from Sigma- 
Aldrich (Poole, UK). Sodium acid phosphate, sodium phosphate, sodium chloride, 5 
M HC1, anhydrous N,N-dimethylformamide (DMF), ethanol, diethyl ether, methanol, 
acetone, acetic acid, paraformaldehyde (PFA) and sucrose were all purchased from 
Fisher Scientific (Loughborough, UK). N,NjSf,N-Tetramethyl-Ethylenediamine 
(TEMED) was from Bio-Rad (Perth, UK). Glycine was purchased from ICN 
Biomedicals, Inc.. DL-amino-2-propanol was from Acros (Loughborough, UK). 
Sulfo-NHS was from Fluka (Gillingham, UK). Bromophenol blue was from BDH 
(Poole, UK). Oregon Green 488 cadaverine *5-isomer (OG) was from Invitrogen 
Molecular Probes (Paisley, UK). EGF was from Prospec-Tany Technogene Ltd 
(Rehovot, Israel). Unless otherwise stated, all chemicals were of analytical grade.
2.1.2 Chemicals for cell culture and tissue culture media
Tissue culture grade dimethyl sulfoxide (DMSO, 3-(4,5-dimethylthiazol-2yl)- 
2,5-diphenyl tetrazolium bromide (MTT), trypan blue and optical grade DMSO were 
from Sigma-Aldrich (Dorset, UK).
2.2 Cells and tissue culture media
The cell line MCF-7 (human breast carcinoma) was provided by Tenovus Centre
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for Cancer Research (Cardiff, UK), HT29 cells (human colon cancer) were obtained 
from the European Collection of Cell Cultures, Centre for Applied Biology, 
Microbiology and Research (ECACC) (Salisbury, UK) and B16F10 murine 
melanoma were from American Type Culture Collection (ATCC) (Manassas, USA). 
All cell lines were screened and found to be free of mycoplasma contamination. 
Foetal calf serum (FCS) (untreated and heat-inactivated (HI FCS)), 0.05 % w/v 
trypsin-0.53 mM EDTA, RPMI 1640 with L-glutamine (with and without phenol red 
as pH indicator), RPMI 1640 with GlutaMAX and McCoy’s 5A were obtained from 
Invitrogen Life Technologies (Paisley, UK). PBS was prepared using the chemicals 
listed above, and autoclaved.
2.3 Equipment
2.3.1 Equipment for cell culture
With the exception of the centrifugation steps, all cell work was performed in 
Bioair (Siziano, Italy) and Bioquell Microflow (Andover, UK) class II laminar flow 
cabinets. For general cell culture a Leica inverted bright-field microscope was used 
(Wetzlar, Germany). Bright-field images of cell morphology were taken using an 
inverted Leica DM IRB microscope (Wetzlar, Germany) with 12-bit cooled 
monochrome Retiga 1300 camera (Surrey, Canada). For routine cell counting, a 
Marienfield silver stained Neubauer haemocytometer (Lauda-Konigshofen, 
Germany) was used. Tissue culture flasks (25, 75 and 150 cm3) and tissue culture 
sterile plates (6-well, 96-well) were from Coming Inc. (New York, USA). Sterile 
pipettes (5, 10 and 25 mL), sterile cell scrapers, kwills, 7 mL bijoux, universal 
containers and 60 mL pots were from Elkay (Birmingham, UK).
2.3.2 Analytical equipment
Ultraviolet (UV): The UV plate reader (Sunrise Touchscreen) was from Tecan 
(Reading, UK). UV-visible spectrophotometer (Cary 1G) was from Varian Inc. 
(Walton-on-Thames, UK), with software version 2.0.
Fluorescence: A Fluostar Optima fluorescence plate reader from BMG Lab 
Technologies (Offenburg, Germany) and an Amnico-Bowman Series 2 luminescence
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spectrophotometer from Spectronic Instruments (Leeds, UK) were used for 
fluorescence measurements.
Infrared (IR): The FT-IR spectrophotometer (Avatar 360) was from Nicolet 
Instrument Corp. (Newington, USA), fitted with a Nicolet Smart Arc diffuse 
reflectance accessory. Nicolet E-Z Omnic ESP 5.2 software was used for data 
collection.
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE): All 
electrophoresis equipment, including a Power Pac 300 and GelAir Drying Frame 
were from Bio-Rad (Perth, UK).
Gel permeation chromatography (GPC): The aqueous GPC was equipped with a 
JASCO HPLC pump and two TSK-gel columns in series (4000 PW followed by 
3000 PW) and a guard column (progel PWXL) from Polymer Laboratories (Church 
Stretton, UK). The eluate was monitored using a differential refractometer (Gilson 
153) and a UV-visible spectrophotometer at 279 nm (UV Severn Analytical SA6504) 
in series. PL Caliber Instrument software, version 7.0.4, from Polymer laboratories 
(Church Stretton, UK) was used for data analysis.
Fast performance liquid chromatography (FPLC): An AKTA FPLC from 
Amersham Pharmacia Biotech (Little Chalfont, UK) system was used. The unit was 
connected to a pre-packed Superdex 75 HR 10/30 column and a Frac-950 fraction 
collector from Amersham Pharmacia Biotech (Little Chalfont, UK). The UV detector 
data was collected using Unicorn 3.20 software and analysed using FPLC director® 
version 1.10 software.
Flow cytometry: Uptake studies were performed using a Becton Dickinson 
FACSCalibur cytometer (Franklin Lakes, USA) equipped with an argon laser (488 
nm) and emission filter for 550 nm. Data were acquired in 1024 channels with band 
pass filters (FL-1 530 nm ± 30 nm; FL-2 585 ± 42 nm; FL-3 670 nm long pass filter). 
Data were processed using CELLQuest™ version 3.3 software.
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Miscellaneous: The pH meter (3150 pH meter) was from Jenway (Leeds, UK). 
Freeze-dryer (Flexi Dry FD-1.540 freezer-dryer) was from FTS Systems (Stone 
Ridge, USA), connected to a high vacuum pump (DD75 double stage) from Javac 
(Middlesbrough, UK). Dialysis membranes Spectra/POR® CE (Cellulose Ester) were 
from Pierce & Warriner (Chester, UK) MW cut-off 10,000 g/mol, 25,000 g/mol and 
50,000 g/mol. Vivaspin 6 tubes were from Sartorius Vivascience (Goettingen, 
Germany) MW cut-off 30,000 g/mol. Thin-layer chromatography (TLC) was 
performed using Sigma-Aldrich silica gel TLC plates (200 pm thick; 25 pm particle 
size; on an aluminium support) (Dorset, UK).
2.4 Methods
This section gives a detailed description of the general methods used in these 
studies. Those specific methods used in each chapter are described in full there.
Methods used for conjugate synthesis and purification are described in detail in 
Chapter 3 (section 3.2). However, the methods used for conjugate characterisation 
are described in this chapter, as they apply to all methods explored for polymer- 
protein conjugation.
2.4.1 Ninhydrin Assay
Prior to conjugation of polymer to protein, it was first important to determine the 
number of available amine groups for conjugation. Two methods were investigated 
for this purpose, namely the ninhydrin assay and the TNBS assay (next section, 
2.4.2). Ninhydrin is a powerful oxidising agent, with the ability to react with all 
primary amino acids between pH 4 and 8 resulting in a purple colour, which forms 
the basis of the quantitative measurement of amine content. (Plummer, 1978).
First, a 4 M lithium acetate buffer solution was prepared by dissolving lithium 
acetate dihydrate (102.02 g) in 150 mL ddH20 . Sufficient acetic acid (glacial) was 
added until pH 5.2 was reached. The volume was made up to a final volume of 250 
mL with ddH20 . Next, ninhydrin (0.8 g) and hydrindantin (0.12 g) were dissolved in 
30 mL DMSO and 10 mL lithium acetate buffer. Buffered ninhydrin reagent (2 mL) 
was added to an equal quantity of sample/ standard solution and heated in a water
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bath at 100 °C for 15 min. The mixture was subsequently cooled to room temperature 
and 3 mL of 50 % v/v ethanol was added, before spectrophotometric analysis at 570 
nm. A typical calibration curve is shown in Figure 2.1a.
2.4.2 TNBS Assay
The TNBS assay works by the delocalisation of the Jt-electrons of the benzene 
ring of TNBS, and the subsequent absorption of UV light as the ring binds to primary 
amines (Mokrasch, 1967).
Samples were prepared by first making a 1 mg/mL solution of enzyme in ddHzO 
and allowing it to fully dissolve. Next, 100 pL of this solution was diluted to 10 mL 
in ddH20  to produce a 0.01 mg/mL solution of enzyme. This stock solution was used 
to make up the final solutions of enzyme. Standard samples were prepared in ddH20  
by diluting 10 pL DL-amino-2-propanol in 10 mL ddH20 . Next, 100 pL of this 
solution was made up to 10 mL with ddH20 . This stock solution was used to make 
up the final solutions of amino acid standards with concentrations in the range of 
1.29 -  9.04 x 105 mol/L.
An aliquot of each enzyme solution (0.08 mL) was added to a well in a 96 well 
plate. The same was done for the standards. To each well containing either sample or 
calibration solution, TNBS (0.01 mL, 0.017 M) and borate buffer (0.2 mL, pH 9.3) 
were added. For blanks, borate buffer (0.28 mL, pH 9.3) and TNBS (0.01 mL, 0.017 
M) were used.
Every well was replicated six times. The plate was then covered in aluminium 
foil and placed on a rocker for 30 min. The plate was read at 430 nm. A typical 
calibration curve is shown in Figure 2.1b.
2.4.3 Purification of polymer-enzyme conjugates
Several methods were used to purify polymer-protein conjugates to remove 
salts, unreacted protein and linking agents (see Chapter 3). FPLC was later chosen as 
the method of choice (see below).
Purification o f polymer-protein conjugates by FPLC
FPLC was used for purification of HPMA copolymer-protein and dextrin-
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Figure 2.1 Ninhydrin and TNBS assays to quantify the num ber of prim ary amines 
available for conjugation. Panel (a) represents a typical calibration curve for the 
ninhydrin assay using DL-amino-2-propanoI standards. Panel (b) represents a typical 
calibration curve for the TNBS assay using DL-amino-2-propanol standard. Data 
represents mean ± SEM (6). Where error bars are invisible they are within size of data 
points.
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protein conjugates. An AKTA FPLC (Amersham Pharmacia Biotech, UK) system 
was used to separate free protein and conjugated protein according to their molecular 
weight.
A pre-packed Superdex 75 HR/10/30 column was washed with 2 column 
volumes (~ 48 mL) of filtered (0.2 pm; Millipore) and sonicated ddH20 . Next, the 
column was equilibrated with 3 column volumes (~ 72 mL) of filtered and sonicated 
mobile phase (PBS buffer, pH 7.4) prior to use. First, the column was calibrated (0.5 
mL/min flow rate) using standardised proteins of various molecular weight: aprotinin 
from bovine lung 6,500 g/mol; cytochrome c from bovine heart 12,400 g/mol; 
carbonic anhydrase from bovine erythrocytes 29,000 g/mol; albumin from bovine 
serum 66,000 g/mol; and alcohol dehydrogenase 150,000 g/mol. The calibration 
curve can be seen in Figure 2.2. Then samples (1 mL) were injected into a 2 mL loop 
(partial fill method) and allowed to run at a flow rate of 0.5 mL/min. When 
conjugates were being purified, fractions (1 mL) were collected and assayed for 
protein content (section 2.4.4.3) before pooling the appropriate fractions containing 
conjugate.
After use, the column was thoroughly washed with eluant, followed by ddHzO 
and finally was stored in 20 % v/v ethanol.
2.4.4 Characterisation of polymer-enzyme conjugates
Once the conjugates were made, it was necessary to characterise the products in 
respect of protein content, free protein, molecular weight and polydispersity.
2.4.4.1 Size Exclusion Chromatography (SEC) for characterisation of 
conjugates
Polymer-protein conjugates are notoriously difficult to characterise as they are 
neither protein nor polymer. Therefore, while it was not possible to accurately assign 
the molecular weight of the conjugate, GPC and FPLC were used in combination 
with SDS PAGE to quantitatively define the molecular weight of the conjugate and 
its purity in respect of free enzyme. The BCA assay was used to quantify the total 
protein content of the conjugate.
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Figure 2.2 FPLC analysis of protein molecular weight standards using a Superdex 
HR 10/30 size exclusion column. Panel (a) shows the chromatogram of the protein 
standards: (1) aprotinin (6,500 g/mol); (2) cytochrome c (12,400 g/mol); (3) carbonic 
anhydrase (29,000 g/mol); (4) albumin (66,000 g/mol); and (5) alcohol dehydrogenase 
(150,000 g/mol). V0 and Vb represents the void and bed volume, respectively. Panel (b) 
represents the calibration curve for estimation of sample molecular weight.
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Characterisation by FPLC
FPLC (as described previously) was also used to estimate the conjugate’s 
molecular weight in comparison to standardised proteins of various molecular 
weights (detailed in section 2.4.3) and measure the ratio of free and bound protein. 
The same FPLC system as was used for purification was used for characterisation. 
After appropriate equilibration and calibration, samples of purified conjugate (200 
pL) were injected into a 100 pL loop then allowed to run at a flow rate of 0.5 
mL/min. Output from the UV detector was analysed using Unicorn 3.20 software 
from Amersham Pharmacia (Little Chalfont, UK).
Characterisation by GPC
HPMA copolymer-trypsin and dextrin-trypsin conjugates were analysed using 
aqueous phase GPC. GPC is commonly used to separate polymers according to their 
size and shape (hydrodynamic radius). Polysaccharide (pullulan) standards (MW 
from 11,800 to 210,000 g/mol) were used to produce a calibration curve (Figure 2.3). 
All samples were prepared in PBS (3 mg/mL). Of these solutions, approximately 60 
pL was injected (injection loop 20 pL). PBS (filtered and sonicated for 30 min) was 
used as the mobile phase (flow rate 1.0 mL/min). Both RI and UV detection (k  = 279 
nm) were used and data were analysed using PL Caliber Instrument software.
2.4.4.2SDS PAGE
The method used for the electrophoresis was adapted from one described by 
Laemmli (1970). First, the following reagents were prepared: 10 % w/v SDS (stored 
at room temperature), 10 % w/v ammonium persulfate (made up fresh daily), running 
buffer gel and stacking gel buffer (see Table 2.1 for composition). The two glass 
plates, side spacers and clamps were rinsed in ddH20  and assembled. The assembly 
was then stood upright, using the clamps as supports, and filled with ethanol to test 
for leaks.
Next, the separating gel was prepared according to Table 2.1, adding TEMED 
last. This solution was gently inverted to mix, without introducing air bubbles. This 
solution was immediately pipetted into the spaces between the glass plates, up to a 
level of 3 cm from the top. A thin layer of isopropanol was applied to form an even
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Figure 2 3  GPC analysis of pullulan molecular weight standards using TSK-gel 
columns G4000 PWXL and G3000 PWXL in series. Panel (a) shows the 
chromatogram of the pullulan standards ( 5,900 - 788,000 g/mol). V0 and Vb represents 
the void and bed volume, respectively. Panel (b) represents the calibration curve for 
estimation of sample molecular weight.
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Table 2.1 Sum m ary of the composition of buffers and solutions used for SDS 
PAGE.
Lower (separating) gel Upper (stacking) gel Running buffer
8.44 mL ddHzO 5.85 mL ddHzO 3 g Tris HC1
5 mL separating buffer (Tris 
base, pH 6.8,1.5 M)
2.5 mL stacking buffer (Tris 
base, pH 6.8,0.5 M)
14.4 g glycine
200 pL 10 % w/v SDS 
solution
100 pL 10 % w/v SDS 
solution
10 mL 10 % w/v 
SDS solution
6.25 mL 40 % w/v 
acrylamide/bis-acrylamide
1 mL 40 % w/v 
acrylamide/bis-acrylamide
ddHzO up to 1 L 
pH 8.3
100 pL 10 % w/v ammonium 
persulfate solution
50 pL 10 % w/v ammonium 
persulfate solution
lOpLTEM ED 5 pLTEMED
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surface on the gel and prevent oxidation, which inhibits polymerisation. The 
separating gel was then left to polymerise for 30-60 min, during which time the 
stacking gel was prepared as detailed in Table 2.1, adding TEMED last. Again, this 
mixture was gently inverted to mix, taking care not to introduce bubbles. The 
isopropanol was poured out of the assembly, and the stacking gel was pipetted onto 
the separating gel. The 10-well comb was inserted, the glass plate assemblies topped 
up with stacking gel and this construction was left to polymerise for 30-45 min.
Meanwhile, the samples were prepared by adding 1 volume of 2x denaturing 
buffer (ddH20  (3.8 mL), Tris HC1 (pH 6.8,0.5 M, 5 mL), Glycerol (4 mL), 10 % w/v 
SDS (8 mL), 2-mercaptoethanol (2 mL), and bromophenol blue 1 % w/v (0.4 mL)) to 
1 volume of each sample and protein markers. The eppendorf tubes were capped and 
heated for 5 min at 100 °C, then immediately chilled on ice for a further 5 min. These 
samples were finally centrifuged for approximately 5 s. Once the stacking gel had 
polymerised, the comb was removed and the plates were loaded onto the frame. The 
assembly was subsequently lowered into the tank, which was filled up with running 
buffer (see Table 2.1).
Each well was filled with 10 pL sample, while the first well of every gel was 
filled with 10 pL molecular weight markers (1 mg/mL). The lid was put on the tank, 
and connected to a power supply. The gel was then run at 200 V for 1 h, or until dye 
reached the bottom of the gel.
The gels were then removed and the plates separated. The gels were removed 
from the glass plates, transferred into plastic trays containing 100-200 mL coomassie 
blue stain and gently agitated for 1 h. Next, this solution was poured off and replaced 
with a strong destain solution (35 % v/v methanol, 5 % v/v acetic acid) and left for 1 
h. Finally, this solution was poured off and replaced with weak destain solution (7 % 
v/v methanol, 5 % v/v acetic acid), until the background became clear. The gels were 
then placed between two water-prewetted thin films, air bubbles removed and left to 
dry at room temperature for two days.
The ratio of the distance travelled by the protein band to that of the solvent front 
(Rf value) was used to determine the molecular weight distribution of the conjugate. 
Molecular weight standards (myosin 194,239 g/mol; P-galactosidase 115,660 g/mol;
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bovine serum albumin 97,316 g/mol; ovalbumin 53,533 g/mol; carbonic anhydrase 
(37,248 g/mol; soybean trypsin inhibitor 29,385 g/mol; lysozyme 20,415 g/mol; and 
aprotinin 6,919 g/mol) were used to prepare a calibration curve of Rf values (Figure 
2.4). This was then used to estimate the molecular weight of polymer-protein 
conjugates in relation to the standardised proteins.
2.4.4.3 BCA protein assay
The BCA assay was used to determine the total protein content of the polymer- 
protein conjugates (Smith et al, 1985). The assay consists of two steps. First, the 
protein reduces the Cu2+ to Cu1+ by the biuret reaction. The resulting Cu1+ forms a 
coloured coordination complex with four to six nearby peptide bonds. Next, the BCA 
forms complexes with the remaining Cu2+, which produces a purple coloured 
solution and is detectable at 562 nm. The intensity of the colour is directly 
proportional to the number of peptide bonds participating in the reaction (Figure 2.5).
A 96-well microtitre plate was used. Each well was prepared to contain 20 pL of 
polymer-conjugate sample (1 mg/mL; n = 6), or standard (0-1 mg/mL; n = 3), and 
200 pL of BCA reagent (1 mL BCA: 20 pL Cu (II) sulfate). The plate was gently 
agitated and left in the dark, at 37 °C, for 20 min, and then read on the 
spectrophotometer at 550 nm. Typical calibration curves for BSA, trypsin and PLA2 
are shown in Figure 2.6 and were used to determine the protein content of polymer 
conjugate.
2.4.5 Biological characterisation of enzymes and polymer-enzyme conjugates
Detailed methods for these enzyme activity assays are described in Chapters 3 
and 4 (sections 3.2 and 4.2).
2.4.6 Cell Culture
Cell culture was performed according to the United Kingdom Co-ordinating 
Committee on Cancer Research (UKCCCR) guidelines. In order to ensure sterility of 
the incubator the safety cabinets and equipment were sprayed with 70 % v/v ethanol 
in water. Those items not supplied pre-sterilised were sterilised by (a) autoclaving 
(120 °C, 15 lb/m2, 15 min) for glassware, certain plastics, PBS and ddHzO; (b)
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Figure 2.4 Calibration curve for SDS PAGE using protein molecular weight 
standards. Data shown represents mean ± SD (n = 3). Where error bars are invisible 
they are within size of data points.
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Figure 2 5  BCA assay for protein quantification: mechanism (adapted from Pierce 
Chemical Technical Library, 2002).
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Figure 2,6 Typical BCA assay calibration curves obtained using PLA2, BSA and 
trypsin as protein standards. Data shown represents mean ± SD (n = 3). Where error 
bars are invisible they are within size of data points.
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microfiltration (0.2 pm) for solutions; or (c) UV irradiation (30 min).
2.4.6.1 Defrosting cells
Cells were grown from frozen stock (vials containing 1 mL of cell suspension). 
First, cells were thawed rapidly in a water bath at 37 °C, then transferred to a 
universal container containing 9 mL of cell-specific medium (Table 2.2) with 20 % 
FCS. Cells were centrifuged at 20 °C for 5 min at 1000 rpm, and the supernatant 
removed by aspiration. The cells were then resuspended in 5 mL of the appropriate 
complete medium. Next, the cell suspension was transferred to a 25 cm3 flask and 
stored in the incubator at 37 °C. After 24 h, the medium was replaced with fresh 
medium and the cells allowed to grow until they reach ~ 80 % confluency and can be 
passaged.
2.4.6.2 Cell maintenance and passaging
Cells were grown in vented 75 cm2 tissue culture flasks in their cell-specific 
complete medium (see Table 2.2) at 37 °C, in humidified atmosphere with 5 % C 02. 
Once ~ 80 % confluence was reached, the cells were passaged as described below. 
First, the old media was removed by aspiration with a kwill and the cells were 
washed with 10 mL sterile PBS to remove residual media and any dead cells. 
Trypsin-EDTA solution (1.5 mL) was added and cells were incubated for 
approximately 3 min or until detached. Fresh medium (8.5 mL) was added and the 
cell suspension was collected in a universal container and centrifuged for 5 min at 
1000 rpm, at 20 °C. The supernatant was removed by aspiration and the cells were 
resuspended in fresh medium. This suspension was used to prepare new flasks after 
appropriate dilution. MCF-7 cells to be used in experiments were grown in RPMI 
1640 without the pH indicator (WRPMI 1640), as it has been shown that phenol red 
has mitogenic activity towards this cell line (Devleeschouwer et al, 1992), and might 
therefore interfere with the oestrogen pathway.
2.4.63 Counting cells and seeding cells
Cells were washed with PBS, trypsinised and resuspended as described 
previously. Cells were subsequently passed though a needle (23 G), to ensure a
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Table 2.2 Cell lines and culture conditions.
Tumour
origin
Cell line Culture media Split Supplier
Human
breast
carcinoma
MCF-7 5 % v/v FCS, RPMI 1640,5 mM L- 
glutamine
*(5 % v/v FCS, RPMI 1640 (without 
phenol red), 5 mM L-glutamine)
1:10 Tenovus
Human
colon
cancer
HT29 10 % v/v FCS, McCoy’s 5A, 5 mM L- 
glutamine
1:10 ECCAC
Murine
melanoma
B16F10 10 % v/v FCS, RPMI 1640, glutaMAX 1:10 ATCC
* = culture media used for performing experiments
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homogenous suspension of cells. An aliquot of the suspension (100 pL) was 
removed and diluted with an equal volume of trypan blue (0.2 % trypan blue in 
PBS). After 1 min, some of this cell suspension was placed in a haemocytometer. 
Cells from ten 0.1 mm3 squares (five taken from the top chamber, and five taken 
from the bottom chamber of the haemocytometer) were counted. Non-viable cells 
(stained with trypan blue) were not included in the count.
The following formula was used to determine the cell concentrations:
Cells/mL = mean cell count x 2 x 104
Where: mean is the arithmetic mean of the 10 values
2 takes into account the trypan blue dilution 
104 accounts for the conversion from 0.1 mm3 to mL 
Subsequently, the cell suspension was diluted with medium to obtain the 
appropriate seeding density for the experiment.
2.4.6.4 MTT assay as a means to assess cell viability: growth curve
The MTT assay is a method of assessing cell viability. A redox reaction of the 
yellow substrate solution (MTT 5 mg/mL in PBS) with mitochondrial respiration 
products NADH and NADPH, results in the formation of insoluble blue crystals 
(Mosmann, 1983).
Cells were seeded into 96-well plates (MCF-7 and HT29: 4 x 104; B16F10: 1 x 
104 cells/ mL) and allowed to adhere for 24 h. A sterile filtered solution of MTT (20 
pL) was added to each well and the reaction allowed to proceed for 5 h at 37 °C. The 
solution containing MTT and medium was carefully removed, ensuring not to 
remove the precipitated crystals. Next, the crystals were dissolved in 100 pL of 
sterile DMSO and incubated for a further 30 min at 37 °C. The absorbance of the 
solution was read in a UV absorbance plate reader (X = 550 nm). This measurement 
was performed on a daily basis. After reading absorbance, the DMSO solution was 
removed and replaced with sterile PBS, to maintain moist conditions for the 
remaining cells in the plate. Growth curves were produced by plotting absorbance 
against time and used to calculate cell doubling times.
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2.4.6.5 MTT assay as a means to assess cell viability: treatment effects
Cell viability in the presence of PLA2, dextrin, dextrin-PLA2, EGF, gefitinib, 
doxorubicin, daunorubicin and DaunoXome® was evaluated using the MTT assay 
(72 h incubation) (Sgouras and Duncan, 1990), with the human breast cancer cell 
line, MCF-7, murine melanoma cell line, B16F10, and human colon carcinoma cell 
line, HT29. Cell viability was always measured while cells were in exponential 
growth phase, as determined using the methods described in section 2.4.6.4.
Cells were seeded into sterile 96-well microtitre plates (MCF-7 and HT29: 4 x 
104 cells/ mL, B16F10: 1 x 104 cells/mL) in 0.1 mL/well of media (WRPMI 1640/ 
McCoy’s 5A/ RPMI 1640, respectively) with FCS (5-10 % v/v) and allowed to 
adhere for 24 h. After 24 h, the medium was removed and test compounds (0.2 pm 
filter-sterilised) were added to the cells. After a further 67 h incubation, MTT (20 pL 
of a 5 mg/mL solution in PBS) was added to each well and the cells were incubated 
for 5 h. The medium was then removed and the precipitated formazan crystals were 
solubilised for 30 min with the addition of optical grade DMSO (100 pL). 
Absorbance, which was proportional to cell viability, was measured at 550 nm. Cell 
viability was expressed as a percentage of the viability of untreated control cells. The 
IQo values were expressed as concentration of test compound (± SEM).
2.4.6.6 Determination of cellular uptake of polymer conjugates by flow 
cytometry
Flow cytometry was used to study the uptake of OG-labelled dextrin, PLA2 and 
dextrin-PLA2 by MCF-7 cells. Cells were seeded in 6-well plates (1 x 106 cells/mL) 
in their respective media, supplemented with FCS, and allowed to adhere for 24 h. In 
order to account for external binding, the experiment was performed at 37 °C and 4 
°C. Solutions for treatment were prepared in medium and equilibrated to 37 °C or 4 
°C. For experiments performed at 37 °C, cells were kept under normal cell culture 
conditions throughout the incubation period, while cells used in experiments at 4 °C 
were incubated at 4 °C for 30 min prior to the addition of treatment media. OG- 
labelled dextrin, PLA2 or dextrin-PLA2 (synthesis and characterisation described in 
Chapter 6) was added at a concentration of 1.5 pg/mL in medium. Cells were then 
incubated for 60 min at 37 °C or 4 °C.
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At the end of the incubation period, the plates were placed on ice to prevent 
further uptake and kept at 4 °C. The cells were washed three times with ice-cold PBS 
( 3 x 1  mL). Next, PBS (1 mL) was added and the cells scraped from the plates, 
collected in falcon tubes and centrifuged at 4 °C, 1000 x g for 5 min. Finally, cells 
were re-suspended in ice-chilled PBS (200 pL) and analysed using a Becton 
Dickinson FACSCalibur cytometer equipped with an argon laser (488 nm) and 
emission filter for 550 nm.
Data were collected with 10,000 total cell counts per sample and processed 
using CELLQuest™ version 3.3 software. Control cells (incubated with medium 
only) were used in all cases to account for background fluorescence output (M l). 
Data was acquired in 1024 channels with band pass filter FL-1 (530 nm ± 15 nm). 
Results were expressed as (geometric mean x % positive cells)/ 100 (See Chapter 6 
for details).
Several methods were used to interpret the flow cytometry data. An increase in 
fluorescence of the cell population can be estimated using two methods. Firstly, by 
measuring the increase in average fluorescence of the population using the mean, 
geometric mean or median. The second method involves analysis of the number of 
cells that have taken up the fluorescently labelled compound. In this instance control 
cells were compared to cells exposed to OG-labelled probe to account for 
background fluorescence. From this data, two regions were arbitrarily set (Figure 
2.7). Region M l corresponds to a region covering 98 % of the control population 
events, while M2 relates to any area with higher fluorescence than M l. As cell- 
associated fluorescence increases, so too does the number of events in the M2 region.
2.5 Statistical Analysis
Data were expressed as mean ± the error, calculated as either standard deviation 
(SD) or standard error of the mean (SEM), where appropriate. Statistical significance 
was set at p < 0.05 (indicated by *). Where only two groups were compared, 
student’s t-test for a small sample size was used. In situations where more than two 
groups were compared evaluation of significance was achieved using a one-way 
analysis of variance (ANOVA) followed by bonferroni post hoc tests that correct for
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Figure 2.7 Typical flow cytometry distribution. Region M l corresponds to a region 
covering 98 % of the control population events, while M2 relates to any area with higher 
fluorescence than M l.
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multiple comparisons. All statistical calculations were performed using GraphPad 
Prism, version 4.0c for Macintosh, 2005.
59
Chapter 3 Synthesis of Polymer-Trypsin Conjugates
Chapter Three
Synthesis and Characterisation ofHPMA Copolymer- and 
Dextrin-Trypsin Conjugates
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3.1 Introduction
To develop the concepts of polymer-PLA2 conjugates as (i) anti-cancer 
therapeutics, and (ii) triggers for PELT (see section 1.5.2) it was first necessary to 
optimise the methods to be used for polymer-protein conjugation. It was important to 
choose both an appropriate polymer and a conjugation chemistry that would be 
reproducible, and give the best yield. From the biological point of view, it was 
important to generate a stable conjugate that would retain enzymatic activity.
Furthermore, it is well known that conjugation of a polymer to a protein 
(particularly enzymes) can significantly improve biological efficacy in vivo by 
reducing proteolytic degradation, extension of plasma circulation time and by 
reducing protein immunogenicity (reviewed in Harris and Chess, 2003; reviewed in 
Roberts et al, 2002; reviewed in Sato, 2002; Werle and Bernkop-Schnurch, 2006). 
Many methods have been previously described for conjugation of proteins to 
polymers. Numerous polymers have been used to prepare such conjugates, and Table
1.1 summarises some polymer-enzyme conjugates described in the literature.
3.1.1 Choice of polymer
In these studies it was first necessary to consider which polymer would be best 
for PLA2 conjugation. Any polymer used must be non-toxic and non-immunogenic, 
contain suitable functionality for conjugation (using either a polymer with a single 
reactive group (e.g. mPEG (reviewed in Pasut et al, 2008)) or a multi-functional 
polymer (e.g. HPMA copolymer (Satchi-Fainaro et al, 2002) or dextrin (Hreczuk- 
Hirst et al, 2001b)). To design a polymer conjugate that would have the required 
stability, pharmacokinetic profile and pharmacological activity, features such as the 
polymer molecular weight, the linking chemistry, and the number of reactive groups 
on the polymer were considered.
The main polymers used clinically to synthesise polymer therapeutics have been 
introduced in Chapter 1 (sections 1.2.1 and 1.3) and they include PEG, dextran, 
PGA, HPMA copolymers and dextrin. Of these, dextrin and HPMA copolymers were 
selected for conjugation and they are described in more detail below.
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HPMA Copolymers
HPMA copolymers were chosen because they have already been used to prepare 
polymer therapeutics including polymer-anticancer drug conjugates, polymer-protein 
conjugates (reviewed in Duncan, 2005; reviewed in Duncan, 2006) and gene delivery 
systems (Oupicky et al, 2000). HPMA copolymers have already proven to be non­
toxic, non-immunogenic in patients (Vasey et al, 1999), and they can be synthesised 
to be either semi-telichelic (one functional group), or multi-functional. Many 
different linker chemistries have been used in HPMA copolymer conjugates 
(reviewed in Duncan, 2005; Kopecek, 1984). Peptide linkers have been most widely 
used to bind anti cancer agents, e.g. -Gly-Phe-Leu-Gly-, which is degraded by the 
lysosomal thiol-dependent proteases following uptake of the conjugate by 
endocytosis (Vasey et al, 1999). Typically, -Gly-Gly- linkers have been used to 
prepare HPMA copolymer-protein conjugates (Satchi-Fainaro et al, 2003). As PLA2 
is probably not required to enter the cell to exert its therapeutic effect, it was decided 
that lysosomal degradation of the linker was not important, and so -Gly-Gly- was a 
more appropriate linker group.
A frequently encountered problem with protein conjugation is the potential loss 
of biological activity; therefore, it is also of particular interest to consider the site of 
conjugation. This will be affected by the availability and reactivity of functional 
groups in the protein as well as the nature of reactive groups on the polymer. 
Reduced biological activity is often due to steric hindrance of the protein by the 
polymer chain, often as a result of covalent binding of the polymer in or close to the 
active site of the enzyme. It has been suggested that a 1:1 polymer-protein ratio may 
minimise loss of biological activity (Satchi, 1999) especially when non-degradable 
polymers (e.g. PEG, HPMA copolymers) are used. Use of biodegradable polymers 
(Duncan et al, 2008) or polymer-protein linkers (Pan et al, 2006) can circumvent this 
problem, for example dextrin, where degradation by a-amylase results in an 
unmasking effect. In the case of HPMA copolymer, however, a conjugation ratio of 
1:1 was aimed for, to also reduce the risk of cross-linking.
It is possible to conjugate a polymer to a protein using hydroxyl and thioether
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reactive groups, however these derivatised bonds tend to produce weaker linkages 
and the stability of the conjugate would be questionable. Therefore in these studies, 
HPMA copolymers containing a carboxylic acid were reacted with amine groups 
within the structure of trypsin, leading to the formation of a stable amide bond. 
Primarily, primary NH2 groups of lysine (pKa = 10.53) residues found on the surface 
of enzymes, arginine (pKa = 12.48), histidine (pKa = 6.10), as well as terminal NH2 
groups (pKa = ~ 9) are also able to react in this way.
Several approaches for HPMA copolymer-trypsin conjugation were explored in 
these studies using methods adapted from previous techniques described in the 
literature (see Figure 3.1 for reaction schemes). Conjugation typically involves a 
polymer analogous reaction using a polymer precursor containing a reactive leaving 
group that can be displaced by the protein (e.g. HPMA copolymer -ONp). Initially, 
non-specific aminolysis was investigated as this method had successfully been used 
previously to synthesise HPMA copolymer-cathepsin B and HPMA copolymer-p- 
lactamase conjugates (Satchi et al, 2001; Satchi-Fainaro et al, 2003) producing 
conjugates with a yield of 30-35 wt. %. However, as this method was not successful 
here, two further conjugation methods were investigated. These methods also used 
HPMA copolymer-ONp, but employed different reaction conditions that had been 
described for the synthesis of anti-O antibody- and transferrin-polymer conjugates 
(Kopececk et al, 1985b).
A final conjugation method was explored for HPMA copolymer-trypsin 
conjugation. This utilised the crosslinking agents EDC and sulfo-NHS. EDC reacts 
with the carboxyl groups of an HPMA copolymer-COOH intermediate, forming an 
amine-reactive O-acylisourea intermediate. This can then react with the amine of 
lysine residues in a protein, to give a conjugate joined by a stable amide bond. 
However, EDC alone is not particularly efficient. Failure to react quickly with an 
amine results in hydrolysis and regeneration of the carboxyl, making it unstable and 
short-lived in aqueous solution. The addition of sulfo-NHS stabilises the amine- 
reactive intermediate by converting it to an amine-reactive sulfo-NHS ester, thus 
increasing the efficiency of EDC-mediated coupling reactions. The amine-reactive
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a) 4 °C, dark (8 h)
pH 7.2 -  8.5, by addition of tetraborate buffer (30 min)
b) 0.5 mL HCI (pH 3.0)
0.6 mL Sorensen’s buffer (pH 8.0, 0.15 M NaCI)
c) 20 0 C (75 min)
0.25 mL HCI (pH 3.0)
1.25 mL Sorensen’s buffer (pH 8.0, 0.1 M NaCI)
d) Hydrolysis of HPMA copolymer-Gly-Gly-ONp:
NaOH (0.1 M, 10 eq.), ddH20, 4-5 h 
Conjugation of trypsin:
20 °C, EDC (10 min), sulfo-NHS (45 min)
18 h, pH 8
Figure 3.1 Schematic of reaction to conjugate trypsin to HPMA copolymer-Gly- 
Gly-ONp. Reaction conditions tested in these studies are given. Where m and n are 
reaction products, x is a side product that occurs by hydrolysis of HPMA copolymer- 
Gly-Gly-COOH.
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sulfo-NHS ester intermediate has sufficient stability to permit two-step crosslinking 
procedures, which allows the carboxyl groups on the protein to remain unaltered.
Dextrin
A number of other naturally occurring polymers, such as dextran (Vercauteren et 
al, 1990; Vercauteren et al, 1992) and PGA (Singer et al, 2003) are inherently 
biodegradable, low levels of chemical modification results in the generation of non- 
degradable adducts. In addition, some natural polymers are not suitable for repeated 
administration due to their immunogenicity (Bisaccia et al, 2007).
Dextrin was chosen as a suitable polymer for protein conjugation as it has 
proven biocompatibility and clinical tolerability. It is routinely used in the clinic as a 
peritoneal dialysis solution (Peers and Gokal, 1998) and also has been developed as a 
carrier solution for intraperitoneal administration of 5-fluorouracil (Kerr et al, 1996). 
Unlike HPMA copolymers, which are not biodegradable, dextrin has the advantage 
of elimination by a-amylase degradation to give maltose and isomaltose.
The PUMPT concept has recently been coined by Duncan et al (2008) using 
dextrin as the model polymer. The hypothesis was that conjugation of a 
biodegradable polymer to a biologically active protein can mask activity and enhance 
stability in the bloodstream, while subsequent regeneration of activity can be 
achieved by triggered degradation of the polymer at the target site. A detailed 
description of this concept is given in Chapter 4.
Since dextrin doesn’t contain a convenient amine or carboxy group for protein 
conjugation, functionalisation has, in the past, been achieved using several methods. 
For example, cyanogen bromide activation (Costa and Reis, 2004), chloroformate 
activation (Bruneel and Schacht, 1993b), periodate oxidation (Bruneel and Schacht, 
1993a) and succinoylation (Bruneel and Schacht, 1994). These activation techniques 
are summarised in Table 3.1. However, since the reagents for succinoylation are 
relatively non-toxic, the synthesis of dextrin-protein conjugates has typically used 
activation of the polymer by incorporation of functional groups by succinoylation, 
which can react directly with the trypsin (Hreczuk-Hirst et al, 2001a; Hreczuk-Hirst 
et al, 2001b).
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Table 3.1 Methods of polysaccharide activation by introducing pendant groups. 
Activation method Method overview Disadvantages Example
polysaccharides
Cyanogen bromide activation
Chloroformate activation
Periodate oxidation
Succinoylation
Primary amine groups are Reactive intermediates Hyaluronate (Mlcochova
introduced directly into produced during activation of et al, 2006) 
reactive intermediate, under hydroxyl group can disrupt Starch (Costa and Reis, 
aqueous conditions at room polymer backbone 2004)
temperature Hydrogen cyanide is toxic and
must be carefully removed 
Linkage is not stable, resulting 
in slow release of pendant 
group
Introduces hydroxyl groups Possibility of formation of Cellulose (Rupprich et al, 
within the polymer intra- or inter-chain carbonate 1990)
esters Dextran (Chiu et al, 1999)
Formation of five-member 
rings can interfere with polymer 
backbone
Formation of an aldehyde Aldehyde groups canlead to Dextran (Devakumar and
group by oxidation of 1,2-diol toxicity if not completely Mookambeswaran, 2007)
groups neutralised Mannan (Ramirez et al,
2006)
Uses succinic anhydride to Starch (Lawal, 2004),
introduce a carboxyl group Chitosan (Kato et al,
without disrupting polymer 2004)
backbone
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Succinoylation has been used to modify pullulan (Bruneel and Schacht, 1994) 
and pullulan was reacted with succinic anhydride in DMSO, using DMAP as a 
catalyst. Hreczuk-Hirst et al (2001a) optimised dextrin succinoylation with respect to 
temperature and reaction time. They concluded 50 °C with a minimum of 8 h 
reaction time to be optimal for dextrin succinoylation. Using these conditions it was 
possible to reproducibly succinoylate dextrin with a coefficient of variation of < 10 
% and a yield of ~ 50 %. Further, it was demonstrated that different degrees of 
dextrin succinoylation (0.5 - 30 mol %) could be achieved by variation of the 
reactant ratios, and that the rate of a-amylase degradation of succinoylated dextrins 
could be prolonged by increasing the degree of modification to the polymer 
(Hreczuk-Hirst et a l, 2001a). As dextrin is normally degraded in the body very 
quickly by a-amylase (t1/2 < 1 0  min) this fundamental study suggested the potential 
of controlling the rate of dextrin degradation by tailoring backbone modification. 
This approach made dextrin a more practical polymer for use in targeted drug 
delivery and also for use in protein modification in the context of PUMPT.
Hreczuk-Hirst et al (2001b) also developed the conjugation chemistry 
techniques for coupling drugs and other amino-group containing compounds. Gilbert 
et al (2005) subsequently applied this methodology to the preparation of dextrin- 
trypsin conjugates. EDC and sulfo-NHS were used as linking agents and first studies 
investigated the effect of dextrin molecular weight (comparing 7,700 and 47,200 
g/mol) and degree of succinoylation on enzyme activity and ability to regenerate 
enzyme activity in the presence of a-amylase (Gilbert et al, 2005). It was concluded 
that the higher molecular weight dextrin (47,200 g/mol) with ~ 25 mol % 
succinoylation achieved the optimal trypsin masking and then allowed unmasking. 
The same reaction conditions were therefore chosen for these studies.
In summary, HPMA copolymer was selected for conjugation because it has the 
advantages of a narrow polydispersity (usually 1.3 -  1.5), it has been previously used 
for protein modification, and the loading of protein can be controlled.
On the other hand, dextrin was chosen because, while it has a higher 
polydispersity index than HPMA copolymers (> 2.0), its a-amylase-triggered 
degradation lends it to masking protein activity and subsequent reinstatement of
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activity by unmasking (PUMPT concept described in detail in Chapter 4). However, 
unlike HPMA copolymer, dextrin requires chemical modification to introduce 
reactive groups for protein conjugation.
3.1.2 Selection of trypsin and analysis of enzyme kinetics
Trypsin was chosen as a model enzyme for the first conjugate studies since it is 
a well-characterised enzyme (Johnson et al, 2002) and many polymer-trypsin 
conjugates had been described in the literature (Table 1.2) so it was easy to make 
comparisons. Additionally, as outlined in Chapter 1 trypsin has a similar molecular 
weight, number of lysine residues and pi to PLA2, making it a good choice for 
optimisation of the conjugation reaction. Trypsin preferentially cleaves peptides on 
the c-terminal side of arginine and lysine amino acid residues. Its activity can also be 
reproducibly assayed using synthetic derivatives of amino acids such as BAEE, p- 
toluenesulfonyl-L-arginine methyl ester (TAME), L-BAPNA (Buck et al, 1962; 
Kell, 1971) so comparisons can be easily made between the activity free and 
conjugated trypsin.
In order to quantify the activity of free and polymer-bound trypsin and allow 
comparisons between experimental conditions, a direct continuous assay was used. 
L-BAPNA was chosen as a chromogenic substrate. Incubation of L-BAPNA with 
trypsin results in the release of NAp, which is not coloured when bound but yields a 
yellow-coloured product when released that can be measured spectrophotometrically. 
Mathematical analysis of the initial rate of release can be used to establish classical 
enzyme kinetics parameters, namely Vmax, K™ and K^.
• Vmax represents the maximum rate for the reaction.
• Km corresponds to the affinity of the enzyme for the substrate and denotes 
the substrate concentration required for effective catalysis.
• K ^, also known as the turnover number, is a measure of the number of 
substrate molecules turned over by each enzyme, per second.
These parameters are based on the Michaelis-Menten equation:
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V (velocity) = KJE1/S1 = K2[ES]
(K* [S])
K, K2
Where E + S< ► ES------------^ E  + P
K,
[E]t = total enzyme, [E] = free enzyme, [ES] = complexed enzyme
This equation assumes that the reverse reaction is negligible, resulting in a 
simple, first-order reaction, whose rate is determined by [ES] and K2. Briggs and 
Haldane (1925) noted that [ES] increases rapidly after initiation of the reaction by 
mixing of enzyme and substrate. However, after a short while, steady state is reached 
and maintained until almost all the substrate is consumed (Eisenthal and Danson, 
1998). Steady state occurs when [ES] is almost constant.
Enzyme kinetic data may be analysed by several mathematical models. The first 
of these is the Lineweaver-Burk plot (Figure 3.2a) which is derived from the inverse 
of the Michaelis-Menten equation. For a reaction obeying Michaelis-Menten 
kinetics, the fit should yield a straight line. The advantage of this model is that it 
doesn’t require a direct measurement of Vmax. However, it requires a long 
extrapolation for the determination of K,,,, which gives rise to inaccuracies if there 
are significant experimental errors. Hence, this equation is not normally 
recommended for the determination of kinetic parameters.
The Eadie Hofstee plot is shown in Figure 3.2b. However, this model is also 
poorly able to handle data containing significant experimental error. The inaccuracy 
of the Eadie Hofstee plot is not as severe as for the Lineweaver-Burk plot, and is 
considered to be a more reliable method (Cornish-Bowden, 2004). Furthermore, in 
this case the horizontal axis is not truly independent of the vertical axis as the values 
contain an element of the reaction rate. Therefore, any error in the experiment will 
affect both axes.
A third model for analysing kinetic data utilises the Hanes-Woolfe plot. This is 
shown in Figure 3.2c. This plot has less scatter as the two axes are completely 
independent of each other. For this reason, the Hanes-Woolfe plot was selected here 
to estimate trypsin kinetic constants.
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Figure 3.2 Enzyme kinetics models for data interpretation, based on the Michaelis- 
Menten equation. Panel (a) Lineweaver-Burk plot, (b) Eadie-Hofstee plot, and (c) 
Hanes-Woolfe plot.
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3.1.3 Experimental aims
The aims of this study were to:
• Try to optimise methods for conjugation of
o HPMA copolymer-Gly-Gly (5 mol %) -ONp, 
o HPMA copolymer-Gly-Gly (5 mol %) -COOH, and 
o succinoylated dextrin to trypsin
• Establish methods for characterising the polymer-protein conjugates 
proposed, with respect to:
o total protein content (BCA assay) 
o free protein content (FPLC, SDS PAGE)
o molecular weight and molecular weight distribution (GPC, FPLC and 
SDS PAGE)
• Set up a biological assay to investigate the retention of trypsin activity 
following polymer conjugation
3.2 Methods
A number of general methods (Chapter 2) were used for characterisation of the 
polymer-trypsin conjugates synthesised; BCA assay (section 2.4.4.3), SDS PAGE 
(section 2.4.4.2), FPLC and GPC (section 2.4.4.1). In addition, the trypsin NH2 
groups were quantified using the ninhydrin (section 2.4.1) and TNBS assays (section
2.4.2) as described in Chapter 2.
3.2.1 Synthesis of HPMA copolymer-trypsin conjugates
First, the extinction coefficient (e) of ONp was calculated in all the solvents used 
to explore the aminolysis reaction; ddH20 , DMSO and DMF. Samples of ONp (5-30 
pg/mL) were prepared in each solvent (1 mL) and added to a quartz cuvette. A UV 
scan was made between 200 nm and 500 nm. The value of e was derived from the 
gradient of a calibration curve of ONp concentration vs. maximum absorbance at ~ 
320 nm.
In addition, it was necessary to determine the stability of HPMA copolymer- 
Gly-Gly-ONp in the different solvents that would be used for the aminolysis reaction
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(ddH20 , PBS buffer, DMSO and DMF). Solutions of HPMA copolymer-GIy-Gly- 
ONp (1 mL, 1 mg/mL) were made up in each solvent and ONp release was 
monitored spectrophotometrically at 400 nm over 30 min.
To synthesise HPMA copolymer-trypsin conjugates four different conjugation 
methods were explored. These are described in detail below.
a) Synthesis o f HPMA copolymer-Gly-Gly-trypsin using aminolysis
Initially, a non-specific aminolysis reaction was investigated using the method 
described earlier for cathepsin B and p-lactamase conjugation to HPMA copolymer- 
Gly-Gly-ONp (Satchi et al, 2001; Satchi-Fainaro et al, 2003) (Figure 3.1a).
Briefly, HPMA copolymer-Gly-Gly-ONp (40 mg) was dissolved in ddHzO (20 
mL) in a 100 mL round-bottomed flask and trypsin (81 mg) in 0.05 M phosphate 
buffer (pH 7.2,40.5 mL) was added at 4 °C, under stirring. This mixture was stirred 
for 30 min in the dark at pH 7.2. Then the pH was increased over 4 h by the addition 
of saturated sodium tetraborate buffer to obtain a pH of 8.5. This helped to prevent 
enzyme denaturation. The mixture was then stirred for a further 4 h and the reaction 
was terminated by addition of D,L-amino-2-propanol (0.5 eq. of ONp groups). Next, 
the solution was acidified to pH 7.2 with 0.1 M HCI, and was dialysed (molecular 
weight cut-off 25,000 g/mol) against 5 L of ddHzO with ~ 8 water changes, with 1-2 
h between each. The contents of the dialysis sac were then collected and freeze-dried 
for 2 days.
Reaction of HPMA copolymer-Gly-Gly-ONp copolymer with trypsin by 
aminolysis was initially followed by UV to monitor ONp release. This was possible 
as there is a difference in UV maximum absorption of bound (270 nm) and free (400 
nm) ONp. After termination of the reaction, the crude reaction products were 
analysed by SDS PAGE and GPC to determine the reaction yield.
b) Conjugation o f HPMA copolymer-Gly-Gly-ONp to trypsin according to anti-0 
antibody-polymer method (Kopecek et al, 1985b)
The procedure is summarised in Figure 3.1b. Briefly, HPMA copolymer-Gly- 
Gly-ONp (77 mg) was dissolved at 5 °C in diluted hydrochloric acid (0.5 mL, pH
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3.0). Sorensen’s buffer (0.6 mL, pH 8.0) containing 0.15 M NaCI was then added 
followed by the dropwise addition of trypsin solution (0.67 mL, containing 39.5 mg 
trypsin) in the same buffer. The reaction was allowed to proceed for 30 min at 5 °C. 
During the following 30 min the temperature was gradually increased to 20 °C. (At 
the beginning of the reaction the molar ratio of reactive groups ONp: NH2 =1:1 and 
the concentration of macromolecules was 6.6 % wt.). After 1 h a solution of D-L- 
amino-2-propanol in 0.2 mL Sorensen’s buffer (10 % v/v, 0.2 mL, pH 8.0) 
containing NaCI (0.15 M) was added. After 10 min the reaction mixture was 
transferred into a visking dialysis tubing and dialysed against phosphate buffered 
saline (pH 7.2).
c) Conjugation o f HPMA copolymer-Gly-Gly-ONp to trypsin according to 
transferrin-polymer method (Kopecek et al, 1985b)
The method is summarised in Figure 3.1c. HPMA copolymer-Gly-Gly-ONp 
(27.4 mg) was dissolved in diluted hydrochloric acid (0.25 mL, pH 3.0). Sorensen’s 
buffer (1.25 mL, pH 8.0) containing NaCI (0.1 M) was then added followed by a 
solution of trypsin (0.5 mL, 28.4 mg/mL) of the same buffer. After 45 min, D-L- 
amino-2-propanol dissolved in Sorensen’s buffer (200 pL, 50 pL/mL) was added to 
the mixture. After 30 min the reaction was stopped and transferred to visking dialysis 
tubing and dialysed against phosphate buffered saline (pH 7.2).
d) Conjugation o f HPMA copolymer-Gly-Gly-COOH to trypsin with EDC! sulfo- 
NHS
First, HPMA copolymer-Gly-Gly-ONp was hydrolysed to HPMA copolymer- 
Gly-Gly-COOH. HPMA copolymer-Gly-Gly-ONp (~ 100 mg) was dissolved in 
ddH20  and 10 molar eq. of a solution of NaOH (0.1 M) was added and stirred for 4-5 
h at room temperature. The resultant product was then dialysed (molecular weight 
cut-off 2,000 g/mol) to remove free ONp in 5 L of ddH20  for ~ 8 water changes, 
allowing 1-2 h between water changes. The product was then isolated and freeze- 
dried for 2 days.
This procedure is summarised in Figure 3.Id. Next, the HPMA copolymer-Gly-
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Gly-COOH (~ 10 mg) was dissolved in ddHzO (1 mL) in a 25 mL round-bottomed 
flask. EDC (range between 10-30 eq.) was added to the reaction mixture under 
stirring, and the mixture was left to stir for 10 min. Then sulfo-NHS was added 
(concentration range between 10-30 eq.) and the mixture was stirred for 40 min. 
Next, trypsin was added as an aqueous solution (1 trypsin: 2 COOH groups). The pH 
was adjusted to ~ 8 by dropwise addition of NaOH (0.1 M) solution, and the mixture 
left stirring for 18 h at room temperature. After 18 h, the mixture was dialysed 
(molecular weight cut-off 25,000 g/mol) in ddH20  for ~ 8 water changes. The 
contents of the dialysis sac were then freeze-dried for 2 days.
3.2.2 Synthesis of dextrin-trypsin conjugates
First, succinoylated dextrin was synthesised according to the method of 
Hreczuk-Hirst et al (2001b) as summarised in Figure 3.3a.
Briefly, dextrin (100 mg) was dissolved in anhydrous DMF (10 mL) in a 50 mL 
round bottom flask. Succinic anhydride (37 mg) and DMAP (16 mg) were 
subsequently added to the flask. The reaction mixture was then purged with nitrogen, 
sealed and left to stir at 50 °C for 18 h. Next, the reaction mixture was poured into 
vigorously stirring diethyl ether (250 mL) and stirred overnight. The ether was 
removed by filtration under vacuum and the residual solid was dissolved in minimal 
ddH20 ,  poured into a dialysis membrane (molecular weight cut-off 10,000 g/mol) 
and dialysed against 4 x 5 L ddH20 . The resultant solution was freeze-dried to yield 
succinoylated dextrin.
The degree of succinoylation was quantified by titration against a standard 
solution of NaOH (4.925 x 10'5 M) with bromophenol blue as indicator. The product 
was further characterised by FT-IR, *H-NMR and 13C-NMR.
To conjugate succinoylated dextrin to trypsin (Figure 3.3b), succinoylated 
dextrin (117 mg, 1.50 x 10‘2 mol COOH) and EDC (16 mg) were dissolved in ddH20  
(2 mL). After 10 min, sulfo-NHS (17 mg) was added under stirring and allowed to 
react for 40 min at room temperature. Trypsin (30 mg, 1.25 x 10"4 mol) was added 
and sufficient NaOH (0.1 M) was added to bring the reaction mixture to pH 8.0 (this
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Figure 3.3 Reaction scheme for (a) succinoylation of dextrin, and (b) conjugation of 
succinoylated dextrin to trypsin.
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helps reduce risk of enzyme denaturation). This mixture was subsequently allowed 
to stir overnight at room temperature. Free enzyme was removed by dialysis 
(molecular weight cut-off 50,000 g/mol) against 8 x 5 L ddH20 . The product was 
freeze-dried.
3.2.3 Assay of trypsin activity using L-BAPNA
First, it was necessary to determine if any of the components of the assay would 
interfere with the absorbance of NAp at 400 nm. Consequently, the UV-vis 
absorbance of HPMA copolymer-Gly-Gly-COOH (lmg/mL), dextrin (lmg/mL), 
succinoylated dextrin (1 mg/mL), trypsin (1 mg/mL), dextrin-trypsin conjugate (1 
mg/mL), L-BAPNA (0.644 mM) and Tris buffer (40 mM Tris, 16 mM CaCl, pH 8.2) 
was measured over 200-500 nm.
Measurement o f trypsin activity
The activity of trypsin (1.28 x 10*4 mM and 8.55 x 10‘5 mM) in Tris buffer (pH
8.2) at 37 °C was measured using L-BAPNA. eNAp was taken to be 8,800 L/mol/cm 
(Johnson et al, 2002).
First, a solution of trypsin in Tris buffer (0.1 mg/mL) was prepared fresh daily 
and stored on ice throughout the experiments. Next, a solution of L-BAPNA (7 
mg/mL in DMSO) was prepared. The UV spectrophotometer was set to 400 nm and 
37 °C and the machine allowed to equilibrate for 30 min. The required volume of 
substrate (10-60 pL) was pipetted into a quartz cell (1 cm3) and made up to 980 or 
970 pL with Tris buffer (pH 8.2). A blank cell was also prepared containing L- 
BAPNA (0.081-0.644 mM in DMSO) in Tris buffer (pH 8.2). To start the assay, 
cuvettes were loaded into the UV spectrophotometer, trypsin (20 or 30 pL of 0.1 
mg/mL to make up to 1 mL) was added to the sample cuvette, and the rate of NAp 
release at 400 nm was monitored over 10 min at 37 °C. Each substrate concentration 
(L-BAPNA) was measured in triplicate, so that an average could be calculated.
The data was analysed using the Hanes-Woolfe plot (section 3.1.2).
Measurement o f polymer-trypsin conjugate activity
In order to assess the retention of trypsin activity following polymer
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conjugation, the conjugates were also analysed using the L-BAPNA assay described 
here. Using the trypsin content of the conjugate, determined by the BCA assay, 
solutions of polymer-trypsin conjugate were prepared to contain 1.28 x 10-4 mM 
trypsin eq.. The activity of the conjugate was then assessed against the substrate L- 
BAPNA (0.081-0.644 mM in DMSO) as above. Conjugate activity was expressed as 
a percentage of the activity of free trypsin. The kinetics rate constants were also 
assessed using the Hanes-Woolfe plot (section 3.1.2).
3.3 Results
The extinction coefficients estimated for ONp in ddH20 ,  DMSO and DMF were 
calculated using the Beer-Lambert law, the values obtained were: ddHzO e318 nm = 
10,307 L/mol/cm, DMSO e323 nm = 9,501 L/mol/cm, and DMF e318 = 11,675
L/mol/cm (Figure 3.4).
The release of ONp from HPMA copolymer-Gly-Gly-ONp precurser in aqueous 
(ddH20 , PBS buffer) and organic (DMSO, DMF) solvents was monitored by UV 
spectroscopy (Figure 3.5). There was little release observed in ddHzO, DMF, and 
DMSO, but there was a rapid release of ONp by hydrolysis in PBS buffer.
33.1 Synthesis and characterisation of HPMA copolymer-Gly-Gly-trypsin 
conjugates
The ninhydrin assay indicated that trypsin had 12.1 ±3.7  (SD) NH2 groups per 
molecule. This figure (12), which also includes terminal amine groups and several 
other NH-containing amino acids (arginine, histidine), was used to calculate molar 
ratio of trypsin to succinoylated dextrin (NH2 : COOH) for all conjugation reactions 
and not the total number of lysine groups in trypsin (10).
HPMA copolymer-Gly-Gly-trypsin conjugate: Cathepsin B method
Initially, when the methods of Satchi et al (2001) (section 3.2.1a) were used to 
react HPMA copolymer-Gly-Gly-ONp with trypsin in aqueous medium, conjugation 
was not achieved. Later, this was repeated with varying reaction conditions and ratio 
of trypsin: polymer in an attempt to improve the conjugation. However, still SDS 
PAGE showed only a band for free trypsin (MW ~ 20,000 g/mol), suggesting that no
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Figure 3.4 UV absorption spectra of ONp. Panel (a) in DMSO (Xmax = 323 nm), panel 
(b) in ddH20  (Xmax = 318 nm),and (c) in DMF (Xmax = 318 nm). Panel (d) shows a 
calibration curve for ONp in ddHzO, DMSO, and DMF. Data shown represents n = l.
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Figure 3 3  Stability of HPMA copolymer-Gly-Gly-ONp during incubation in 
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PBS buffer. Panel (e) shows release of ONp over time. All at 1 mg/mL, recorded every 5 
min for 40 min. % bound ONp calculated from peak absorbance at 280 nm. Data shown 
represents n = l.
79
Chapter 3 Synthesis of Polymer-Trypsin Conjugates
conjugation was achieved (Figure 3.6, lanes 3-12). Even altering the rate of addition 
of saturated borate buffer did not improve reaction efficiency. The reaction 
conditions explored are summarised in Table 3.2.
FPLC was used to better characterise these reactions. First, the FPLC was first 
calibrated using protein standards (Figure 2.2). Then samples of reaction mixtures 
were analysed. It was noted that the elution profile for unconjugated trypsin was 
complicated by some contamination with smaller molecular weight peptides (Figure 
3.7). This was also observed in the SDS PAGE gels (Figure 3.6, lane 2). However, 
there was a pronounced peak at ~ 12 mL, corresponding to trypsin and, even after 
purification of the trypsin by PD-10 column (results not shown), there was no 
noticeable polymer conjugation and the reaction mixtures showed only a peak 
appearing at the same elution volume as free trypsin (~ 12 mL) (data not shown).
HPMA copolymer-Gly-Gly-trypsin conjugate: Anti-O antibody and transferrin 
methods
When conjugation was attempted using the methods described by Kopecek et al 
(1985b) (section 3.2.1b and 3.2.1c), SDS PAGE began to show a faint smearing 
indicative of a HPMA copolymer-Gly-Gly-trypsin conjugate. However, there was 
also a strong band corresponding to free trypsin (Figure 3.8, lanes 3-6). GPC also 
showed some evidence of conjugation (Figure 3.9) but there remained a very large 
amount of free trypsin present in conjugates synthesised using both of these methods. 
Further purification by dialysis resulted in a very low yield of conjugate (Figure 3.8 
and 3.9). Therefore, conjugates synthesised using this method were not progressed to 
biological testing.
HPMA copolymer-Gly-Gly-COOH: Use ofEDC and sulfo-NHS
When EDC and sulfo-NHS were used to conjugate trypsin to HPMA copolymer- 
Gly-Gly-COOH (section 3.2.1.d) SDS PAGE (Figures 3.10 (lane 3)) of the reaction 
mixtures showed a dark smearing down the sample lane indicating that a polymer- 
protein conjugate had been successfully synthesised. However, there was also a clear 
band of free trypsin. FPLC confirmed conjugate synthesis (peak at ~ 8 mL) but there
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Figure 3.6 SDS PAGE of HPMA copolymer-Gly-Gly-trypsin conjugates prepared 
according to method described in 3.2.1a. Where MWM = molecular weight marker 
and EF## = attempts to synthesise HPMA copolymer-trypsin under different reaction 
conditions (detailed in Table 3.2).
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Table 32 Examples of variables examined in the synthesis of HPMA copolymer-Gly-Gly-trypsin conjugates.
Batch
no.
HPMA: trypsin 
(weight ratio)
HPMA copolymer 
solution (2 
mg/mL)
Trypsin 
solution (2 
mg/mL)
Reaction conditions
EFla 1:1 1 mL 1 mL Increase pH to 8.5 (borate buffer) over 4 h. 
Reaction time = 4 h at 4 °C
EFlb 1:1 1 mL 1 mL Increase pH to 8.5 (borate buffer) at start of reaction. 
Reaction time = 4 h at 4 °C
EF2a 1:2 1 mL 2 mL Increase pH to 8.5 (borate buffer) over 4 h. 
Reaction time = 4 h at 4 °C
EF2b 1:2 1 mL 2 mL Increase pH to 8.5 (borate buffer) at start of reaction. 
Reaction time = 4 h at 4 °C
EF3a 1:3 1 mL 3 mL Increase pH to 8.5 (borate buffer) over 4 h. 
Reaction time = 4 h at 4 °C
EF3b 1:3 1 mL 3 mL Increase pH to 8.5 (borate buffer) at start of reaction. 
Reaction time = 4 h at 4 °C
EF4a 2:1 2 mL 1 mL Increase pH to 8.5 (borate buffer) over 4 h. 
Reaction time = 4 h at 4 °C
EF4b 2:1 2 mL 1 mL Increase pH to 8.5 (borate buffer) at start of reaction. 
Reaction time = 4 h at 4 °C
EF5a 3:1 3 mL 1 mL Increase pH to 8.5 (borate buffer) over 4 h. 
Reaction time = 4 h at 4 °C
EF5b 3:1 3 mL 1 mL Increase pH to 8.5 (borate buffer) at start of reaction. 
Reaction time = 4 h at 4 °C
50 pL taken at t=0 min, 0.1 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h (frozen immediately for SDS PAGE analysis) 
5 j.iL taken at t=0 min, 0.1 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h (analysed in UV spectrophotometer)
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Figure 3.7 FPLC analysis of free trypsin. Where a) trypsin. V0 = void volume (7.7 
mL), and Vb = bed volume (24 mL). UV absorbance taken at 280 nm.
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Figure 3.8 SDS PAGE analysis of free and bound trypsin, purified by dialysis.
Method b = anti-O antibody method (described in 3.2.1b), method c = transferrin method 
(described in 3.2.1c). Where a) trypsin, and b) HPMA copolymer-Gly-Gly-trypsin. 
MWM = molecular weight marker.
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Figure 3.9 Characterisation by GPC of HPMA copolymer-Gly-Gly-trypsin 
conjugates. Panel (a) shows the GPC trace of HPMA copolymer-Gly-Gly-trypsin 
conjugates prepared using method b = anti-O antibody method (described in 3.2.1b), and 
panel (b) shows conjugates synthesised using method c = transferrin method (described 
in 3.2.1c). Molecular weight given is relative to pullulan standards. V0 = void volume 
(13 mL), and Vb = bed volume (20 mL).
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marker.
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was also a large amount of free trypsin (peak at ~ 12 mL) (Figure 3.11a).
Even when experiments were performed to try and optimise the ratios of 
coupling agents to get a better conjugate yield, analysis by SDS PAGE and GPC also 
revealed no improvement in conjugation efficiency (Figure 3.12a).
The HPMA copolymer-Gly-Gly-trypsin conjugates synthesised in this way had a 
total trypsin content of 59 - 84 % w/w (HPMA copolymer-Gly-Gly-COOH showed 
minimal interference with the BCA assay) and in the final purified batch there was < 
2 % w/w free trypsin.
The characteristics of the HPMA copolymer-trypsin conjugates synthesised here 
are summarised in Table 3.3. However, after removal of unreacted trypsin, the yield 
was so low that HPMA copolymer conjugates were not progressed further.
3.3.2 Synthesis and characterisation of dextrin-trypsin conjugates
When dextrin (51,000 g/mol) was succinoylated, the degree of modification was 
confirmed by titration to be 17 - 23 mol %. Typically, the reaction conversion 
efficiency for succinoylation was ~ 30 - 40 % of the theoretical maximum. A 
summary of the batches of succinoylated dextrins produced for these studies is 
shown in Table 3.4.
GPC using pullulan standards suggested an increase in dextrin molecular weight 
following succinoylation (MW increase from 60,455 to 73,802 g/mol) with little 
change in polydispersity. Characterisation of succinoylated dextrins by FT-IR 
(Figure 3.13a) showed characteristic peaks at 3,350 (OH), 1,723 (ester), 1,630 
(carboxyl) and 1,020 cm'1 (0-CH2). After succinoylation, the ester peak at 1,723 cm'1 
was seen to increase in signal strength in relation to degree of modification. When 
NMR was used to analyse succinoylated dextrin, !H-NMR demonstrated peaks at 2.8 
ppm, which can be assigned to aliphatic carbons that are not present in unreacted 
dextrin (Figure 3.13b). 13C-NMR also showed the presence of two aliphatic carbons 
(30 ppm) (Figure 3.13c).
When the succinoylated dextrin intermediate was conjugated to trypsin using
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Figure 3.11 FPLC analysis of free and conjugated trypsin. Panel (a) shows 
characterisation of HPMA copolymer-Gly-Gly-trypsin conjugates, and panel (b) shows 
dextrin-trypsin conjugates. Polymer-trypsin conjugates were prepared using EDC and 
sulfo-NHS as linking agents. V0 = void volume (7.7 mL), and Vb = bed volume (24 mL). 
UV absorbance taken at 280 nm.
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Table 3 3  Summary of the biological characteristics of free trypsin and the polymer-trypsin conjugates.
Polymer Characteristics Protein Content 
(% )
Activity
(% )
K ,
(mM)
VT max
(mM/min)
i^ c it
(s1)
Trypsin 23,400 g/mol 100 100 0.666 0.048 6.24
HPMA copolymer ~ 30,000 g/mol, 5 mol % -Gly-Gly- 
10 eq. EDC and sulfo-NHS 84.1 31.9 0.430 0.015 1.99
20 eq. EDC and sulfo-NHS 74.5 24.4 0.523 0.012 1.52
30 eq. EDC and sulfo-NHS 59.4 32.7 0.329 0.016 2.04
Dextrin ~ 51,000 g/mol, 20-25 mol % succinoylated 
10 eq. EDC and sulfo-NHS 41.7 30.1 0.371 0.015 1.88
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Table 3.4 Characteristics of batches of succinoylated dextrin, and their uses.
Name Batch size 
(mg)
Theoretical 
(mol %)
Actual 
(mol %)
Conversion
(%)
Uses
Efdexl 200 60 16.8 27.9 Dextrin-trypsin
Efdex2 1000 60 23.2 38.7 Dextrin-PLA2 (batches DexPLAl, DexPLA2)
Efdex3 1000 60 23.3 37.1 Dextrin-PLA2 (batches DexPLA3, DexPLA4)
EFdex4 1000 60 19.4 33.3 MTT of S.dextrin, haemolysis of S.dextrin
EFdex5 1000 60 20.9 34.8 Dextrin-PLA2 (batches DexPLA5, DexPLA7)
EFdex6 1000 60 22.3 37.2 Dextrin-OG, dextrin-PLA2 (DexPLA6)
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Figure 3.13 Characterisation by FT-IR and NMR of succinoylated dextrin. Panel (a) 
shows an FT-IR spectra illustrating the increase in peak intensity at 1720 cm'1(’i‘) when 
succinoyl ester groups are incorporated into dextrin. Also shown are (b) *H and (c) 13C 
NMR spectra of dextrin and succinoylated dextrin (inserted panel).
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EDC and sulfo-NHS, SDS PAGE confirmed the presence of a high molecular weight 
conjugate with dark smearing appearing between ~ 50,000 - 194,000 g/mol 
(corresponding to polydisperse conjugate). There was also a band at ~ 20,000 g/mol 
corresponding to free trypsin (Figure 3.10, lane 4). Similarly, FPLC showed a peak 
corresponding to dextrin-trypsin conjugate in the region of the column’s V0 (7.7 
mL), with a second peak (~ 13 mL) corresponding to free trypsin (Figure 3.11b). 
Final confirmation of successful conjugation was achieved using GPC, where 
retention time was reduced for the dextrin-conjugate (~ 14.2 min), compared to free 
trypsin (~ 18.5 min) (Figure 3.12b). Following purification by dialysis, this method 
produced conjugates with a higher yield than was seen with HPMA copolymer-Gly- 
Gly-trypsin, and <5 % free trypsin.The dextrin-trypsin conjugates contained~42 % 
w/w trypsin (Table 3.3). As with HPMA copolymer-Gly-Gly-COOH, dextrin was 
shown to cause minimal interference (< 2 %) in the absorbance of the BCA assay 
(data not shown).
The successful synthesis of a dextrin-trypsin conjugate led this conjugate to 
progression to biological testing.
3.33 Trypsin activity of free and polymer-conjugated enzyme
When the absorbance of dextrin, succinoylated dextrin, trypsin, dextrin-trypsin, 
L-BAPNA and Tris buffer was analysed by UV-vis, no absorbance was seen at 400 
nm, and therefore a control cell of Tris buffer containing L-BAPNA (0-0.644 mM in 
DMSO) was used to allow for background absorbance.
Activity o f free trypsin
Trypsin activity was measured at two concentrations of enzyme (1.28 x lO"4 mM 
and 8.55 x 10'5 mM) in order to determine the most appropriate enzyme 
concentration to use when testing polymer-trypsin conjugates as well assessing the 
reproducibility of the assay. In both cases, the rate of NAp release when substrate 
was incubated with native trypsin increased as L-BAPNA concentration was 
increased (Figures 3.14 and 3.15). In addition, an initial linear rate of NAp release 
was observed using both concentrations. When investigating the effect of pH,
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Figure 3.14 Activity of trypsin (8.55 x 10'5 mM) against the substrate L-BAPNA.
Progress curves in panel (a) show the UV absorbance (400 nm) of NAp release from L- 
BAPNA by trypsin (8.55 x 10'5 mM) over 10 min. Panel (b) shows concentration- 
dependent rate of NAp release, and panel (c) shows a Hanes-Woolfe plot to determine 
kinetics rate constants from the data. Data shown represents the mean ± SD (n=3). 
Where error bars are not visible, error is within the data point.
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Figure 3.15 Activity of trypsin (1.28 x 10‘4 mM) against the substrate L-BAPNA.
Progress curves in panel (a) show the UV absorbance (400 nm) of NAp release from L- 
BAPNA by trypsin (1.28 x 10*4 mM) over 10 min. Panel (b) shows concentration- 
dependent rate of NAp release, and panel (c) shows a Hanes-Woolfe plot to determine 
kinetics rate constants from the data. Data shown represents the mean ± SD (n=3). 
Where error bars are not visible, error is within the data point.
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maximum enzyme activity was seen at pH 8.2, while activity was most markedly 
reduced at pH 5.39 (Figure 3.16).
Activity o f polymer-trypsin conjugates
When enzyme activity was measured following conjugation, 1.28 x lO"4 mM 
trypsin eq. was used at pH 8.2. Since HPMA copolymer-Gly-Gly-trypsin conjugates 
synthesised using EDC and sulfo-NHS were the most successful in terms of yield, 
only these conjugates were assessed for activity retention. When compared to the 
activity of free trypsin, enzyme activity was reduced for both dextrin (to ~ 30 %) and 
HPMA copolymer conjugates (to 24-33 %) (Figure 3.17, Table 3.3).
For HPMA copolymer-Gly-Gly-trypsin conjugates synthesised using different 
concentrations of EDC and sulfo-NHS, 10 eq. and 30 eq. produced conjugates with ~ 
32 % native trypsin activity, while conjugates produced using 20 eq. EDC and sulfo- 
NHS had just ~ 24 % activity of the native enzyme.
The rate constants K™, Vmax and derived from the Hanes-Woolfe plot are 
summarised in Table 3.3. All the Hanes-Woolfe plots had a correlation coefficient of 
> 0.98 (2 s.f.). Free trypsin typically had a of ~ 6 s'1, and this value was 
unaffected by changing enzyme concentration. K™ also remained similar at both 
concentrations of enzyme (~ 0.6 mM), but Vmax was increased at higher trypsin 
concentration (0.0335-0.0480 mM/min).
After polymer conjugation, remained similar to that of free trypsin, while 
Vmax decreased (0.048 to 0.012-0.016 mM/min). Similarly, of trypsin also 
decreased following polymer conjugation (6.24 to 1.52-2.04 s"1). correlated well 
with the trypsin activity, such that the slowest turnover rates were seen in HPMA 
copolymer-Gly-Gly-trypsin conjugate (30 eq. EDC and sulfo-NHS) having maximal 
enzyme masking (32.7 % activity remaining). Varying the amount of EDC and sulfo- 
NHS used in the reaction resulted in slightly different kinetic constants, as 
summarised in Table 3.3.
3.4 Discussion
The overall aim of these studies was to synthesise HPMA copolymer-Gly-Gly-
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Figure 3.16 Effect of pH on the cleavage rate of L-BAPNA by trypsin. Absorbance 
(400 nm) of NAp measured over 5 min. Trypsin concentration = 1.28 x 10*4 mM using 
different substrate concentrations. Data shown represents n = l.
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Figure 3.17 Effect of polymer conjugation on the rate of NAp release from L- 
BAPNA by trypsin. Where HPMA copolymer-Gly-Gly-trypsin 1 = 10 eq. EDC and 
sulfo-NHS, HPMA copolymer-Gly-Gly-trypsin 2 = 20 eq. EDC and sulfo-NHS, and 
HPMA copolymer-Gly-Gly-trypsin 3 = 30 eq. EDC and sulfo-NHS. Absorbance (400 
nm) of NAp measured over 10 min. Trypsin concentration = 1.28 x 10"4 mM trypsin eq. 
using different substrate concentrations. Data shown represents the mean ± SD (n=3). 
Where error bars are not visible, error is within the data point. * indicates significance 
compared to free trypsin control, where p<0.05 (ANOVA and Bonferroni post hoc test).
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trypsin and dextrin-trypsin conjugates in order to (i) select the best polymer, and (ii) 
optimise the conjugation chemistry for future synthesis of polymer-PLA2 conjugates.
When quantifying the NH2 groups available for polymer conjugation, the 
ninhydrin assay estimated a different number (12) from the actual value (10) 
(ExPASy, 2004). The discrepancy between the actual and calculated NH2 groups 
could result from impurities in the trypsin purchased from Sigma, leading to a slight 
overestimation of amine groups. In fact, the TNBS assay was also explored for 
amine quantification, however it gave markedly different values (6.6 ±1.5 SD). Due 
to the mechanism of action of the TNBS assay, it is important to have a standard 
which is either the same as the sample, or at least with the same chemical influence 
on the TNBS ring structure. As there is no such standard available for trypsin, the 
TNBS assay is liable to giving a false estimate of NH2 numbers. This problem is not 
so pronounced with the ninhydrin assay, and so this amine quantification method 
was used for these studies.
3.4.1 Polymer-trypsin conjugation
It was possible to synthesise reproducibly HPMA copolymer-Gly-Gly-trypsin 
and dextrin-trypsin conjugates with protein content of 41-84 wt. %.
HPMA copolymer-trypsin conjugates
Several methods of protein conjugation were studied. Initially the methods used 
previously for the synthesis of HPMA copolymer-Gly-Gly-P-lactamase and HPMA 
copolymer-Gly-Gly-cathepsin B conjugates were used (Satchi et al, 2001; Satchi- 
Fainaro et al, 2003). A buffered enzyme solution was initially used in an attempt to 
maintain enzyme activity. However, when conjugating HPMA copolymer to any 
protein it is also important to minimise the hydrolysis of the ONp groups, while 
maximising aminolysis due to protein conjugation. These studies showed clear 
release of ONp when HPMA copolymer was dissolved in PBS buffer, so it is likely 
that the competition between hydrolysis and aminolysis was responsible for 
compromising the protein conjugation efficiency. After trying a variety of solvents, 
reaction conditions and reactant ratios, SDS PAGE still showed no sign of
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conjugation. It soon became apparent that this method was not suitable for synthesis 
of the HPMA copolymer-trypsin conjugates, despite the fact that it had successfully 
been used to prepare many polymer-protein conjugates in the past (see Table 3.5). 
The precise reasons for failure of this method was unclear and even passage of the 
trypsin solution through a PD-10 desalting column prior to adding it to the reaction 
mixture did not improve conjugation efficiency. However, as trypsin has a pi of 10.2 
- 10.8 (Malamud and Drysdale, 1978), this may explain the problems encountered 
when trying to conjugate trypsin to HPMA copolymer-Gly-Gly-ONp by aminolysis.
For this reason, it was decided to try conjugation of HPMA copolymer-Gly-Gly- 
COOH to trypsin using EDC and sulfo-NHS as coupling agents. Trypsin was thought 
to be a good model, as PLA2 has a similar pi (10.5 ± 1.0) (Malamud and Drysdale, 
1978). However, although this approach improved conjugation efficiency the yield 
was still very low.
Dextrin-trypsin conjugates
Synthesis of dextrin-trypsin conjugates following the methods of Duncan et al 
(2008) was much more successful. Succinoylation of dextrin was reproducible, with 
an overall reaction efficiency of 30 - 40 % (determined by titration). As reported 
previously by Hreczuk-Hirst et al (2001b), the reaction yield was lower than the 
theoretical value: ~ 40 - 50 % conversion was achieved.
GPC analysis of dextrin and the succinoylated intermediates demonstrated a 
decreased retention time following modification, which represented a greater 
increase in molecular weight than would be expected. This is likely to be due to 
conformational changes associated with incorporation of COOH groups resulting in 
an increased hydrodynamic radius. This observation is consistent with the studies of 
Hreczuk-Hirst et al (2001b) where they also reported a higher than expected increase 
in dextrin molecular weight following succinoylation.
Synthesis of a dextrin-trypsin conjugate using the methods described by Duncan 
and Gilbert (Duncan et al, 2008; Gilbert et al, 2005) was successful, with a higher 
yield than HPMA copolymer-trypsin conjugates.
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Table 3.5 Examples of HPMA copolymer-protein conjugates prepared to date.
Reaction 
time (h)
Conditions Yield Reference
Chymotrypsin 5 0.15 MNaCl, 0.01 M 
CaCl2 
5 °C
Not stated (Oupicky and 
Ulbrich,
1999)
Bovine seminal 
ribonuclease
5 0.15 M N aCl,0.01 M 
CaCl2 
5 °C
Not stated (Oupicky and
Ulbrich,
1999)
Cathepsin B 8.5 0.05 M phosphate 
buffer, pH 7.2 
4 °C
30-35 (Satchi et al, 
2001)
p-lactamase 0.33 DMSO room 
temperature
30-35 (Satchi- 
Fainaro et al, 
2003)
Intraglobin F 
(human
immunoglobulin)
19 ddH20  
pH 7.8 
20 °C
16-18 wt.
%
(Sirova et al, 
2007)
Prostaglandin E 6 THF
DMAP 0.1 mmol, 
0°C
DCC 0.97 mmol, 6 h 
4 °C
3.7 mol % (Pan et al, 
2006)
RGD4C: avp3
integrin-targeting
peptide
22 DMF
Pyridine (1:1 ONp) 
N2, 20 °C
0.377
mmol/g
polymer
(Mitra et al, 
2006)
RGE4C: non­
active peptide
22 DMF
Pyridine (1:1 ONp) 
N2, 20 °C
0.5089
mmol/g
polymer
(Line et al, 
2005)
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Challenges for characterisation o f polymer-trypsin conjugates
Characterisation of a polymer-protein conjugate is difficult, as it doesn’t behave 
like either component. This is especially significant when using GPC to determine 
molecular weight. In these studies, pullulan molecular weight standards were used to 
calibrate the GPC since the use of protein standards greatly underestimated the 
molecular weight of conjugates (results not shown). Pullulan, like dextrin, is a 
polysaccharide that would be expected to take on a random coil structure in solution, 
and therefore is expected to behave similarly to dextrin. However, due to the 
globular structure of proteins, protein standards, and not pullulan, would be the most 
appropriate standard for analysing trypsin. For these studies, pullulan was deemed 
the most appropriate choice of molecular weight standard, however, it was 
recognised that estimation of polymer-trypsin conjugate molecular weight is likely to 
be difficult.
Similarly, it remains impossible to obtain an absolute molecular weight of 
conjugate using FPLC because of the properties of the conjugate as compared to the 
protein standards. Proteins have a unique tertiary structure that is, not only, 
dependent on their molecular weight, but also on their charge, thus making accurate 
calibration of the FPLC column difficult. Also, a polymer-protein conjugate doesn’t 
have the same properties as a native enzyme, due to the influence of the polymer on 
the shape and conformation of the protein and the steric effects of the polymer.
SDS PAGE was used to confirm an increase in the molecular weight of the 
protein, suggestive of successful conjugation of dextrin and trypsin. Free enzyme 
was compared to the purified reaction product, and both were evaluated in relation to 
a series of molecular weight markers. The smearing seen for polymer-protein 
conjugates indicates that polydisperse HPMA copolymer-Gly-Gly- and dextrin- 
trypsin conjugates were produced due to the random coil nature of dextrin and 
HPMA copolymer, uneven protein distribution along the polymer chain, as well as 
between different chains, could occur. There are numerous conformations that a 
dextrin-trypsin conjugate could take, as a result of the multiple binding sites on 
succinoylated dextrin which have the potential to bind one or more amine residues
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on the trypsin, resulting in a variety of conjugate conformations (summarised in 
Figure 3.18). The potential of cross-linking was reduced by using an excess of NH2 
residues. Knowing the protein content of the conjugates (BCA assay) it is possible to 
estimate the number of polymer molecules to protein molecules. The trypsin 
conjugates synthesised here are estimated to contain polymer : protein ratios of: 1:3.5 
(HPMA copolymer-Gly-Gly-COOH, 10 eq. EDC and sulfo-NHS), 1:3 (HPMA 
copolymer-Gly-Gly-COOH, 20 eq. EDC and sulfo-NHS), 1:2.5 (HPMA copolymer- 
Gly-Gly-COOH, 30 eq. EDC and sulfo-NHS), and 1:1.5 (dextrin-trypsin).
Protein content of dextrin-trypsin conjugates (42 %) was lower than HPMA 
coplymer conjugates (59-84 %). However, this variation did not appear to affect 
enzyme activity of the conjugate, which is understandable considering the difference 
in molecular weight of HPMA copolymer and dextrin. Since HPMA copolymer has a 
molecular weight of ~ 30,000 g/mol and dextrin’s molecular weight is ~ 50,000 
g/mol, the molar protein loading is similar for the conjugates and explains the similar 
trypsin activity observed for the conjugates.
3.4.2 Retention of enzymatic activity
Trypsin-conjugates activity
As expected, trypsin activity was reduced by polymer conjugation (p < 0.05, 
ANOVA and Bonferroni post hoc test). Activity masking was similar for all 
conjugates tested here and did not seem to vary greatly between polymers or ratio of 
linking agents (EDC and sulfo-NHS), in the case of HPMA copolymer. Polymer 
conjugation of enzymes has been widely studied in the literature (summarised in 
Table 3.6), demonstrating a wide range of yields and retention of activity after 
conjugation. The conjugates synthesised in these studies showed better activity 
masking than the PEG conjugates in the literature, and similar activity retention to 
dextran. While PEG-protein conjugation aims to retain protein activity by limiting 
binding to one reactive group, the conjugates synthesised in these studies used 
multi valent polymers to intentionally mask activity of the enzyme. The reduction in 
trypsin activity following conjugation to multivalent HPMA copolymer and dextrin 
is, therefore, likely to be due to the polymer sterically hindering access of substrate
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Table 3.6 Examples from the literature showing the effect of polymer modification on protein activity retention.
Polymer (g/mol) Protein NH2/sulfone: 
polymer (molar 
ratio)
Modification (%) Remaining 
activity (%)
Reference
PEG (5,000) Trypsin 2:1 47 40 (Mero et al, 2008)
PEG (5,000) Trypsin 1:1 22 70 (Mero et al, 2008)
POZ* (5,300) Trypsin 2:1 57 40 (Mero et al, 2008)
POZ* (5,300) Trypsin 2:1 26 80 (Mero et al, 2008)
PEG (12,000) IFN-alpha2b 
(Intron A)
1:1 50 28 (Grace et al, 2001)
PEG (40,000) IFN-alpha2b 
(Intron A)
1:1 30-55 5-10 (Ramon et al, 2005)
PEG (5,000) Asparaginase 1:1.3 91 99 (Balan et al, 2007)
PEG (10,000) Asparaginase 1:1.3 91 99 (Balan et al, 2007)
PEG (20,000) Asparaginase 1:1.3 91 98 (Balan et al, 2007)
POZ = Poly(2-ethyl-2-oxazoline)
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to the active site of the enzyme.
When attempting to produce HPMA copolymer-trypsin conjugates, varying the 
molar ratio of EDC and sulfo-NHS showed no obvious relationship with activity 
retention of the conjugates. However, the protein content was reduced as the amount 
of linking agents was increased (84 -  59 %). This could also be caused by steric 
hindrance blocking access of the substrate to trypsin’s active site, which is 
unaffected by the degree of polymer conjugation. Each lysine residue on trypsin’s 
structure will vary in its susceptibility to polymer conjugation, so it is likely that one 
of the most susceptible residues is located near the active site and further conjugation 
does not enhance protein masking to a great extent.
Previous studies with dextrin showed that the most effective protein masking 
was achieved when 51,000 g/mol dextrin was modified to ~ 26 % succinoylation 
(Duncan et al, 2008), and the reported activity remaining (34 %) was similar to the 
results from these studies (30 %). Ideally, the enzyme’s activity would be 100 % 
masked, however it has not been possible in these or many other previous studies to 
reduce activity to such an extent. Given that L-BAPNA has a low molecular weight, 
it is unlikely to be fully obstructed by the polymer as it diffuses into the active site. 
Also, conjugating the hydrophilic polymers to trypsin’s surface would be expected to 
influence the conformation of the enzyme and alter trypsin’s microenvironment.
An exciting advantage of using dextrin for protein conjugation is its application 
in the recently coined concept of PUMPT. Since the unmasking capabilities of a - 
amylase-triggered degradation of dextrin have been shown to unmask the conjugated 
enzyme and enable reinstatement of activity (Duncan et al, 2008), this concept was 
investigated when dextrin-PLA2 conjugates were synthesised (concept described in 
detail in Chapter 4).
Michaelis-Menten kinetics
As might have been expected, significant masking of activity was achieved after 
HPMA copolymer and dextrin conjugation. In order to assess the influence of 
polymer conjugation and compare HPMA copolymer-trypsin and dextrin-trypsin 
conjugates, it was considered necessary to establish kinetic parameters using a
106
Chapter 3 Synthesis of Polymer-Trypsin Conjugates
derivative of the Michaelis-Menten equation. As described in section 3.1.2, kinetic 
data are commonly analysed using the Lineweaver-Burk, Eadie-Hofstee and Hanes- 
Woolfe plots (Cornish-Bowden, 2004). Despite the initial acceptance of the 
Lineweaver-Burke and Eadie-Hofstee plots, they rely on subjective, and sometimes 
inaccurate, estimations of initial velocities and have failed to produce reliable kinetic 
constants. Therefore, the Hanes-Woolfe plot was used in these studies. This method 
of calculating kinetic parameters is not without faults, but these were minimised by 
ensuring that a suitably large range of substrate concentrations were studied. Also, 
since experimental conditions, such as temperature and pH can influence the K,,, 
(Cornish-Bowden, 2004) and enzyme purity and concentration can affect the Vmax 
values (Cornish-Bowden, 2004; Samoshina and Samoshin, 2005), these variables 
were kept constant unless being specifically studied (i.e. when effect of pH and 
trypsin concentration were measured). K^, however, should not be greatly affected 
by experimental conditions. Therefore, it was possible to compare the trypsin Kcal 
values obtained in these studies to those obtained by Johnson et al (2002). The 
results obtained in these studies calculated a value of 6.24 and 6.53 s'1, while 
Johnson et al (2002) reported values of 2.89 s'1. This value was calculated using 
the least squares fit of the Michaelis-Menten equation to the reciprocal data using 
LUCENZIII, a computer software programme. Additionally, Johnson et al (2002) 
performed these experiments at 35 °C, using 0.1-1.5 mM L-BAPNA in 0.1 M Tris- 
HC1 and 10 mM CaCl2, while the studies performed in these investigations were 
undertaken at 37 °C, using 0.081-0.644 mM L-BAPNA in 40 mM Tris-HCl and 16 
mM CaCl2. These variations could explain the disparity between the values 
calculated here and those in the literature. Following polymer conjugation, the K^, of 
HPMA copolymer bound trypsin decreased to 152-2.05 s'1 and, for dextrin-trypsin 
conjugates, a value of 1.88 s'1 was calculated. No obvious relationship was seen 
between values for trypsin conjugates of HPMA copolymer and dextrin.
Enzyme kinetics revealed a decrease in the apparent Km of trypsin upon 
attachment to both HPMA copolymer and dextrin, suggesting that apparent affinity is 
increased by polymer conjugation. However, since was lower following polymer 
conjugation, overall enzyme efficiency was lower. This is in agreement with the 
observed reduction in conjugate activity and is likely to be due to steric hindrance
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restricting access of the substrate to the active site.
It is desirable for the ideal conjugate to be able to hydrolyse its substrate rapidly 
(high K^t) and be able to work efficiently at low substrate concentrations (low K^). 
These results indicate that both trypsin conjugates retained sufficient activity to fulfil 
these requirements and provide encouraging evidence for implementing this method 
with PLA2.
3.5 Conclusions
From these pilot studies dextrin was selected as the best polymer for future 
synthesis of PLA2 conjugates. The main advantage of this polymer is its proven 
ability to ‘unmask’ the enzyme by degradation of dextrin by a-amylase, which 
would be a valuable property for a PLA2-conjugate. Although it was apparent that 
trypsin conjugates with similar activity retention could be prepared with HPMA 
copolymer-Gly-Gly-COOH, as well as dextrin, reaction yield for HPMA copolymer- 
trypsin conjugates was extremely. It was also evident that it would be easier to purify 
the dextrin conjugate using FPLC, and this conjugate also has the added potential of 
masking the activity of PLA2 after administration. Investigations into 
masking/unmasking of dextrin-PLA2 will be described in the following chapter. This 
work showed that it is possible to synthesise trypsin conjugates containing dextrin 
with an approximate trypsin content of 42 % w/w and retention of 30 % enzyme 
activity.
Therefore, the next studies were intended to use the chemistry optimised here to 
synthesise dextrin-PLA2 conjugates. After characterisation of the conjugates, the 
applicability of PUMPT was assessed and non-specific toxicity was measured.
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Chapter Four
Synthesis of Dextrin-PLA2 Conjugates and Characterisation
ofPLA2 Activity
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4.1 Introduction
Before synthesis of dextrin-PLA2 conjugates, it was first necessary to select the 
most appropriate source of the enzyme. As mentioned in Chapter 1 (section 1.1), 
PLA2 has been investigated previously as a potential anticancer agent. In fact, it is 
not only crotoxin that has shown anticancer activity though. PLA2 extracted from 
crotalus terrificus venom (Cura et al, 2002), Naja nigricollis venom (Chwetzoff et 
al, 1989) and Russell’s viper venom (Maity et al, 2007) have also shown activity. It 
was therefore very important to select the best source of enzyme for these studies. 
Ideally, the PLA2 would be commercially available, be selective for cancer cells, and 
exert minimal toxic side effects. Initially studies were undertaken to evaluate the 
potential of PLA2 derived from bee venom and bovine pancreas.
4.1.1 Introduction to PLA2s chosen for these studies
PLA2s have been previously described in section 1.4. Briefly, they are small 
secreted proteins (~ 14,500 g/mol) with between 5-8 disulfide bonds (summarised in 
Table 4.1). This group of enzymes require Ca2+ (mM concentrations) for catalysis 
and contain a histidine residue at their active site. To date, 19 distinct groups of 
enzyme have been identified, and classified according to their primary structure and 
the location of disulfide bonds in the protein (Dennis, 1997; Murakami and Kudo, 
2004; Six and Dennis, 2000). PLA2 isoforms have been assigned to one of five 
distinct types; namely the secreted PLA2s (sPLA2), the cytosolic PLA2s (cPLA2), the 
Ca2+-independent PLA2s (iPLA2), the platelet-activating factor acetylhydrolases 
(PAF-AH), and the lysosomal PLA2s. They represent a very diverse range of 
catalytically active and inactive forms of PLA2, that display a range of biological 
activities, including neurotoxicity, myotoxicity, cardiotoxicity, necrotoxicity, 
haemolysis, hypotensivity, and haemorrhagic and oedema-inducing activities (Kini, 
2003). The secreted form of PLA2 was selected for this work since a number of 
studies have shown anti-tumour activity of these isoforms (Chwetzoff et al, 1989; 
Cura et al, 2002; Lee et al, 2006). The abbreviation “PLA2” is used throughout the 
rest of this thesis to describe these secreted PLA2s.
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Table 4.1 Sub-groups of PLA2 and their characteristics.
GROUP IA* IB* IIA* IIB IIC III* V X
Source Cobras,
Kraits
Mammalian
pancreas,
spleen
Rattlesnakes,
vipers,
human
synovial
fluid/
platelets
Vipers Rat/
Mouse
testis
Insects,
Lizards,
Mammals
Human/Rat/Mouse 
macrophages Jung
Human
leucocytes,
spleen,
thymus,
lung, colon,
pancreas
No. o f amino 
acids
119 130 124 122 117 134 118 123
Molecular 
weight (g/mol)
13-15,000 13-15,000 13-15,000 13-15,000 15,000 16-18,000 14,000 14,000
Co-factor mM Ca2+ mM Ca2+ mM Ca2+ mMCa2* mMCa2+ mM Ca2+ mM Ca2+ mM Ca2+
Disulfides 7 7 7 6 8 5 6 8
Molecular His-Asp His-Asp His-Asp His-Asp pair, His-Asp His-Asp His-Asp pair Carboxyl
characteristics pair pair, elapid 
loop
pair,
carboxyl
extension
, carboxyl 
extension
pair,,
carboxyl
extension
pair extension, 
propeptide 
at NH2 
terminal
N-type
receptor
affinity
115 2,000,000 9 N/S N/S 80 N/S N/S
M-type
receptor
affinity
>300,000 30,000 36,000 N/S N/S >>300,000 N/S N/S
Kq5 = values of inhibition, expressed in pM; * = commercially available from Sigma-Aldrich; N/S = not stated
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Honeybee venom PLA2 was largely used in this thesis. It is a group III PLA2 
(MW = 15,800 g/mol) that is secreted by cells and is composed of 123 amino acids 
twelve of which are lysine residues. It also contains five disulphide bonds (Shipolini 
et al, 1974). The protein structure is shown in Figure 4.1. Bee venom PLA2 requires 
millimolar concentrations of Ca2+ as cofactor, and consequently, addition of EDTA 
inhibits enzyme activity (Scott et al, 1990). Bee venom-derived PLA2 has been 
shown to have an optimum pH for hydrolytic activity of 8.0 (Shipolini et al, 1971). 
Interestingly Op den Kamp et al (1974) found that while bee venom PLA2 is active 
against liposomes containing dilauroyl-, dimyristoyl-, and 
dipalmitoylphosphatidylcholine at temperatures other than the transition temperature 
(0, 23 and 41 °C respectively, liquid crystalline to gel phase), the pancreatic enzyme 
is active only at or near the transition temperature. This could be useful 
therapeutically since the enzyme would be required to act at 37 °C inside the body.
For comparison to the bee venom PLA2 bovine pancreatic PLA2 was also 
studied, but only as the native enzyme and it was subsequently not used to prepare 
polymer conjugates. Pancreatic PLA2 is a group IB secretory enzyme. It is composed 
of 133 amino acids (~14,500 g/mol) and it contains 7 disulfide bonds. The protein 
structure is shown in Figure 4.2. Like all sPLA2s, this enzyme also has a requirement 
for millimolar concentrations of Ca2+ as a cofactor. While there appears to be little 
sequence homology between the bee venom- and pancreatic-derived PLA2s (Puijk et 
al, 1977), the Thr-His-Asp residues found in pancreatic PLA2 also appear in the bee 
venom sequence and these are thought to be essential for the catalytic activity 
(Drenth et al, 1976). Mammalian forms of PLA2 show little selectivity for the 
particular fatty acids they hydrolyse, however, they do show higher activity towards 
phospholipids containing anionic headgroups (Diez et al, 1994; Diez et al, 1992).
Mechanism o f action ofPLA2
A description of the mechanism of action of PLA2 has already been given in 
Chapter 1 (section 1.4). Briefly, these enzymes catalyse the hydrolysis of fatty acids 
at the sn-2 position to release free fatty acids such as arachidonic acid, and 
lysophospholipids (Murakami and Kudo, 2002). These products are precursors to a
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Figure 4.1 Protein structure of bee venom PLA2. Panel (a) shows the Amino acid 
sequence of bee venom PLA2. Numbers in parentheses indicate the positions of cysteines 
involved in disulfide bonds. *, residues involved involved in the coordination of Ca2+ 
co-factor; ■, amino acids containing NH2 groups as potential conjugation sites for 
succinoylated dextrin. Panel (b) represents the 3-D image of bee venom PLA2 structure. 
Image taken from Expasy (2004).
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Figure 4.2 Protein structure of bovine pancreas PLA2. Panel (a) shows the amino acid 
sequence of bovine PLA2. Numbers in parentheses indicate the positions of cysteines 
involved in disulfide bonds. *, residues involved involved in the coordination of Ca2+ 
co-factor; ■, amino acids containing NH2 groups as potential conjugation sites for 
succinoylated dextrin Panel (b) represents the 3-D image of bovine pancreas PLA2 
structure. Image taken from Expasy (2005).
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number of signalling molecules with numerous biological functions. However, PLA2 
doesn’t only exert an effect through its enzymatic activity mediated by the hydrolysis 
of phospholipids (Lambeau and Lazdunski, 1999). It also interacts with at least two 
other membrane receptors, and these have been called N-type and M-type receptors 
(Lambeau et al, 1995; Lambeau and Lazdunski, 1999; Valentin and Lambeau, 2000). 
The N-type receptor is composed of at least two classes of binding site and it is most 
abundant in the brain. Binding of PLA2 to N-type receptors is very sensitive to the 
presence of Ca2+ ions, and this is responsible for the neurotoxic effects of PLA2 
(Nicolas et al, 1997). Conversely, the M-type receptor consists of only one type of 
binding site and it is found abundantly in the skeletal muscle of rabbits. Binding of 
sPLA2 to these receptors is independent of Ca2+, and the receptor is believed to 
behave as a physiological PLA2 inhibitor in humans. That is, interaction with the M- 
type receptor can lead to internalisation, and subsequent removal of PLA2. Different 
types of PLA2 have different affinities for the M-type receptor. While the honeybee 
venom PLA2 has very low M-type affinity, crotoxin and bovine pancreas display a 
relatively higher affinity for the receptor (Valentin and Lambeau, 2000), resulting in 
an apparent reduced bovine PLA2 activity.
4.1.2 Rationale for synthesis of dextrin-PLA2 conjugates
PLA2 was selected as the active enzyme in these studies after crotoxin showed 
promising results as an anticancer agent in Phase I clinical trials (Cura et al, 2002) 
(details of trials discussed in section 1.1). However, despite noting 2 partial 
responses and 1 complete response in the 23 patients involved in the trial, neurotoxic 
side effects were observed in 13 patients. Since PLA2 is also notoriously cytotoxic 
and haemolytic, the proposal to synthesise dextrin-PLA2 conjugates hoped to 
minimise this adverse effect on normal cells while still allowing full enzyme activity 
at the site of action within the tumour.
Dextrin was chosen for conjugation after previous studies using trypsin as a 
model enzyme showed good conjugation efficiency, successful masking of activity 
and straightforward characterisation (Chapter 3). Dextrin is also an appealing 
polymer since it can be used to inactivate a protein during transit (masking), but
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triggered degradation of the polymer can reinstate protein activity at a tailored rate 
(PUMPT) (Duncan et al, 2008). As mentioned earlier, preliminary studies by Duncan 
et al (2008) investigated the effect of molecular weight (7,700 and 47,200 g/mol) and 
degree of succinoylation (9, 32 mol %) on the ability of dextrin to mask/unmask 
trypsin activity. They found that the higher molecular weight polymer succinoylated 
to 26 mol % gave optimum masking/unmasking for PUMPT. This combination led 
to masking of activity to 34-69 % of free trypsin, with subsequent regeneration of 
activity to a maximum of 92-115 %. Similarly, these studies also confirmed the 
applicability of dextrin in PUMPT when conjugated to melanocyte stimulating factor 
(MSH), a receptor-binding ligand. In this case, activity was reduced to 11 % of free 
activity. However, in this case, it was only possible to reinstate 33 % of the control 
value, possibly due to MSH degradation during incubation and/or irreversible 
inactivation of MSH by dextrin conjugation.
The method used in Chapter 3 for dextrin-trypsin conjugation was used here for 
the conjugation of succinoylated dextrin to PLA2 using EDC and sulfo-NHS (Figure 
4.3). It was reasonable to assume that dextrin-PLA2 could be prepared using the 
linking agent method implemented for trypsin, as they are a similar size (16,000 
compared to 23,000 g/mol) and have a similar number of NH2 groups available for 
conjugation (12 compared to 10).
4.1.3 Choice of PLA2 activity assay
A number of assays have been described to measure the activity of PLA2 
(summarised in Table 4.2). The egg yolk assay was chosen for these studies because 
it is a rapid, simple and inexpensive technique that has been used before to assay 
PLA2 activity (Reynolds et al, 1991). It is based on the concept that PLA2 can 
hydrolyse the phospholipids in an egg yolk suspension, resulting in a decrease in 
turbidity of the solution (Marinetti, 1965). This solution ‘clearing’ can be followed 
spectrophotometrically in a continuous assay to measure PLA2 activity. However, the 
assay does have some disadvantages; the most significant being its low sensitivity. It 
is also not capable of producing quantitative results, and instead provides only 
relative activities rather than moles of phospholipids hydrolysed.
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Figure 4.3 Reaction scheme for conjugation of succinoylated dextrin to PLA-
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Table 4.2 Advantages and disadvantages of different methods of PLA2 activity measurement. Summarised from (Reynolds et al, 
1991). ________________________________
Method name Brief description Advantages Disadvantages
Titrametric (pH 
stat)
One of most commonly used PLA2 
assay. pH is held constant by titration 
of liberated fatty acids, and PLA2 
activity is quantitated continuously 
according to amount of base 
consumed. Detection limit: 20 nmol
Straightforward & requires 
relatively inexpensive 
equipment 
Continuous assay
Not sensitive enough to detect intracellular
PLA2 before purification
Does not detect reaction product, but proton
release
Acidametric Detects protons released from fatty 
acid liberation by monitoring pH 
change over time.
Detection limit: 100 nmol
Continuous and simple 
detection possible
pH of assay varies throughout assay 
Change in pH is highly dependent on 
presence of buffers, including 
substrate/enzyme
Sensitivity is determined by starting pH & 
therefore varies over time course
Radiometric Follows hydrolysis of synthetic, 
radio-labelled phospholipids by 
direct measurement of hydrolysis 
products.
Detection limit: 1 fmol-1 pmol
Most sensitive and widely used 
assay
Commercially available radio-labelled 
substrates can be expensive 
Sensitivity depends on specific radioactivity 
of labelled substrate 
Discontinuous assay 
Requires time-consuming separation 
radioactive substrate from products (e.g. 
TLC, HPLC, solvent extraction)
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Table 4.2 Advantages and disadvantages of different methods of PLA2 activity measurement. Summarised from (Reynolds et al, 
1991) (cont.) ___________________
Method name Brief description Advantages Disadvantages
NMR Commonly involves 31P and 13C. 
Detection limit: 20 (imol
Natural abundance levels of 31P 
means natural substrates can be 
used- no need for synthetic 
substrates
Very low sensitivity (>10 mM substrate, 10 
% hydrolysis required for quantitation) 
Natural abundance and sensitivity of C is 
low, so levels must be enhanced
Monolayer Phospholipid monolayers are 
formed in monolayer troughs. PLA2 
activity is determined by measuring 
the decrease in surface area required 
to maintain a constant surface 
pressure
Extremely sensitive and 
utilises natural substrates
Difficult to study PLA2 £ Km since very low 
concentrations of substrate are used 
Requires specialised, often expensive, 
equipment
Spectrophotometric Often involve generation of a 
chromophore following hydrolysis 
of synthetic phospholipids 
substrates
Rapid, convenient, continuous, 
and can be adapted for large 
sample numbers
Turbidometric Follows decrease in turbidity of 
phospholipid solution (e.g. egg yolk 
suspension) during hydrolysis
Continuous, rapid, simple and 
cheap
Can also be performed with a 
multibilayer liposome 
substrate
Low sensitivity
Difficult to quantitate amount of 
phospholipids hydrolysed- only gives 
relative activity, not moles of lipid 
hydrolysed
Turbidity is dependent on assay conditions 
(pH and metal ions can affect substrate 
solubility)
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4.1.4 Assessment of non-specific toxicity
If the dextrin-PLA2 conjugate was to be tested in vivo, or to be used clinically as 
an anticancer agent, it would be administered by IV injection. Therefore, it was 
essential to assess potential non-specific toxicity of the dextrin-PLA2 conjugates. 
PLA2 is believed to exert its cytotoxic effects by hydrolysis of phospholipids, 
resulting in membrane permeabilisation and rupture. Since RBCs are composed of 
phospholipids and dextrin-PLA2 would encounter these cells following IV 
administration, it was important to test haemolytic activity. A well-established RBC 
lysis model was used that has been applied to test the membrane activity of polymers 
(Duncan et al, 1994; Lavignac et al, 2005), and PLA2 (Lin et al, 1987; Watala and 
Kowalczyk, 1990).
Native PLA2 is known to cause haemolysis of RBCs (Best et al, 2002; Watala 
and Kowalczyk, 1990). Studies by Watala and Kowalczyk (1990) showed RBCs 
were rapidly lysed in a time- and concentration dependent manner by bee venom 
PLA2 (Hb^ = 5.73 pg/mL after 60 min incubation). However, they also noted that 
incubation of RBCs with purified bee venom PLA2 in concentrations of up to 10 
pg/mL (60 min, 37 °C) was not accompanied by haemolysis. Supplementation with 
melittin (0.6 pg/mL), however, significantly increased RBC lysis.
4.15 Experimental aims
In summary, the aims of this study were to:
• Assess suitability of PLA2s derived from bovine pancreas and bee venom 
for dextrin-conjugation, by testing its purity, enzyme activity and in vitro 
cytotoxicity against MCF-7 cells to select the best one for dextrin 
conjugation.
• Synthesis of dextrin-PLA2 conjugates and optimise the conditions with 
respect to reaction yield and free protein content (FPLC).
• Characterisation of conjugates with respect to purity, molecular weight 
and size distribution (FPLC, SDS PAGE), total protein content (BCA 
assay), free protein content (FPLC).
• Compare enzyme activity of free PLA2 and dextrin-PLA2 conjugate,
• Assess feasibility of unmasking dextrin-PLA2 conjugates by incubation
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with amylase in the context of PUMPT.
• Measure RBC haemolysis by PLA2, dextrin-PLA2 conjugate and 
unmasked dextrin-PLA2 conjugate +/- Ca2+.
4.2 Methods
The method used for synthesis of dextrin-trypsin conjugates (optimised in 
Chapter 3) was initially tested here using a small batch of dextrin-PLA2 (5 mg PLA2) 
to see if the same procedure could be used to synthesise dextrin-PLA2 conjugates. As 
the method was transferable it was subsequently scaled up to 25 mg PLA2 batch sizes 
(as described below).
The methods used for the characterisation of dextrin-PLA2 conjugates were 
essentially the same as those described to characterise dextrin-trypsin conjugates 
(Chapter 3). They are described in detail in sections 2.4.1, 2.4.4.1, 2.4.4.2, 2.4.4.3 
and 2.4.6.5 (ninhydrin assay, FPLC, SDS PAGE, BCA assay, MTT assay 
respectively).
4.2.1 Synthesis of dextrin-PLA2 conjugates
Succinoylated dextrin (51,000 g/mol; 19-23 mol % succinoylation) was prepared 
and characterised using methods outlined in Chapter 3 (section 3.2.2). It was then 
conjugated to PLA2 using EDC and sulfo-NHS as coupling agents as described in 
Chapter 3. Briefly, succinoylated dextrin (154 mg, 3.02 x 10"6 mol) was dissolved 
under stirring in ddH20  (2 mL) in a 10 mL round-bottomed flask. To this, EDC (21.1 
mg, 0.1 mol) was added, and the mixture allowed to dissolve for 10 min. Next, sulfo- 
NHS (22.4 mg, 0.1 mol) was added and the mixture left stirring for 40 min. 
Subsequently, PLA2 (25 mg, 1.58 x 1 O'6 mol) dissolved in ddH20  (1 mL) was added, 
followed by NaOH (0.5 M) dropwise to raise the pH to 8.0. The reaction mixture was 
left stirring overnight (18 h).
The conjugate was then purified from the reaction mixture by FPLC. Fractions 
(1 mL) were collected and desalted using Vivaspin tubes (10,000 g/mol cut-off) 
before pooling the appropriate fractions containing conjugate for activity testing 
(Figure 4.4). The final conjugate was lyophilised and stored at -20 °C.
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Dextrin-PLA2 conjugates were characterised in respect of free PLA2 by SDS 
PAGE (section 2.4.4.2) and using the same FPLC system as was used for purification 
(section 2.4.4.1). The total protein content of the conjugate was determined by the 
BCA assay (section 2.4.4.3).
4.2.2 PLA2 activity measured using the egg yolk assay
The enzyme activity of PLA2 and the dextrin-PLA2 conjugate was measured 
using an egg yolk suspension assay according to Marinetti (1965). Native PLA2 or 
dextrin-PLA2 conjugate was dissolved in Tris buffer (equivalent to 0.5 mg/mL PLA2, 
pH 8.2). All samples were prepared fresh before use and placed on ice throughout the 
experiments. The egg yolk solution (0.9 mL of a 0.05 - 0.25 % v/v solution in Tris 
buffer at pH 8.2) was added to a 1 cm3 quartz cell. To start the assay, free enzyme or 
conjugate (0.1 mL) was added to the cuvette.
Degradation of phospholipids was monitored by measuring the increase in 
absorbance at 400 nm for 30 min. Tris buffer (0.1 mL) was added to the blank 
sample in the place of the PLA2 or dextrin-PLA2 conjugate solution. Results were 
expressed as absorbance change (% ± SD, n = 3) over time (30 min). This data was 
subsequently interpreted to produce a graph showing rate of absorbance change 
against egg yolk emulsion concentration. Significance of the data was assessed using 
ANOVA and Bonferroni post hoc test.
4.2.3 Degradation of dextrin and succinoylated dextrin by a-amylase
In order to compare the rate of a-amylase degradation of dextrin and 
succinoylated dextrin, solutions (2 mL, 4 mg/mL in PBS, pH 7.4) of each polymer 
was prepared. Then a-amylase (2 mg/mL) was added. These solutions were 
incubated at 37 °C for 0 -  1440 min. At time points samples (100 pL) were taken, 
immediately snap frozen in liquid N2 to stop the reaction and then stored at -20 °C 
until analysis by GPC.
Prior to GPC analysis, samples were placed in a water bath (100 °C) for 5 min to 
denature the enzyme activity of the a-amylase and stop polymer degradation. The
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Figure 4.4 FPLC of dextrin-PLA2 conjugation reaction mixture (UV absorbance at 
280 nm). Where the peaks represent a) purified dextrin-PLA2, b) dextrin-PLA2, c) free 
PLA2, d) and e) peptides
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supernatant was then analysed by GPC (section 2.4.4.1) to determine the change in 
molecular weight over time.
4.2.4 Unmasking of dextrin-PLA2 conjugates by incubation with a-amylase
To study the effects of a-amylase on the activity of dextrin-PLA2 conjugates, 
dextrin-PLA2 conjugates (0.5 mg/mL PLA2 eq.) were first incubated with a-amylase 
(2 mg/mL, 200 Sigma units (SU)/mL) for 16 h at 37 °C in Tris buffer (1.5 mL, pH
8.2). The enzyme activity assay using an egg yolk emulsion in Tris buffer (see 
section 4.2.2 for method) was then followed.
4.2.5 Assessment of haemolytic activity
Rat RBCs were prepared as previously described by Duncan et al (1994). 
Briefly, blood was obtained from a male Wistar rat (~ 250 g body weight) by cardiac 
puncture and collected in a heparin/lithium blood tube, in PBS (pH 7.4). The tubes 
were centrifuged at 1500 g for 10 min at 4 °C. The supernatant was removed and the 
RBC pellet was resuspended in PBS at 4 °C and transferred to a pre-weighed, clean 
disposable centrifuge tube. The centrifugation step was repeated twice, followed by 
the removal of the supernatant, and resuspension of the pellet in PBS. After the final 
removal of the supernatant, the pellet (of known weight) was resuspended in PBS to 
produce a 2 % w/v RBC suspension. Erythrocyte suspension was stored at 4 °C and 
always made fresh on the day of the experiment.
Subsequently, this RBC suspension (100 pL) was added to a 96-well plate 
containing the PLA2 test compound solutions to be tested.
PBS was used as a negative control, and triton X-100 (1 % v/v) was used to 
achieve 100 % haemolysis. The plate was then incubated for 1 h at 37 °C, then the 
plate was centrifuged at 1500 g for 10 min at 4 °C. The supernatant (100 pL) of each 
well was then carefully removed and placed into a clean 96-well plate. The 
absorbance at 550 nm was read, using a microtitre plate reader, to assess the degree 
of RBC lysis. The background values from incubation of the RBCs with PBS was 
subtracted from the sample values and the results were expressed as haemoglobin 
released (% ± SEM) relative to the triton X-100 control. The significance of the data 
was assessed using ANOVA and Bonferroni post hoc test.
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Since calcium is an essential cofactor for PLA2 activity, these experiments were 
also performed in the absence and presence of Ca2+ by supplementing the buffer with 
calcium carbonate to produce a final Ca2+ concentration of 8 mM.
4.3 Results
4.3.1 Comparison of PLA2 sources: purity and enzyme activity
Before conjugating dextrin to PLA2, the properties of PLA2s derived from 
bovine pancreatic and bee venom were compared. The bee venom-derived PLA2 
contained 76 wt. % protein, while bovine pancreatic PLA2 had an apparent protein 
content of just 13 wt. %. However, the bovine PLA2 was relatively free from protein 
contaminants (Figure 4.5, lane 2 and 4.6a), whereas the bee venom PLA2 displayed 
several peaks on the FPLC trace- at ~ 10.5, ~ 12.5 and ~ 18 mL (Figure 4.6b), and 
multiple bands on SDS PAGE analysis (Figure 4.5, lane 3). FPLC and SDS PAGE of 
melittin, a common contaminant of bee venom PLA2, revealed a peak at ~ 18.5 mL 
(Figure 4.6c) and a band coincident with a band in the PLA2 lane (Figure 4.5, lane 4).
The in vitro cytotoxicity of bovine pancreatic and bee venom PLA2s (all 
conjugate MTT results are described in the next chapter) showed that bovine 
pancreatic PLA2 was non-toxic to MCF-7 cells up to 1 mg/mL, while bee venom 
PLA2 had an IC^ of 308.6 ± 6.9 pg/mL (Figure 4.7).
Consequently, bee venom PLA2 was selected for conjugation to dextrin.
4.3.2 Synthesis and purification of dextrin-PLA2 conjugates
The ninhydrin assay indicated that PLA2 has 9.8 ± 1.1 (SD) NH2 groups per 
molecule, and this value (10) was used to calculate molar ratios of PLA2 to 
succinoylated dextrin (NH2:COOH) for all conjugation reactions, and not the total 
number of NH2 groups in PLA2 (12).
When conjugation of dextrin-PLA2 was initially attempted, the method 
optimised for the synthesis of dextrin-trypsin was used. First, a small batch of 
dextrin-PLA2 was synthesised to confirm the method and to investigate an
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Figure 4.5 SDS PAGE analysis of bovine pancreatic PLA2, bee venom PLA2, and 
melittin. Key: a) PLA2 monomer, b) PLA2 dimer, c) PLA2 monomer, d) melittin 
contaminant, e) PLA2 contaminant, and f) melittin. MWM = molecular weight marker.
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Figure 4.6 FPLC analysis of bovine pancreatic PLA2, bee venom PLA2>, and 
melittin. Key: a) PLA2, b) PLA2 dimer, c) PLA2 monomer, d) melittin contaminant (9.4 
%), e) melittin. V0 = void volume (7.7 mL), and Vb = bed volume (24 mL). UV 
absorbance taken at 280 nm.
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Figure 4.7 Effect of bovine pancreatic and bee venom PLA2 on MCF-7 cell viability.
Data represents % control cell growth ± SEM (n = 18). Where error bars are invisible 
they are within size of data points. * indicates significance compared to bovine pancreas 
PLA2, where p<0.05 (student’s t-test).
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appropriate conjugate purification method. Initial studies using dialysis showed 
incomplete removal of free enzyme and reaction by-products when reanalysed by 
SDS PAGE (Figure 4.8, lane 4). However, no free PLA2 band was detectable in the 
dextrin-PLA2 conjugate after FPLC with Vivaspin purification (Figure 4.8, lane 5). 
Consequently, FPLC with Vivaspin was selected to separate the conjugate from the 
reaction mixture.
4.3.3 Characterisation of dextrin-PLA2 conjugates
Typical FPLC elution profiles of the crude reaction mixture (Figure 4.4) and free 
PLA2 and purified conjugate are shown (Figure 4.9). There was a good separation 
between bound and free PLA2, with the conjugate eluting at the void volume (V0) of 
the column (~ 7.7 mL), thus enabling the separation of free and bound PLA2 using 
this method. FPLC showed a peak corresponding to dextrin-PLA2 conjugate in the 
region of the column’s VQ.
SDS PAGE of the conjugates confirmed the presence of a high molecular weight 
conjugate (~ 200,000 g/mol), with dark smearing appearing between ~ 50,000 g/mol 
and the top of the gel (suggestive of a polydisperse conjugate) (Figure 4.8, lane 5).
Dextrin-PLA2 conjugation showed good batch-to-batch reproducibility and a 
reaction yield of 93-100 % (see Table 4.3). The conjugates contained 3-9 % w/w 
protein using a BCA assay calibrated with free PLA2 (see Figure 2.6). Control 
studies showed that succinoylated dextrin had minimal interference with the assay, 
with a relative contribution of absorbance of 0-1.8 %. The pilot scale batch (5 mg 
PLA2) synthesised initially had PLA2 content of 3.7 wt. %, but scaled-up conjugate 
batches (25 mg PLA2) had a PLA2 content of 7-9 wt. %.
To determine the amount of free PLA2 in the batches, SDS PAGE was calibrated 
by running different concentrations of free PLA2 to determine the lowest detectable 
concentration (data not shown). Further control experiments showed that unreacted 
dextrin gave no band, while free PLA2 showed two prominent bands where the 
monomeric and dimeric forms of the enzyme would be expected to appear (~ 15,000 
and 30,000 g/mol, respectively) (Figure 4.8, lane 2). FPLC was also used to
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Figure 4.8 SDS PAGE analysis of dextrin-PLA2 (purified by dialysis), dextrin-PLA2 
(purified by FPLC with Vivaspin), and bee venom PLA2 and dextrin controls. Key: 
a) PLA2 dimer, b) PLA2 monomer, c) dextrin-PLA2 conjugate, d) free PLA2, and e) 
dextrin-PLA2 conjugate. MWM = molecular weight marker.
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Figure 4.9 FPLC analysis of free and conjugated PLA2. Key: a) dextrin-PLA2 
(DexPLA5), b) dextrin-PLA2 (DexPLAl) and c) PLA2. V0 = void volume (7.7 mL), and 
Vb = bed volume (24 mL). UV absorbance taken at 280 nm.
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Table 43  Characterisation of dextrin-PLA2 conjugates.
Conjugate0 Batch size 
(mg)
Protein content8 Molecular weightb 
(wt. % ± SD) (g/mol)
Uses
DexPLAl 5 mg 3.7 ±0.014 160,000 Purification and characterisation optimisation
DexPLA2 25 mg 7.2 ±0.014 185,000 Egg yolk activity assays
DexPLA3 15 mg 5.0 ±0.010 180,000 Unmasking studies
DexPLA4 25 mg 7.0 ±0.006 210,000 Haemolysis
DexPLA5 25 mg 7.3 ±0.013 215,000 MTT
DexPLA6 5 mg 6.1 ±0.011 190,000 OG-labelled for uptake studies
DexPLA7 25 mg 9.4 ±0.014 195,000 PELT
a relative to native PLA2 (BCA assay) 
b FPLC, relative to protein standards (see text for details) 
c Free PLA2 was always < 1 % w/w
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quantitatively detect the presence of free PLA2 in the purified dextrin-PLA2. The 
conjugates always contained < 1 % free protein.
4.3.4 PLA2 activity of free and dextrin-conjugated PLA2
Degradation of egg yolk in the presence of PLA2 is shown in Figure 4.10a. 
There was a short lag phase followed by a linear rate of degradation. This linear part 
of the data was used to calculate the concentration-dependence of degradation 
(Figure 4.10b). The activity of the dextrin-PLA2 conjugates was reduced (35.8 % ±
4.5 (SD)) compared to free PLA2 (Figure 4.10b).
Enzyme activity measured following incubation of the dextrin-PLA2 conjugate 
with a-amylase was increased (Figure 4.10b) to 114.6 % ± 2.6 (SD) that of free 
PLA2.
4.3.5 Degradation of dextrin and succinoylated dextrin by incubation with a- 
amylase
When a-amylase was added to dextrin there was a rapid decrease in apparent 
molecular weight (seen using GPC (Figure 4.11)) with a t1/2 of 0.5 min. 
Succinoylated dextrin was degraded more slowly, such that its t1/2 was 30 min, and a 
plateau in molecular weight was seen.
4.3.6 Haemolysis of RBCs
Free PLA2 was very haemolytic at concentrations > 100  pg/mL native PLA2, 
while no lytic activity was seen with dextrin-PLA2 up to 500 pg/mL (Figure 4.12a). 
Furthermore, it was shown that, even following unmasking by a-amylase, dextrin- 
PLA2 did not induce red blood cell haemolysis at concentrations at which haemolysis 
is seen for the native enzyme. Addition of calcium to the incubation buffer enhanced 
the haemolytic potency of native PLA2 (Figure 4.12b), such that 56 % RBC lysis was 
seen at 50 pg/mL, compared to 6 % haemolysis in the absence of calcium. This 
effect was not observed with the dextrin-PLA2 conjugate. Control experiments with 
a-amylase and dextrin showed <10%  haemolysis (data not shown).
133
Chapter 4 Synthesis & Characterisation of Dextrin-PLA2
0 . 10- -
^0.08
n 0.06
S 0.04
Egg yolk 
concentration
0.25 % v/v
0.20 % v/v
0.15% v/v 
0.10 % v/v
0.05 %  v/v
20
Time (min)
2 .0 - Unmasked dextrin-PLA
PLA1.6 -
O)
1 . 2 -
■g 0.8- Dextrin-PLA
*5 0.4-
0.0
0.0 0.1 0.2 0.3
[egg yolk] (% v/v)
Figure 4.10 PLA2 activity measured using an egg yolk emulsion. Progress curves in 
panel (a) show the UV absorbance (540 nm) of egg yolk clearing in increasing 
concentrations of egg yolk emulsion by PLA2 (0.5 mg/mL) over 30 min. Panel (b) shows 
concentration-dependent rate o f clearing of egg yolk solutions. Data shown represents 
the mean ± SD (n=3). Where error bars are not visible, error is within the data point. * 
indicates significance compared to free PLA2 control, where p<0.05 (ANOVA and 
Bonferroni post hoc test).
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Figure 4.11 Degradation of dextrin and succinoylated dextrin over time, when 
incubated with the dextrin degrading enzyme a-amylase. This graph shows the 
change in molecular weight of the main peak fraction over time for dextrin and its 
succinoylated intermediate. Data shown represents n=l. Molecular weight given is 
relative to pullulan standards.
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Figure 4.12 Haemolysis of RBCs by PLA2 and dextrin-PLA2 (masked and 
unmasked). Panel (a) shows haemoglobin release from RBCs after 60 min incubation 
with PLA2, dextrin-PLA2 and ‘unmasked’ dextrin-PLA2. Panel (b) demonstrates the 
effect of Ca2+ on haemolytic activity of PLA2 and dextrin-PLA2. Data represents % RBC 
lysis relative to triton-XlOO solution ± SEM, (n=9). Where error bars are not visible, 
error is within the data point. * indicates significance compared to free trypsin control, 
where p<0.05 (ANOVA and Bonferroni post hoc test).
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4.4 Discussion
Although bovine pancreatic and bee venom PLA2 were considered for 
conjugation to dextrin the bovine PLA2 was found to be non-toxic up to 1 mg/mL 
when incubated with the breast cancer cell line MCF-7. In contrast the bee venom 
PLA2 had an IQo of 308.6 pig/mL (discussed in more detail in Chapter 5). These 
results were not surprising, given the affinity constants of these enzymes to the bl­
and M-type receptors (Table 4.1) and the likelihood that bovine PLA2 is susceptible 
to N-type receptor mediated internalisation, while bee venom PLA2 is not. It has 
been shown that melittin can enhance and stimulate the lipolytic activity of PLA2, so 
it is possible that the contamination seen in bee venom PLA2 could be attributed to 
this effect, and not to PLA2 alone. However, it is unlikely that melittin alone is 
responsible for the enhanced cytotoxicity since it only accounts for < 10 % bee 
venom PLA2 and would be removed during the conjugate purification steps.
Given the greater cytotoxicity of bee venom PLA2, this was chosen for 
conjugation to dextrin.
The method used to synthesise the library of dextrin-PLA2 conjugates (Table
4.3) was reproducible and gave a protein content of 5-9 wt. % with < 1 % free PLA2. 
This protein loading was less than was seen for the dextrin-trypsin conjugates 
synthesised in Chapter 3 (41-84 % w/w), despite having similar polymer: enzyme 
(and NH2: COOH) ratios in the reaction mixture. This could be due to bee venom 
PLA2’s tendency to form dimers which can conceal some Lys residues, reducing the 
number available for conjugation. It was also noted, however, that the protein 
loading achieved was greater for larger batch sizes and similar to yields described in 
the literature for polymer-protein conjugation (~ 10 %) (reviewed in Harris and 
Chess, 2003) but still lower than other dextrin-protein conjugates described in the 
literature (Table 4.4).
Although this method of conjugation is not site-specific, the polymer is likely to 
react preferentially with certain NH2 groups, depending on their pKa and their 
protein conformation. The ninhydrin assay predicted that there were ~ 10 accessible 
NH2 groups PLA2, while the literature suggests there are 12 lysine residues, as well
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Table 4.4 Summary of the activity of various dextrin-protein conjugates before and 
after addition of a-amylase.
Protein 
content 
(wt. %)
M asked
activity
(%)
Unmasked
activity
(%)
Reference
Trypsin 50-80 34 58 (Duncan et al, 2008)
MSH 37 11 33 (Duncan et al, 2008)
EGF 16 6.5 101 (Hardwicke et al, submitted)
RNase 48.4 13.7 - (Treethammathurot et al, 
unpublished)
p l a 2 7.2 36 116 (Ferguson et al, 2006)
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as a terminal amine group and several other NH-containing amino acids (arginine, 
histidine) (Scott et al, 1990; Shipolini et al, 1971). Interestingly, Bianco et al (2002) 
reported that PEGylation of PLA2 could be enhanced by isolating the conjugate 
fraction from the high MW PEG-PLA2 complexes. They suggest that access of the 
reactive polymer to some of the Lys of the remaining PLA2 was impaired in highly 
PEGylated proteins and that some of the reactive Lys residues were not initially 
available for conjugation due to dimerisation of the enzyme.
FPLC was found to be the only reliable method of conjugate purification. It 
should, however, be born in mind that it is that it is not possible to distinguish 
between dextrin-PLA2 conjugate and free dextrin using FPLC as they both elute at 
the same point. Duncan et al (2008) used two-dimensional diffusion-ordered NMR 
spectroscopy (DOSY) to show that there was free dextrin remaining in dextrin- 
trypsin conjugates. Although it is not ideal to include free dextrin in the product, 
dextrin is known to be non-immunogenic and is already used clinically so it’s 
presence would not be a concern at this stage. This is however an issue that would 
need addressing in the future before clinical use.
As with dextrin-trypsin conjugates, accurate characterisation of the molecular 
weight of dextrin-PLA2 conjugates proved problematic due to difficulties selecting 
appropriate calibration standards (discussed in Chapter 3). However, both SDS 
PAGE and FPLC were useful indicators that a conjugate had been synthesised, and 
for the detection of the presence of free PLA2. These methods also showed that the 
conjugates were a polydisperse mixture of species. This is not surprising and can be 
attributed to the multivalency of both dextrin and PLA2, which would, in theory, lead 
to a variety of conjugated species. It can be estimated from the protein assay that, on 
average, the dextrin-PLA2 conjugates synthesised contained between 1 protein: 3-9 
dextrin.
4.4.1 Enzyme activity
As has been observed with other dextrin conjugates (Gilbert et al, 2005) PLA2 
activity was retained following conjugation. Incomplete inactivation suggests that
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dextrin does not always bind to a region which would block access to the enzyme’s 
active site. There is no clear trend in protein content of polymer-protein conjugates 
and activity retention. In these studies, dextrin-PLA2 conjugates retained slightly 
higher activity than dextrin-trypsin conjugates (36 % compared to 24-32 %) and had 
a lower protein content (5-9 % compared to 41-84 %). However, the conjugates in 
Table 4.4 do not all follow this trend and it is likely that site of polymer conjugation 
relative to the enzyme’s active site influences activity masking the most.
Degradation and reinstatement o f activity o f dextrin-PLA2 conjugates
Full reinstatement of activity was seen following a-amylase incubation (16 h) 
with dextrin-PLA2. Previous a-amylase ‘unmasking studies’ using dextrin 
conjugates showed differences in the ability of a-amylase to reinstate protein activity 
(summarised in Table 4.4). While only partial reinstatement of activity was seen for 
dextrin-trypsin (34 % (masked) to 58 % (unmasked)), and dextrin-MSH conjugates 
(11 % (masked) to 33 % (unmasked)) (Duncan et al, 2008), full unmasking was 
achieved for dextrin-EGF conjugates (6.5 % (masked) to 101 % (unmasked)) 
(Hardwicke et al, submitted). The differences in masking could be due to the 
different protein sizes. MSH (2,644 g/mol and EGF (6,666 g/mol) are substantially 
smaller than trypsin and PLA2, and would therefore be more susceptible to activity 
masking by polymer conjugation.
It is also possible that irreversible inactivation of trypsin and MSH occurs 
following dextrin binding in the active site region of the enzyme. In fact, MSH has 
just one Lys residue, which is located one amino acid away from the active site 
sequence, and a terminal amine. Therefore, steric hindrance of the active site by 
remaining maltose residues could hinder full reinstatement of activity. PLA2, on the 
other hand, has many more NH2-containing amino acids. While it is reported that 
K14, R23, R58, K85 and K133 are found in the collar of the active site and are 
involved in the enzyme’s interaction with phospholipids, there remains a further 5-7 
NH2 groups available for dextrin conjugation, located away from the active site 
(Bollinger et al, 2004; Ghomashchi et al, 1998).
Since these unmasking experiments were performed in Tris buffer (pH 8.4), it is
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worth noting that the optimal pH for a-amylase is actually 7.0 (Sky-Peck and 
Thuvasethakul, 1977). This buffer was selected to provide the optimum conditions 
for the activity of PLA2 in the egg yolk assay, but it is important to note that full a- 
amylase activity may not be achievable under these conditions. In fact, studies show 
that a-amylase is stable between pH 5-10.5 (Sky-Peck and Thuvasethakul, 1977), 
and since the unmasking is performed at its optimal temperature (37 °C) for a long 
duration (16 h), it is reasonable to assume that complete unmasking is achieved.
When GPC was used to compare the degradation rates of dextrin and 
succinoylated dextrin before conjugation, a reduction in molecular weight of ~ 80 % 
and ~ 50 %, respectively, was seen. After 24 h incubation, dextrin’s apparent 
molecular weight was ~ 10 % of the initial molecular weight, while succinoylated 
dextrin had only degraded to ~ 35 % of its original weight. Succinoylation has 
previously been shown to control the degradation rate of dextrin by a-amylase 
(Hreczuk-Hirst et a l, 2001a). However, the concentration of a-amylase (200 SU/mL) 
and degree of succinoylation (~ 23 mol %) used here was markedly different to 
Hreczuk-Hirst et al (2001a)’s method (2.5 SU/mL and 34 mol %, respectively), so it 
is not surprising that the t1/2 was also different (30 min compared to > 180 min, 
respectively). Still, there was a distinct difference between degradation rates of 
dextrin and succinoylated dextrin (0.5 min compared to 30 min, respectively).
Although the concentration of a-amylase used in these experiments (200,000 
SU/L) is much higher than those found in human plasma (40-125 IU/L) it is also 
worth remembering that some breast cancers have shown elevated levels of a - 
amylase (up to 85-fold normal) (Inaji et al, 1991; Weitzel et al, 1988), which may 
help reduce toxicity to normal tissues. Previous studies have shown a correlation 
between Sigma units (SU) and international units (IU) used clinically to describe 
amylase concentrations (1 SU = 0.466 IU) (Hardwicke et al, submitted).
Having confirmed that dextrin-PLA2 conjugates could retain biological activity 
in a physiological setting it was important to consider their possible toxicological 
profile. Haemocompatibility of dextrin-PLA2 conjugates would be essential for safe
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systemic administration by IV injection that would be needed to benefit from the 
EPR effect. PLA2 is extremely haemolytic. This occurs due to hydrolysis of RBC 
phospholipids and/or generation of lysophospholipids and free fatty acids, which are 
also lytic and can cause further membrane damage. In this study, it was found that 
PLA2 showed concentration-dependent RBC lysis after 1 h (Hb^ = 300 pg/mL (- 
Ca2+); 50 pg/mL (+ Ca2+)).
The fact that dextrin-PLA2 conjugates had no haemolytic activity suggests an 
improved safety profile for IV administration. It is possible that dextrin-conjugation 
enhances enzyme activity by modifying the surface charge of PLA2. It has been 
postulated that a conformational change in PLA2 upon binding is required for 
interfacial activation (Peters et al, 1992; van den Berg et al, 1995), and the presence 
of dextrin, or even maltose, following a-amylase degradation of dextrin, could 
interfere with this.
Effect o f Ca2+ on haemolysis
The addition of 8 mM Ca2+ enhanced the haemolytic potency of native PLA2, 
however it did not influence the toxicity of dextrin-PLA2 conjugates towards RBCs. 
The results seen for native PLA2 were as predicted since it has been shown 
previously that the enzymatic activity of PLA2 is Ca2+-dependent, with optimum 
activity seen in the presence of 10 mM Ca2+ (Kingma et al, 2002).
Physiological Ca2+ levels are normally in the range of 1.9-2.7 mM (Alscher et al, 
2001), while metastatic breast cancer cells are reportedly exposed to levels as high as 
40 mM (Joume et al, 2004). This is a particularly interesting finding since it means 
that PLA2 may show enhanced enzyme activity in metastases. It is proposed that 
dextrin conjugation blocks calcium coordination with the calcium binding loop of 
PLA2 by steric hindrance. It is possible that dextrin binds to Lys 14, which is situated 
very close to 3 residues involved in the coordination of Ca2+ cofactor (Figure 4.1).
4.5 Conclusions
Here a method was developed for the synthesis and purification of dextrin-PLA2 
conjugates. Dextrin-PLA2 conjugates containing 5-9 wt. % PLA2 and a molecular 
weight of ~ 200,000 g/mol were reproducibly synthesised. It was shown that
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conjugation reduces enzyme activity (36 %), but addition of a-amylase restores 
activity by degradation of dextrin. Haemolytic activity of PLA2 was also reduced by 
dextrin conjugation.
Therefore, these preliminary studies confirmed the potential of polymer-PLA2 
conjugates for further evaluation as an anti-cancer therapy. The following studies 
(Chapter 5) examined in more detail the mechanism of action of dextrin-PLA2.
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Chapter Five
Investigating the In Vitro Cytotoxicity and Mechanism of 
Action of Dextrin-PLA2 Conjugates
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5.1 Introduction
As described in Chapter 1 (section 1.4), PLA2 is a potent membrane active agent. 
Since dextrin-PLA2 has already shown greatly reduced haematoxicity (Chapter 4), it 
was important to demonstrate that the conjugate still retained cytotoxicity towards 
cancer cells. Therefore, in these studies, the cytotoxicity of dextrin-PLA2, and dextrin 
and free PLA2 (as reference controls) was evaluated using the human breast cancer 
cell line, MCF-7, murine melanoma cell line, B16F10, and human colon carcinoma 
cell line, HT29.
In addition this study was designed to investigate the role of EGFR in the 
cytotoxicity of dextrin-PLA2 since this receptor has been implicated in the cytotoxic 
mechanism of PLA2 (Donato et aly 1996). Thus, it was felt that elucidating any link 
between PLA2 activity and EGF receptor status would be of fundamental importance 
in defining the potential tumour specificity for dextrin-PLA2 activity. Many studies 
have been undertaken to quantify the number of EGFR expressed by different cell 
types (examples given in Table 5.1). MCF-7 cells have been reported to have 
between 800-2,800 EGFR per cell (Fitzpatrick et al, 1984b; Imai et al, 1982). This is 
significantly lower than other breast cancer cell lines, such as MDA-MB-231 
(700,000 per cell) and BT-474 (68,000 per cell). HT29 cells, on the other hand, have 
been reported to have 44,000 EGF binding sites per cell (Heimbrook et al, 1990), 
which is 15-55 times more receptors than the MCF-7 cell line. Given that B16F10 
cells are of mouse origin, they would not express human EGFR so they were chosen 
as controls.
Finally, since combination therapy is showing the greatest efficacy in cancer 
treatment (Early Breast Cancer Trialists' Collaborative Group, 1998), it was 
considered interesting to assess whether the dextrin-PLA2 conjugate could be used to 
enhance the cytotoxicity of the commonly-used anticancer agent, doxorubicin.
5.1.1 EGFR: epidermal growth factor receptor
The EGFR is a 170 kDa transmembrane glycoprotein and a member of the ErbB, 
or type I, receptor tyrosine kinase (TK) receptor family. It is present on a number of
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Table 5.1 Comparison of EGFR expression described in the literature using various methods of quantification.
Cell
line
Origin EGFR
(sites/cell)
EGFR (fmol/mg 
protein)
Method of 
quantification
Reference
MCF-7 Human mammary epithelial carcinoma 800 12 125I-EGF binding (Fitzpatrick et al,
from pleural effusion assay 1984b)
2,800 - 125I-EGF binding (Imai et al, 1982)
assay
- £ 20 EGFR mAb (Bier et al, 1998)
immunoassay
HT29 Human colon carcinoma metastatic - 3430 125I-EGF binding (Magne et al,
lesions assay 2002)
44,000 - (Heimbrook et al,
1990)
RT4 Recurrent papillary bladder carcinoma 44,000 _ Flow cytometry (Brockhoff et al,
1994)
J82 Invasive urothelial bladder carcinoma 42,500 Flow cytometry (Brockhoff et al,
1994)
A431 Human epidermoid carcinoma 1,600,000 _ l25I-EGF binding (Good et al, 1992)
assay
DU4475 Human mammary epithelial carcinoma Non Non detectable I25I-EGF binding (Imai et al, 1982)
(suspension) detectable assay
Non Non detectable 125I-EGF binding (Fitzpatrick et al,
detectable assay 1984a)
COS Simian fibroblasts 40,000 125I-EGF binding (Livneh et al,
assay 1986)
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normal and cancerous cells (see Table 5.1). It is comprised of an extracellular 
binding domain (621 amino acids) and an intracellular tyrosine kinase domain (542 
amino acids), linked by a small lipophilic transmembrane segment (23 amino acids). 
These receptors are most commonly found on the cell surface (Cohen, 1987), 
although further intracellular receptors have been described (Wiegant et al, 1986).
The signalling pathway of EGFR is illustrated in Figure 5.1. Activation of EGFR 
occurs when one of its ligands, such as EGF, transforming growth factor (TGF)-a, 
amphiregulin, betacellulin, heparin-binding EGF or epiregulin (Yarden, 2001), binds 
to the receptor in its open conformation. Ligand binding causes oligomerisation of 
two or more receptor-ligand complexes, which are subsequently internalised by 
clathrin-coated pits; although high concentrations of ligand can stimulate 
internalisation by non-clathrin-mediated pathways (Sigismund et al, 2005). 
Phosphorylation of tyrosine residues in the carboxyl tail domain initiates a number of 
cascades leading the signal towards the nucleus. EGFR in A431 cells was shown to 
have a half life of 13 h, although addition of EGF caused this to drop markedly to 
less than 6  h (Goldkorn et al, 1997). Following internalisation, receptor-ligand 
complexes are either degraded in the lysosome or recycled to the cell surface.
Activation of EGFR triggers a variety of cellular events, resulting in cellular 
proliferation, differentiation, protection from apoptosis, cell migration and adhesion, 
and stimulation of angiogenesis. While these processes are essential for normal cell 
survival, they also have a great impact on the behaviour of cancer cells.
EGFR has been widely implicated in malignant disease and is regarded as one of 
the most important growth regulatory signal transduction proteins. Research has 
revealed that levels of this receptor are amplified in several human tumours, 
including breast, gliomas, lung bladder and colon cancer, and is therefore considered 
to be a clinical marker of poor prognosis and correlates with poor response to 
treatment, rapid disease progression and poor survival (reviewed in Oliveira et al, 
2006). Previous investigations have shown that EGFR can be detected in 
approximately half of all breast cancer biopsies (Fitzpatrick et al, 1984a), which led 
to EGFR becoming a key target for novel anti-cancer therapies.
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Figure 5.1 Schematic illustration of the EGFR signalling pathway, involving EGF-activated protein kinase to the 
nucleus and stimulation of cell cycle machinery. Adapted from: Nyati, MK et al (2006) and Harari and Huang (2004).
Chapter 5 In vitro Cytotoxicity of Dextrin-PLA2
Following initial studies showing that mAbs were able to inhibit growth of 
cancer cells through their interaction with EGFR (Gill et al, 1984; Sato et al, 1983), a 
number of strategies have been developed over the past 2 0  years which interfere with 
the signalling pathway of EGFR as a novel approach to treating cancers. These new 
therapeutics have shown better efficiency towards tumours with high EGFR 
expression (Hambek et al, 2001). Some examples of such therapies and their mode 
of action are detailed in Table 5.2.
However, while inhibition of EGFR activity was initially heralded as a 
promising novel approach to treating patients with tumours driven by activated 
EGFR, clinical trials have shown only a modest response to these inhibitors and poor 
correlation between EGFR expression and response rates. It is believed that these 
single-targeted agents have only limited efficacy because human epidermal growth 
factor receptor (HER) family members cooperate and compensate for each other. 
Consequently, these compounds are usually used clinically in combination with 
radiotherapy, chemotherapy and radiochemotherapy (Harari and Huang, 2004). 
Therefore, due to the overexpression of EGFR on cancer cells and their modest 
response to current EGFR inhibitors in clinical use, targeting dextrin-PLA2 to cells 
overexpressing EGFR would be an attractive opportunity.
5.1.2 PLA2 mechanism of action
While the general mechanism of action of PLA2 has been described previously 
(Chapter 1 (section 1.4) and 4 (section 4.1.1)), the exact mechanism is poorly 
understood, and PLA2 has been reported to show different activity towards different 
cell types. The possible mechanisms of action of dextrin-PLA2 conjugates as 
cytotoxic agents are summarised in Figure 5.2.
As described earlier (Chapter 1), crotoxin exists as a dimer that must dissociate 
before it can exert its antiproliferative effect (Choumet et al, 1998) and it has been 
suggested that a specific cellular target triggers subunit dissociation (Corin et al, 
1993). A number of studies have shown a correlation between EGFR expression and 
cell sensitivity to PLA2 (Donato et al, 1996; Zhao et al, 2002), though results are 
conflicting as to whether PLA2 has a stimulatory or inhibitoiy effect on cell 
proliferation and/or EGFR activation. Zhao et al (2002) reported inhibition of EGF-
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Table 5.2 Examples of some EGFR inhibitors in clinical use.
Agent and 
manufacturer
Molecule Target site Comments Reference
Cetuximab (IMC- 
C225, Erbitux®); 
ImClone 
Systems/BMS)
Mouse-human 
chimeric mAb
Extracellular
domain
FDA approved for CRC with irinotecan, and with 
radiotherapy for SCSHN. Also as single agent for 
recurrent or metastatic SCSHN after platimum- 
based treatment failure (Apr 2004).
(Astsaturov et al, 
2006)
Panitumumab
(ABX-EGF,
rHuMAb-EGFR);
Amgen
Fully human mAb Extracellular
domain
Phase I/II trials for NSCLC, CRC, renal and 
oesophageal cancer.
(Rowinsky et al, 
2004)
Matuzumab 
(EMD72000); 
EMD Pharma
Mouse-human 
chimeric mAb
Extracellular 
domain of 
EGFR
Phase II trials for NSCLC, gynaecological, 
pancreatic and oesophageal cancers.
(Kollmannsberger 
et al, 2006)
Erlotinib 
(OSI774, 
Tarceva®); 
Genentech Inc.
Anilinoquinazoline; 
reversible binding
Intracellular 
domain (TKI) 
of EGFR
FDA approved for locally advanced or metastatic 
NSCLC after failure of * chemotherapy regimen 
(Nov 2004). FDA approved in combination with 
gemcitabine for locally advanced, unresectable or 
metastatic pancreatic carcinoma (Nov 2005).
(Smith, 2005)
Lapatinib
(GW572016,
Tykerb®);
GlaxoSmithKline
Thiazolylquinazoline; 
reversible binding
Intracellular 
domain (TKI) 
of EGFR and 
ErbBl/2
FDA approved, combined with capecitabine for 
advanced or metastatic breast cancer 
overexpressing HER2 (ErbB2) after previous 
therapy including an anthracycline, a taxane, and 
trastuzumab (March 2007).
(Mukherjee et al, 
2007)
SCCHN, squamour cell carcinoma of the head and neck; CRC, colorectal cancer; NSCLC, non-small cell lung cancer
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Figure 5.2 Proposed mechanisms of action of dextrin-PLA2 conjugate. Where 1. 
PLA2 degrades cancer cell membrane phospholipids (Rosenberg, 1990); 2. PLA2 blocks 
access of EGF to receptor (Hack e t al, 1991); 3. PLA2 blocks TK activity of EGFR 
(Goldberg e t al, 1990); 4. PLA2 degrades endosomal membrane phospholipids.
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induced receptor activation by PLA2 from Agkistrodon halys pallas. Addition of 
PLA2 to A431 (human epithelial carcinoma) cells caused a rise in intracellular 
ceramide formation leading to the release of arachidonic acid. It was therefore 
suggested that PLA2 downregulates EGFR-mediated intracellular signal transduction. 
Conversely, Donato et al (1996) noted a crotoxin-mediated activation of EGFR in a 
number of squamous carcinoma cell lines (ME-180 (parental cervical carcinoma), 
A431 (human epithelial carcinoma), DiFi and HT-29 (colon carcinomas)). In these 
studies, the EGFR-dependent sensitivity to the cytotoxic effects of PLA2 was altered 
when they were co-incubated with EGF and PLA2. Those cells expressing the highest 
levels of EGFR were the most sensitive to PLA2. Zhao et al (2002) attributed the 
differences seen in these experiments to the different PLA2 types used. Thus it was 
considered interesting to study the involvement of EGFR status on the effect of both 
bee venom PLA2 and dextrin-PLA2 conjugate.
5.1.3 Inhibition of TK activity of EGFR by gefitinib
Since it has been suggested that PLA2 might require the TK activity of EGFR 
(Goldberg et al, 1990; Hack et al, 1991) for its activity, it was postulated that co­
administration with a TK inhibitor (TKI) might reduce the cytotoxicity of PLA2 and 
the dextrin-PLA2 conjugate. To study the role of the TK activity of EGFR on PLA2 
activity, gefitinib (also known as ZD 1839 or Iressa®) was selected as a TKI (Figure 
5.3a). TKIs work by competing, either reversibly or irreversibly, with ATP for the 
intracellular catalytic site of EGFR and, in so doing inhibit receptor activation (El- 
Rayes and LoRusso, 2004). Consequently, the downstream signal transduction 
pathways involved in proliferation and survival of the cells, are blocked, without 
affecting EGFR expression (Magne et al, 2002). Gefitinib is a potent orally active 
reversible inhibitor of the intracellular domain of the EGFR TK that was approved 
by the FDA in 2003 for patients with refractory advanced NSCLC. However, in 2005 
the FDA announced that gefitinib should be limited to patients who, in their 
physician’s opinion, are currently benefiting, or have previously benefited from 
gefitinib treatment, after a large study revealed that gefitinib did not, in fact, prolong 
life.
It was considered important to study the dextrin-PLA2/ gefitinib combination to
152
Chapter 5 In vitro Cytotoxicity of Dextrin-PLA2
Cl
a) gefitinib
b) doxorubicin
Figure 5 3  Chemical structure of a) gefitinib (4-(3-chloro-4-fluoroanilino)-7- 
methoxy-6(3-morpholinopropoxy)quinazoline, RMM = 446.9 and b) doxorubicin, 
RMM = 543.52. RMM = Relative molecular mass.
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(i) investigate whether TK activity was important for PLA2 activity, and (ii) to define 
the potential clinical impact of using this combination of drugs clinically.
5.1.4 Combination chemotherapy
As a separate study, it was considered interesting to study dextrin-PLA2 in 
combination with a conventional chemotherapeutic. Due to the molecular complexity 
of cancer, adjuvant chemotherapy with classical combinations of two or more drugs 
including alkylating agents, antimetabolites, taxanes and anthracyclines has shown 
the best 10-year survival rate in women with metastatic breast cancer (Early Breast 
Cancer Trialists' Collaborative Group, 1998). Addition of tamoxifen, a selective 
oestrogen-receptor modulator, to these regimens has improved survival rates among 
oestrogen-receptor positive women by 31 % (Early Breast Cancer Trialists’ 
Collaborative Group, 2005), while trastuzumab, a mAb against HER type 2 (HER2) 
has improved disease-free survival by ~ 50 % among HER2-positive patients 
(Romond et al, 2005).
More recently, studies have been investigating the potential of polymer-based 
combinations (reviewed in Duncan, 2006). PGA-paclitaxel with carboplatin has been 
tested in phase III trials on performance status level 2 (PS2) patients with advanced 
NSCLC (Nemunaitis et al, 2005). Although the trials did not show a difference in 
overall survival compared to free paclitaxel and carboplatin combination, a clear 
gender difference was noted, such that women receiving PGA-paclitexel 
demonstrated an improved survival at 1 year. Current opinion suggests that a 
correlation between oestrogen levels and conjugate activity exist, and oestrogen has 
been shown to increase the expression of cathepsin B, the lysosomal enzyme 
responsible for degradation of PGA (Kremer et al, 1995).
It was therefore considered interesting to investigate whether dextrin-PLA2 
would show enhanced activity when used in combination with a conventional low- 
molecular weight chemotherapeutic agent. Doxorubicin (Figure 5.3b), an 
anthracycline, was selected as a model since it is widely used as a first line treatment 
for breast cancer.
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5.1.5 Methods used for in vitro cell viability assessment
Cell viability is routinely assessed using a number of different methods, 
including i) measuring the incorporation of radiolabelled DNA precursors, such as 
[3H]-thymidine (Amirghofran et al, 2007), ii) measuring the uptake of dyes, such as 
trypan blue (Campbell et al, 2007), as an indication of membrane integrity and iii) 
the MTT assay. Despite the high sensitivity of the radiolabelled DNA precursors, this 
assay is highly hazardous due to the radioelements and can be expensive. The trypan 
blue exclusion assay is a cheaper alternative, however it is time consuming and is 
more suitable to suspension cells than monolayers since dead cells could detach from 
monolayers and would be lost from the assay.
For these studies, the MTT assay was chosen to measure the effect of free and 
dextrin-conjugated PLA2 on cell viability. This assay has been routinely used to 
screen anticancer agents and polymer-anticancer agents (Alley et al, 1988) and was 
selected due to its simplicity, reproducibility and lack of requirement for 
radioisotopes.
5.1.6 Experimental aims
In summary, the aims of this study were to:
• Determine in vitro the cytotoxicity of the dextrin-PLA2 conjugate 
towards high and low EGFR expressing cells (HT29, MCF-7 and 
B16F10) using the MTT assay (72 h). The cytotoxicity of dextrin and 
PLA2 was determined as reference controls.
• Investigate the mechanism of action of PLA2 and dextrin-PLA2, by:
• Studying the influence of EGF co-incubation on the 
cytotoxicity of PLA2 and dextrin-PLA2 in HT29, MCF-7 and 
B16F10 cells
• Studying the effect of gefitinib on the activity of PLA2 and 
dextrin-PLA2 in HT29, MCF-7 and B16F10 cells
• Investigate the cytotoxicity of dextrin-PLA2 in the presence of 
doxorubicin in MCF-7 cells as a possible combination therapy.
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5.2 Methods
Succinoylated dextrin was prepared as described in section 3.2.2. EFdex4 (19.4 
mol % succinoylation) was used as a control for succinoylated dextrin in the 
cytotoxicity assays. EFdex5 (20.9 mol % succinoylation) was used to synthesise 
dextrin-PLA2 conjugates in these studies. Dextrin-PLA2 conjugates were synthesised 
and characterised according to methods described in Chapter 4. DexPLA5 (MW ~
215.000 g/mol; PLA2 content 7.3 wt. %) was used for all the cell viability assays 
described here.
The general method for obtaining cell growth curves is described in section 
2.4.6.4.
5.2.1 Imaging of cell lines
The morphology of the cells was observed whilst in situ in sterile glass- 
bottomed culture dishes. Cells were passaged and counted as described in section 
2.4.6.3. Cells were subsequently seeded in sterile glass-bottomed culture dishes and 
allowed to adhere for 24 h. Bright-field images of cell morphology were taken using 
an inverted Leica DM IRB microscope with 12-bit cooled monochrome Retiga 1300 
camera.
5.2.2 Use of the MTT assay to assess cell viability
For determination of cytotoxicity against MCF-7, HT29 and B16F10 cells, 
treatments were tested by MTT assay (section 2.4.6.5) using media supplemented as 
detailed in Table 5.3.
To study the effect of dextrin-PLA2 conjugate, PLA2 and dextrin on cell viability 
complete media was supplemented with a range of concentrations of each.
The influence of EGF on cell viability was assessed using complete media, 
including heat-inactivated FCS, and was supplemented with a range of EGF 
concentrations. (Heat-inactivated FCS was used to ensure denaturation of the growth 
hormones found naturally in FCS.)
To examine the effect of EGF on PLA2 and dextrin-PLA2 conjugate activity, 
complete media was used including heat-inactivated FCS, supplemented with EGF
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Table 5 3  Conditions and concentration ranges used for MTT assays.
Study HI FCS?* p l a 2 EGF Gefitinib Doxorubicin Dextrin
(Hg/mLeq.) (ng/mL) (M-M) (Hg/mL) (mg/mL)
PLA2 X 0.1-500
Doxorubicin X 0.001-0.5
EGF yes 1-500
Gefitinib yes 0 .0 1 - 1 0 0
PLA2 + dox X 50 0.0025-0.5
PLA2 + EGF yes 0.1-500 1 0
PLA2 + gefitinib yes 0.1-500 1
Dextrin X 0 .1 - 1 0 0 0
Dextrin- PLA2 X 0.1-500
Dextrin- PLA2 + dox X 50 0.0025-0.5
Dextrin-PLA2 + EGF yes 0.1-500 1 0
Dextrin-PLA2 + gefitinib yes 0.1-500 1
* HI FCS = heat-inactivated FCS
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(10 ng/mL).
To study the effect of gefitinib on cell viability, complete media including heat- 
inactivated FCS was used and was supplemented with a range of gefitinib 
concentrations.
When investigating the effect of gefitinib on cytotoxicity of PLA2 and dextrin- 
PLA2 conjugate, complete media including heat-inactivated FCS was also used but in 
this case was supplemented with gefitinib (1 pM) and the concentration of PLA2 or 
dextrin-PLA2 conjugate was varied.
When investigating the cytotoxicity of doxorubicin, complete medium was used 
and the doxorubicin concentration varied.
To study the effect of the dextrin-PLA2 conjugate or PLA2 combination with 
doxorubicin, complete medium was used. A PLA2 or dextrin-PLA2 conjugate 
concentration of 50 pg/mL was used and the doxorubicin concentration varied.
5.3 Results
First, the cell morphology and growth of HT29, MCF-7 and B16F10 cells was 
assessed (Figure 5.4). During the exponential phase of growth of HT29, MCF-7 and 
B16F10 cells, cell doubling times during the exponential growth phase were 1.2 
days, 1.5 days and 1 day, respectively.
Having established the exponential growth phase of the cells, all cell viability 
experiments were carried out during this growth phase.
5.3.1 Cytotoxicity of free and dextrin-bound PLA2
The concentration-dependent cytotoxicity of free PLA2, dextrin and dextrin- 
PLA2 in HT29, MCF-7 and B16F10 cells is shown in Figure 5.5. Table 5.4 
summarises the IC50 values derived from these plots.
As expected, dextrin was not toxic towards any of the cell lines (up to 1 
mg/mL). Free PLA2 was cytotoxic in all cell lines, and toxicity was most marked in 
HT29 cells (IG* = 40.0 pg/mL (HT29), 308.6 pg/mL (MCF-7), 108.3 pg/mL 
(B16F10)). Dextrin-PLA2 was also cytotoxic in a dose-dependent manner in all cell 
lines and there was a tendency towards increased cytotoxicity compared to free PLA2 
(ICso = 16.3 pg/mL (HT29), 62.9 pg/mL (MCF-7), 133.3 pg/mL (B16F10)). Both
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Figure 5.4 Morphology and growth curves for HT29, MCF-7 and B16F10 cells.
Panel (a) HT29, panel (b) MCF-7, and panel (c) B16F10 cells. Panels d, e and f) show 
typical growth curve for the cell lines over 8 days. Pictures taken by bright field 
microscopy. Size bar = 10  pm. Cells were seeded at a density of 4 x 104 cells/mL (HT29 
and B16F10) and 1 x 104 cells/mL (B16F10). Data shown represents the mean (n=6 ) ± 
SD.
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Figure 5 S  Cell viability of HT29, MCF-7 and B16F10 cells incubated with native 
PLA2, dextrin and dextrin-PLA2 conjugate. Data represents % normal growth of 
control cells ± SEM, (n = 18). Where error bars are invisible they are within size of data 
points. * indicates significance compared to free PLA2 control, where p<0.05 (ANOVA 
and Bonferroni post hoc test). NS defines no significant difference, where p>0.05, 
(calculated using ANOVA).
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Table 5.4 IC50 values for PLA2, dextrin and dextrin-PLA2 in HT29, MCF-7 and B16F10 cells.
Cell line Tumour origin p l a 2
ic50 (ng/mL)
Dextrin Dextrin-PLA2 % change
HT29 Human colon cancer 40.0 ±2.0 >1000 16.3 ±2.3 159
MCF7 Human breast cancer 308.6 ±6.9 >1000 62.9 ±5.7 180
B16F10 Murine melanoma 108.3 ±13.8 >1000 133.3 ±21.1 f  23
Data represents IC50 ± SEM, (n = 18).
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free and dextrin-conjugated PLA2 were most toxic in HT29 cells, having the highest 
level of EGFR expression.
5.3.2 Effect of EGF on viability of cells treated with PLA2 and dextrin-PLA2 
conjugate
When cells were incubated with EGF alone (up to 500 ng/mL), there was no 
significant effect on cell viability/ growth (Figure 5.6).
When cells were incubated with EGF and PLA2 or dextrin-PLA2, the IQq values 
were derived from data represented in Figure 5.7 and are summarised in Table 5.5. 
Addition of EGF (10 ng/mL) and PLA2 to HT29, MCF-7 and B16F10 cells led to an 
increase in PLA2 toxicity. The IQo values seen decreased for all cell lines (26.5 
pg/mL, 192.5 pg/mL and 194.0 pg/mL for HT29, MCF-7 and B16F10 cells, 
respectively).
In contrast, when dextrin-PLA2 was added together with EGF there was a 
marked decrease in toxicity. The IC^ values increased in all cell lines tested (91.2 
pg/mL, 463.6 pg/mL and 339.4 pg/mL for HT29, MCF-7 and B16F10 cells, 
respectively). There was a significant difference between cytoxicity of the treatment 
combinations in the different cell types (where p<0.05 (ANOVA and Bonferroni post 
hoc test)).
5.3.3 Effect of gefitinib on viability of cells treated with PLA2 and dextrin- 
PLA2 conjugate
Addition of gefitinib to HT29, MCF-7 and B16F10 cells caused concentration- 
dependent toxicity in all cases (Figure 5.8). The IC50 values were in the micromolar 
range for all cell types, namely 9 pM, 55 pM and 2.5 pM for HT29, MCF-7 and B16 
F10 cells, respectively.
Addition of gefitinib (1 pM) together with PLA2 during incubation of HT29, 
MCF-7 and B16F10 cells led to decreased cytotoxicity (Figure 5.9 and IC^ values 
are summarised in Table 5.6). An increase in the IC^ values was seen for all cell 
lines tested (254.5 pg/mL, > 500 pg/mL and > 500 pg/mL for HT29, MCF-7 and 
B16F10 cells, respectively).
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Figure 5.6 Cell viability of MCF-7, HT29 and B16F10 cells after 72 h incubation 
with EGF. Data represents % normal growth of control cells ± SEM, (n = 18). Where 
error bars are invisible they are within size of data points. NS defines no significant 
difference (p>0.05), calculated using ANOVA.
163
Chapter 5 In vitro Cytotoxicity o f Dextrin-PLA2
EGF ( 10 ng/mL)
Dextrin-PLA.
EG F
Dextrin
P A ,
[PLA2 eq.] (ug/mL)[PLA2 eq ] (pg/mL)
EGE t IQ EGF (1 0  ng/mLi
N S N S
n s  D extrin-PLA
■ S +  EG F
NS
Dextrin'
PA ,
[PLA2 eq.] (ng/mL) [PLA2 eq ] (ng/mL)
EGEJJS1 EGEUSLpg/mL)
> D e x tr in -P A . 
V+ E G F
Dextrin'
P A ,
0.1 1 10 100 1000 0.1 1 10 100 1000 
[PLA2 eq.] (|^g/mL) [PLA2 eq.] (ixg/mL)
Figure 5.7 Cytotoxicity of PLA2, PLA2 + EGF, dextrin-PLA2 conjugate and 
dextrin-PLA2 conjugate + EGF against HT29 (panels a, b), MCF-7 (panels c, d) 
and B16F10 (panels e, f) cells after 72 h incubation. Data represents mean ± SEM (n 
= 18). Where error bars are invisible they are within size of data points. * indicates 
significance compared to PLA2 or dextrin-PLA2 control, where p<0.05 (calculated 
using student’s t-test). NS defines no significant difference, where p>0.05.
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Table 5 3  ICst values of PLAa and dextrin-PLA2 +/- EGF in HT29, MCF-7 and B16F10 cells.
Cell line EGFR status
-E G F
PL A2 (fig/mL) 
+ EGF % change
Dextrin-PL A2 (pg/mL) 
- EGF + EGF % change
HT29 +++ 40.0 ±2.0 26.5 ±4.5 134 16.3 ±2.3 463.6 ±50.0 f  2744
MCF7 + 308.6 ±6.9 192.5 ± 12.0 138 62.9 ±5.7 91.2 ±36.7 f  45
B16F10 108.3 ±13.8 194.0 ±20.8 f  79 133.3 ±21.1 339.4 ±70.8 f  155
Data represents IC^ ± SEM, (n = 18).
0\
Table 5.6 IC50 values of PLA2 and dextrin-PLA2 +/- gefitinib in HT29, MCF-7 and B16F10 cells.
Cell line EGFR status PLA2 (pg/mL) Dextrin-PLA2 (p.g/mL)
- gefitinib + gefitinib % change - gefitinib +gefitinib % change
HT29 +++ 40.0 ±2.0 254.5 ±5.2 f  477 16.3 ±2.3 516.7 ±12.5 f  4135
MCF7 + 308.6 ±6.9 >500 62.9 ±5.7 358.3 ±37.5 f  1170
B16F10 - 108.3 ± 13.8 >500 133.3 ±21.1 383.3 ±41.7 f  293
Data represents IC50 ± SEM, (n = 18).
Chapter 5 
In 
vitro 
Cytotoxicity 
of Dextrin-PLA
2
Chapter 5 In vitro Cytotoxicity o f Dextrin-PLA2
120
100-JZ
%
£
4— l
O)
CO
EL_ MCF-760-oc
v*—o
nO0s- 40-
B16F10 \20 -
HT29
0.01 0.1 1 10 100
[Gefitinib] (pM)
Figure 5.8 Cell viability of HT29, MCF-7 and B16F10 cells incubated with gefitinib
for 72 h. Data represents % normal growth of control cells ± SEM, (n = 18). Where error 
bars are invisible they are within size of data points. * indicates significance compared to 
B16F10 control, where p<0.05 (ANOVA and Bonferronipost hoc test).
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Figure 5.9 Cytotoxicity of PLA2, PLA2 + gefitinib, dextrin-PLA2 conjugate and 
dextrin-PLA2 conjugate + gefitinib against HT29 (panels a, b), MCF-7 (panels be, d 
and B16F10 (panels e, f) cells after 72 h incubation. Data represents % normal growth 
of control cells ± SEM, (n = 18). Where error bars are invisible they are within size of 
data points. * indicates significance compared to PLA2 or dextrin-PLA2 control, where 
p<0.05 (calculated using student’s t-test). NS defines no significant difference, where 
p>0.05.
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Similarly, when gefitinib ( 1  pM) was added together with dextrin-PLA2 
conjugate, toxicity was also decreased for all cell types (IQo values = 516.7 pg/mL,
358.3 pg/mL and 383.3 pg/mL for HT29, MCF-7 and B16F10 cells, respectively). 
This effect was most marked for HT29 cells and was least noticeable in B16F10 
cells. There was a statistically significant difference between cytotoxicity of the 
treatment combinations in the different cell types (where p<0.05 (ANOVA and 
Bonferroni post hoc test).
5.3.4 Combination of doxorubicin with PLA2 or dextrin-PLA2 conjugate
When MCF-7 cells were incubated with doxorubicin and PLA2 or dextrin-PLA2, 
cytotoxicity was significantly increased compared to the doxorubicin control, where 
p<0.05 (ANOVA and Bonferroni post hoc test) (Figure 5.10). Doxorubicin alone had 
an IC5Q value of 173.3 ng/mL, whereas addition of PLA2 or dextrin-PLA2 conjugate 
(50 pg/mL PLA2-equiv.) decreased the IQo values to 36.7 ng/mL and 8.3 ng/mL, 
respectively (summarised in Table 5.7).
5.4 Discussion
5.4.1 Cytotoxicity of PLA2
Previous studies reported the IC50 values of the PLA2, crotoxin, to be in the 
range of 50-100 pg/mL and 42 pg/mL in MCF-7 and HT29 cells, respectively 
(Donato et al, 1996; Yan et al, 2007). These values are similar to those obtained here 
with the bee venom PLA2. Interestingly, Martikainen et al (1993) found no toxic 
effects when incubating MCF-7 cells with bee venom PLA2. However they only 
investigated PLA2 concentrations up to 4.5 U/mL (1.25 pg/mL) for 72 h, and since 
these studies showed that bee venom PLA2 had an IG*, of 308.6 pg/mL over a 72 h 
incubation, this lack of toxicity is not surprising.
5.4.2 Cytotoxicity of dextrin-PLA2 conjugate
The cell viability studies conducted here (Figure 5.5, Table 5.4) showed that the 
dextrin-PLA2 conjugate retained the cytotoxicity of native enzyme against all three 
cell lines studied. In fact, the IC^values observed for the dextrin-PLA2 conjugate 
were lower, suggesting that the conjugate may be more active against these cells
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Figure 5.10 Cell viability of MCF-7 cells incubated with doxorubicin +/- PLA2 and 
dextrin-PLA2 conjugate (50 pg/mL PLA2 eq.) for 72 h. Panel (a) shows effect of 
doxorubicin concentration on cell viability. Data represents % normal growth of control 
cells ± SEM, (n = 18). Where error bars are invisible they are within size of data points. 
* indicates significance compared to doxorubicin control, where p<0.05 (ANOVA and 
Bonferroni post hoc test). NS defines no significant difference, where p>0.05 (calculated 
using ANOVA).
Table 5.7 IC50 values estimated from MTT assay (72 h) of MCF-7 cells 
incubated with doxorubicin +/- PLA2 or dextrin-PLA2 conjugate.
IQ . (ng/mL)
Doxorubicin Doxorubicin Doxorubicin
+ p l a 2 + dextrin-PLA2
173.3 ±45 36.7 ± 3.3* 8.3 ±3.3*
Data represents % normal growth of control cells ± SEM, (n = 18). 
* p<0.05, vs. doxorubicin
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lines than crotoxin. This was surprising given the potential masking of PLA2 activity 
observed in Chapter 4.
It is postulated that while native PLA2 hydrolyses phospholipids rapidly 
(turnover rate (K^) = 1 3 0  s 1 (derived from native bee venom hydrolysis of 1,2- 
dimyristoyl-jn-glycero-3-phosphomethanol (DMPM) vesicles in the scooting mode 
at pH 8)) (Annand et al, 1996), the dextrin-PLA2 conjugate is likely to have a slower 
turnover rate. Therefore, cytotoxicity after 72 h is the same for both free and 
conjugated PLA2. In addition, the FCS present in the cell culture media contains 
proteins, including a-amylase. Over 72 h incubation this would be expected to 
slowly unmask the conjugated PLA2. It was previously shown in Chapter 4 that 
succinoylated dextrin is degraded by a-amylase within 16 h (t1/2 = 30 min).
5.4.3 Mechanism of action of PLA2 and conjugate cytotoxicity
Interestingly, dextrin-PLA2 appeared to be more toxic towards HT29 (IQo =
16.3 pg/mL) than MCF-7 (IC* = 62.9 pg/mL) and B16F10 (IC* = 133.3 pg/mL) 
cells. This might be due to (i) co-localisation of PLA2 to the EGFR (differences in 
expression reviewed in section 5.1.2), or (ii) differences in membrane composition of 
the various cell types.
Donato et al (1996) also noticed that crotoxin caused the most effective growth 
suppression in cells expressing high intrinsic levels of EGFR. Here, DiFi rectal 
carcinoma cells, having ~ 100 fold greater EGFR expression than HT29 cells, 
demonstrated ~ 20 fold greater sensitivity to crotoxin than HT29 cells (IQq = 2.2 
pg/mL (DiFi), 42 pg/mL (HT29)).
While the addition of EGF (10 ng/mL) to PLA2 enhanced the cytotoxicity seen 
in HT29 and MCF-7 cells (Figure 5.7, Table 5.5), the reverse was true when EGF 
was added to dextrin-PLA2. It is interesting to consider why.
Activation of EGFR induces very rapid trafficking of the internalised receptor 
pool to the cell surface resulting in initial upregulation of EGFR numbers (Mathur et 
al, 2000). This is followed by significantly accelerated endocytosis of EGFR-ligand 
complexes by clathrin-coated pits. After internalisation, the receptors are directed via 
endosomes to the lysosomal compartment for proteolytic degradation. This leads to
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EGFR downregulation and an associated reduction of growth factor signalling 
(Sorkina et al, 2002).
Perhaps when cells are treated with PLA2 in the presence of EGF they both 
interact with the cell surface immediately and can therefore take advantage of the 
high number of EGFR on the cell surface. However, since dextrin-PLA2 must first be 
unmasked, it may be that the EGFR are downregulated during the lag phase for PLA2 
release. Consequently, there would be less EGFR available on the cell surface for the 
dextrin-PLA2 conjugate to interact with. This hypothesis would explain the observed 
differences in cytotoxicity but the literature is confused in this respect.
Donato et al (1996) showed that pre-treatment of cells with 2 nM EGF (4 h) 
prior to crotoxin exposure partially suppressed its anti-proliferative activity in A431 
cells. They concluded that this was as a result of downregulation of EGFR since no 
direct binding of crotoxin to the receptor was observed. In another study, Goldberg et 
al (1990) studied the effect of EGF on PLA2 activity in HER14 cells. They showed 
that pre-incubation of cells with 16 nM EGF (20 min) increased PLA2 activity by 
226 ± 30 %.
Another plausible explanation for the relationship between PLA2 and EGFR 
stems from research showing that stimulation of epidermoid cells with EGF triggers 
immediate membrane ruffling and macropinocytosis (Araki et al, 2007; Hewlett et 
al, 1994). Since membrane ruffling requires actin, which in turn relies on TK- 
activated effectors such as Ras, SRC and PI 3-kinase found downstream in the EGFR 
signalling pathway (Figure 5.1), it follows that these two processes are connected. In 
fact, Jones (2007) reviewed a number of studies showing that activation of SRC 
oncogene, a non-receptor kinase, leads to macropinocytosis. Since it has been 
previously shown that PLA2 is most active towards unstable membranes (Burack and 
Biltonen, 1994; Jorgensen et al, 2002), it is feasible that EGF-induced membrane 
ruffling could disturb the cell’s membrane integrity and make it more prone to PLA2. 
Moreover, cells expressing higher levels of EGFR would be expected to display 
more extensive membrane ruffling.
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The PLA2 and dextrin-PLA2 conjugate cytotoxicity showed partial correlation 
with the EGFR expression. They were more cytotoxic towards HT29 than MCF-7 
and B16F10 cells. However, melanoma cells have been reported to constitutively 
express multiple growth factors (Rodeck et al, 1991) and it is possible that there are 
some non-specific effects of EGF occurring in B16F10 cells. For this reason, it is not 
surprising that B16F10 results did not always correlate with the predicted behaviour.
5.43.1 Evidence fo r a role o f the TK domain o f EGFR in the mechanism of dextrin- 
PLA2 cytotoxicity
Since there is evidence that TK activity is required for membrane ruffling and 
macropinocytosis, it is postulated that co-incubation of PLA2 and dextrin-PLA2 
conjugate with gefitinib, a TKI, inhibits these processes and its associated membrane 
destabilising effects. This theory would provide an explanation for the decreased 
sensitivity of cells exposed to PLA2 and dextrin-PLA2 in the presence of gefitinib.
An inverse correlation has been reported between the IQq value of gefitinib and 
the cell’s EGFR expression (Magne et al, 2002). This was also true in part here as 
gefitinib showed greater activity towards HT29 than MCF-7 cells. Interestingly, here 
B16F10 cells showed the greatest sensitivity to gefitinib. This is difficult to explain 
but could be due to non-specific effects of murine growth factor receptor inhibition.
The IQq values obtained in these studies were comparable to those described by 
Magne et al (2002b) who reported IC^ values of 6.1 pM and 31.2 pM for CAL33 
and Hep-2 cells, respectively. Since gefitinib selectively inhibits TK activity only at 
concentrations up to 1 pM (AstraZeneca, 2003) it is unlikely that these results are 
purely related to the effects on the EGFR signalling pathway. It is thought that at 
concentrations above 1 pM, the effects on cell viability cannot be solely attributed to 
inhibition of the EGFR pathway.
Addition of gefitinib (1 pM) to cells incubated with PLA2 or dextrin-PLA2 
conjugate led to diminished cytotoxicity of PLA2 and dextrin-PLA2 conjugate in all 
cases. This is consisitent with previous suggestions that PLA2 requires TK activity of 
the EGFR for its cytotoxic effects (Goldberg et al, 1990). Furthermore, crotoxin has 
been shown to stimulate tyrosine phosphorylation of the EGFR in A431 cells in
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vitro, but with no apparent binding to the receptor itself (Donato et al, 1996).
These results with gefitinib confirm that the EGFR TK domain is indirectly 
involved in the cytotoxicity of dextrin-PLA2 and suggest that it would not be 
clinically beneficial to administer dextrin-PLA2 conjugate with gefitinib as a 
combination therapy.
5.4.32 Alternative explanation
As briefly mentioned in section 5.4.3, there is a second possible explanation for 
the different cytotoxicities seen in the cell lines tested. Cancer cells are known to 
have a different membrane composition to normal cells (Monteggia et al, 2000; 
Punnonen et al, 1989). A PLA2 demonstrates preference towards certain 
phospholipids (PC, PE and SM). Therefore, it is possible that HT29 (and MCF-7, to 
a lesser extent) have a higher proportion of these phospholipids in their cell 
membranes.
Differences between the lipid composition of the cell membrane and the 
endosome membrane have also been described. However, while some research 
suggests that SM and PS are more enriched in endosomes than plasma membranes 
(Urade et al, 1988), others have reported a high SM and low PS content in both 
endosomes and the plasma membrane (Evans and Hardison, 1985). If endosomes and 
lysosomes contain high levels of PC, PE and SM, it is possible that PLA2 (or the 
dextrin-PLA2 conjugate) which has been endocytosed preferentially hydrolyses the 
endosomal membrane, rather than the cell membrane. This could result in cell death 
by the release of acidic contents and/or lysosomal enzymes.
These Endings led us to investigate whether PLA2 is internalised by the cell, and 
if conjugation to dextrin alters this process (Chapter 6).
5.4.4 Potential for combination therapy with doxorubicin
The use of doxorubicin continues to be limited by its cumulative dose-related 
cardiotoxicity and the related resistance mechanisms (reviewed in Hortobagyi, 
1997). Therefore, administering this drug in combination with dextrin-PLA2 might
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lead to improved activity.
In fact, the cytotoxicity of doxorubicin towards MCF-7 cells was enhanced by 
the addition of both PLA2 and dextrin-PLA2. Addition of doxorubicin to PLA2 did 
not enhance cytotoxicity as much as seen for dextrin-PLA2 conjugate. However, 
since dextrin-PLA2 conjugate alone was more toxic than free PLA2 in MCF-7 cells 
(Figure 5.5), the effects seen here appear to be just additive (i.e. A + B = C), and not 
synergistic (A + B = C**).
These findings are interesting considering that low, yet clinically relevant 
concentrations of doxorubicin, have been reported to inhibit iPLA2 activity in vitro 
and in vivo (Swift et aly 2003; Swift et al, 2007). Anthracycline-induced inhibition of 
porcine pancreatic sPLA2 has also been described, suggesting that it is not just iPLA2 
that is susceptible to inhibition (Mustonen and Kinnunen, 1991).
5.5 Conclusions
These studies demonstrated that dextrin-PLA2 was equal to or better than free 
PLA2 as a cytotoxic agent towards HT29, MCF-7 and B16F10 cells in vitro. There 
was generally a correlation between EGFR expression and PLA2-mediated 
cytotoxicity, with cells expressing higher levels of EGFR being more susceptible to 
the anti-proliferative activity of PLA2.
Whereas the activity of free PLA2 was enhanced by the addition of EGF, the 
activity of the conjugate was reduced. This was presumably due to the altered 
kinetics of PLA2 bioavailability.
It has been shown that inhibition of the TK domain of EGFR reduces 
cytotoxicity of PLA2 and dextrin-PLA2, implying that PLA2 requires TK activity of 
the EGFR for its activity.
Finally, addition of doxorubicin to MCF-7 cells incubated with PLA2 or dextrin- 
PLA^ resulted in additive, but not synergistic cytotoxic activity.
To investigate further the cellular fate of the dextrin-PLA2 conjugates flow 
cytometry and confocal microscopy were used to examine cell uptake and 
intracellular trafficking (Chapter 6).
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Chapter Six
Cellular Uptake and Intracellular Localisation of OG-labelled
Dextrin-PLA2 Conjugates
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6.1 Introduction
It has been shown that dextrin-PLA2 conjugates retained the cytotoxicity of free 
PLA2 (Chapter 5). However, it remained unclear whether PLA2 was acting at the cell 
surface, or on endosomal membranes following internalisation (Figure 6.1). 
Therefore, the aim of this study was to investigate to what extent dextrin-PLA2 
conjugates are taken up by cells and to compare uptake to that of unconjugated PLA2 
and dextrin. It was hoped that this might clarify whether PLA2 exerts its lipolytic 
activity at the cell surface, or inside endosomes after internalisation.
Flow cytometry was used to quantitate cell uptake at 37 °C, and cell binding at 4 
°C. In parallel, confocal microscopy was used to visualise the intracellular fate of 
fluorescently labelled dextrin, dextrin-PLA2 conjugate and PLA2.
6.1.1 Need to study endocytosis and trafficking of dextrin-PLA2 conjugates
Although interfacial catalysis by PLA2 has been widely studied in terms of
enzyme kinetics and EGFR involvement (Scott et al, 1990; van den Berg et al, 
1995), its endocytic pathway has not been as well characterised. While most research 
assumes that PLA2 acts at the cell surface, there are a number of factors that suggest 
that PLA2 could preferentially act on endosomal or other intracellular membranes 
following endocytosis. These include: (i) PLA2’s preference for curved membranes 
(Best et al, 2002), and (ii) the potentially higher endosomal content of phospholipids 
that are preferentially hydrolysed by PLA2 (PC, PE and SM) (Diez et al, 1994; 
Monteggia et al, 2000). Moreover, previous studies have shown that crotoxin induces 
upregulation of lysosomal enzymes, and an increased formation of autophagosomes 
and autophagic vacuoles (Yan et al, 2007).
Polymer conjugation has been widely used as a means of improving drug 
delivery (reviewed in Duncan, 2007; reviewed in Haag and Kratz, 2006). However, 
while polymer-protein conjugation has shown particular success for the delivery of 
proteins to extracellular targets, intracellular delivery has proved to be more 
challenging (Brown et al, 2001). Therefore, it was important to establish whether 
conjugation of PLA2 to dextrin would alter its endocytic properties.
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Figure 6.1 Schematic of the possible sites of PLA2 activity. Where (1) co-localisation 
to EGFR triggers hydrolysis of phospholipids in cell membrane, (2) hydrolysis of 
endosomal membrane phospholipids, and (3) hydrolysis of lysosomal membrane 
phospholipids.
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6.1.2 Mechanism of uptake
Given that polymer-protein conjugates typically have a diameter of ~ 20 nm 
(reviewed in Duncan, 2003) they are potentially liable to internalisation by a number 
of different endocytic pathways, as shown schematically in Figure 6.2.
These are briefly described here in more detail:
1. Clathrin-mediated endocytosis: Clathrin-coated pits have a diameter of ~ 120 
nm. Typically, the assembly of a clathrin coated basket-like structure results in 
membrane invagination and eventual internalisation of a variety of ligand-receptor 
complexes into clathrin-coated vesicles (reviewed in Johannes and Lamaze, 2002). 
Since it has been suggested that PLA2 interacts with EGFR and/or its ligand (Donato 
et al, 1996; Hack et al, 1991; Margolis et al, 1988; Zhao et al, 2002) and EGF is 
known to be internalised by clathrin-mediated endocytosis (Sorkina et al, 2002), it is 
plausible that PLA2 could be internalised by this mechanism. Some studies have 
suggested that while negatively-charged nanoparticles do not utilise the clathrin- 
mediated endocytic pathway for endocytosis, positively charged nanoparticles are 
rapidly internalised by this mechanism (Harush-Frenkel et al, 2007). Consequently, 
given that succinoylated dextrin has a net negative charge as a result of the unreacted 
carboxylic acid groups, dextrin-conjugation may influence uptake of PLA2 by this 
route.
2. Caveolae-mediated endocytosis: Caveolae are flask-shaped invaginations of the 
cell membrane with a diameter of 50-90 nm (reviewed in Nichols, 2003), meaning 
that a typical polymer-protein conjugate could be taken up by the cell by this route. 
Studies of cationic polymers have shown that they use the caveolae-mediated route 
of endocytosis for cellular uptake (van der Aa et al, 2007), which could imply that 
dextrin-PLA2 conjugates may be precluded from this route since dextrin would mask 
the enzyme’s charge.
3. Macropinocytosis: Macropinosomes occur as a result of membrane ruffling and 
subsequent formation of big vesicles called macropinosomes (1-5 pm). 
Macropinocytosis occurs constitutively in some tumour cells (reviewed in Johannes
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Figure 6.2 Simplified schematic of the possible routes of uptake of dextrin-PLA2 
conjugates. Adapted from Connor and Schmid (2003); Sorkin (2000).
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and Lamaze, 2002), although it is more commonly a triggered event, most notably 
following stimulation by EGF (West et al, 1989). Since there is evidence that PLA2 
activity is associated with EGFR (Chapter 5), PLA2 may itself stimulate 
macropinocytosis by this mechanism. Furthermore, the large size of macropinosomes 
permits the inclusion of dextrin-PLA2 conjugates, which are ~ 20 nm.
4. Non-clathrin. non-caveolin-dependent endocvtosis: This non-specific
internalisation mechanism is thought to involve formation of vesicles with a diameter 
of ~ 90 nm (reviewed in Connor and Schmid, 2003), which could allow uptake of a 
dextrin-PLA2 conjugate.
Macromolecules can also be endocytosed by phagocytosis. This process is 
conducted primarily by specialised cells, including macrophages, monocytes and 
neutrophils (reviewed in Connor and Schmid, 2003). However, since phagocytosis is 
a highly regulated process involving specific cell-surface receptors and signaling 
cascades, it is not likely that dextrin-PLA2 conjugate would be susceptible to this 
route of cellular uptake. In all cases though, PLA2 and dextrin-PLA2 conjugate could 
be taken up by fluid phase pinocytosis if internalised as solutes.
After internalisation, all macromolecules are directed towards the early 
endosomes (Gruenberg, 2001; Jones et al, 2003). Subsequently, they can be 
transferred to: (i) the degradative pathway (endosomes and lysosomes) (Luzio et al, 
2001); (ii) the recycling pathway (Maxfield and McGraw, 2004); and (iii) the 
endoplasmic reticulum after trafficking through the Trans-Golgi network and Golgi 
apparatus.
Although no correlation has been found between ‘entry route’ of polymer 
therapeutics and their subsequent trafficking, it is important to determine the cellular 
fate of dextrin-PLA2 conjugates, since this may affect the cytotoxicity of PLA2. For 
example, it was previously suggested that polymeric vectors for protein delivery do 
not promote cytosolic access if they are rapidly trafficked to the lysosomes (reviewed 
in Duncan, 2003).
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6.1.3 Selection of a fluorescent probe
In order to follow the intracellular fate of dextrin, PLA2 and dextrin-PLA2 by 
flow cytometry and confocal microscopy it was first necessary to label them with a 
fluorescent probe. Before conjugation, it was essential to select an appropriate probe. 
A hydrophobic probe would promote non-specific cell binding or alter the 
conformation of the polymer or protein, thus altering its intracellular trafficking.
OG was selected as the fluorescent probe of choice here since it has previously 
been conjugated to cationic PAMAM dendrimers and linear and branched PEI (Seib 
et al, 2007) as well as HPMA copolymer conjugates (Wallom, 2008). The 
fluorescence excitation and absorption wavelengths (X.ex = 488 nm and A.em = 520 nm) 
and molar extinction coefficient of OG are similar to those of FITC, a popular 
fluorescent probe, however, FITC has the disadvantage of being susceptible to 
photobleaching and fluorescence quenching at pH < 7 and following protein 
conjugation (Lanz et al, 1997). OG, on the other hand, has demonstrated better 
photostability and the fluorescence of OG is less susceptible to quenching upon 
protein conjugation (Invitrogen Molecular Technologies, 2006).
Intracellular trafficking can expose polymer conjugates to markedly different 
environments within the cell, so it was important for the fluorescent probe to be 
unaffected by the changing pH through the endocytic pathway. pH-dependent 
quenching of fluorescent probes leads to inaccurate quantification of cell-associated 
fluorescence, because equal quantities of fluorescent probe would lead to altered 
fluorescent outputs, depending on its cellular localisation. OG has demonstrated less 
pH dependent quenching between pH 5.5-7.4 than FITC (where pH 5.4, 6.4 and 7.4 
correspond to the pH found in the extracellular environment, endosomes and 
lysosomes, respectively) (Seib et al, 2007).
6.1.4 Flow cytometry
Flow cytometry was used to monitor cell uptake and binding. It allows rapid 
analysis of a large number of cells for the individual measurements of cell 
fluorescence and light scattering (Melamed et al, 1990). Further categorisation and 
cell sorting of cell populations by parallel staining of other cellular parameters, 
including DNA, is also possible using this system (Lostumbo et a l, 2006). This
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technique has been used to assess accumulation of fluorescent drugs, such as 
doxorubicin (Dordal et al, 1995; Greco et al, 2007) and fluorescently labelled 
polymers (Seib et al, 2007; Shukla et al, 2006) in cells. Flow cytometry was chosen 
because it is more sensitive than simple measurement of cell-associated fluorescence 
and does not require fixation or digestion prior to measurement (Ramanathan, 1997).
6.1.5 Confocal microscopy
Confocal microscopy allows visualisation of several co-incubated fluorescent 
probes to enable comparison of their cellular localisation relative to specific 
intracellular organelles and it has been widely used to visualise the cellular fate of 
fluorescently-labelled polymer conjugates (Nan et al, 2005; Seib et al, 2007). It has 
the advantage that live cell imaging avoids fixation artefacts.
However, fixation of cells brings the advantage of enabling immunostaining of 
specific markers and definitive subcellular localisation of fluorescently-labelled 
components. Unfortunately, traditional fixation methods, such as aldehyde cross- 
linking followed by detergent extraction or cold solvent precipitation/extraction are 
inappropriate, since they permeabilise intracellular membranes, allowing non-fixed 
materials, including water-soluble polymers, to diffuse out of their subcellular 
compartments. The main challenge associated with fixation of polymers for 
fluorescence microscopy is ensuring their containment within the vesicular 
compartments they occupy in living cells.
We recently developed a new method of cell fixation to circumvent these 
fixation problems and ensure retention of OG-labelled dextrin within specific 
intracellular vesicles (Richardson et al, 2008). In these studies, the early endocytic 
compartments of MCF-7 cells were identified using an antibody to early endosomal 
antigen 1 (EEA1) (Mills et al, 1999), and late endocytic structures (including late 
endosomes and lysosomes (LE/L)) were characterised using an antibody to 
lysosome-associated membrane protein 1 (LAMP-1) (Luzio et al, 2001). Here these 
techniques were used to follow the intracellular fate of OG-labelled dextrin.
6.1.6 Aims of this study
In summary, the aims of these studies were to:
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• Synthesise, purify and characterise OG-labelled dextrin, PLA2 and 
dextrin-PLA2. Also, it was important to investigate the effect of 
conjugation on the fluorescence properties of OG.
• Measure the intracellular uptake (37 °C) and extracellular binding (4 °C) 
of OG-labelled conjugates by MCF-7 cells over 1 h using flow 
cytometry.
• In parallel, fluorescence microscopy (confocal microscopy) was used to 
visualise the cellular localisation of the OG-labelled conjugates in MCF- 
7 cells using EEA1 to mark early endosomes and LAMP-1 to label late 
endosomes.
6.2 Methods
Succinoylated dextrin was prepared as described in section 3.2.2. EFdex6 (22.3 
mol % succinoylation) was used for these studies. Dextrin-PLA2 conjugates were 
synthesised and characterised according to methods described in Chapter 4. 
DexPLA6 (MW ~ 190,000 g/mol; PLA2 content 6.1 wt. %) was used in these studies.
The general methods used in these studies for conjugate characterisation 
included the BCA assay (section 2.4.4.3), SDS PAGE (section 2.4.4.2) and FPLC 
(section 2.4.4.1).
6.2.1 OG-labelling of dextrin, PLA2 and dextrin-PLA2 , and conjugate 
characterisation
The methods used are summarised in Figure 6.3.
First, OG cadaverine was conjugated to dextrin and PLA2 . Succinoylated dextrin 
(150 mg) and PLA2 (5 mg) were each dissolved under stirring in 1 mL PBS buffer 
(pH 7.4) in a 10 mL round-bottomed flask. To this, EDC (20 molar eq.) was added, 
and the mixture allowed to dissolve for 10 min. Next, sulfo-NHS (20 molar eq.) was 
added to the mixture and left stirring for 40 min. Subsequently, OG (dissolved in 
ddH20 (5 mg/mL) and stored at -20 °C until use; 2 molar eq.) was added. NaOH (0.5
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M) was added dropwise to raise the pH to 8.0 and the reaction mixture was left 
stirring in the dark (5 h) and monitored by TLC.
Free OG solution and a crude reaction mixture were spotted onto a silica gel 
TLC plate (on aluminium support). It was placed in a tank containing the methanol 
solvent and allowed to run until the solvent front was 1 cm from the top. The spots 
were visualised under a UV light.
The conjugate was purified by SEC using a disposable PD-10 desalting column 
containing Sephadex G25 equilibrated with PBS (25 mL added in total). The entire 
reaction mixture was added to the column and 7 mL of the eluted PBS was collected, 
lyophilised and stored at -20 °C. UV spectroscopy was used to determine the total 
OG content. The OG-loading was determined by analysing a 1 mg/mL solution in 
PBS and relating this to a previously derived extinction coefficient for OG in PBS 
(pH 7.4) (75,000 L/mol/cm). Free OG content was always < 2 % of total OG content.
Specific activity (pg OG per mg OG-labelled conjugate) was calculated using 
the following equation:
Specific activity = (ug OG from UV) x % OG bound
(ptg OG/ mg OG conjugate) 100 x mg OG-labelled conjugate
The reaction mixture was characterised by SEC prior to and after purification by 
analysis of SEC fractions for fluorescence (free: bound OG). Fractions (0.5 mL) 
were collected in 0.5 mL eppendorf tubes (total 45 fractions). A sample of each 
fraction (100 pL) was placed in duplicate into a black 96-well microtitre plate and 
measured using a fluorescent plate reader (Kx = 485 nm, Km = 520 nm, gain 1000).
To estimate how much bound and free OG was present in each conjugate, a 
sample (50 pL) of the crude reaction mixture and final product were diluted to 0.5 
mL with PBS and subjected to PD-10 elution with PBS. The values were then plotted 
against fraction volume and bound OG was expressed as percentage of total 
fluorescence measure for all fractions.
Dextrin-PLA2 conjugate was prepared using OG-labelled dextrin synthesised as
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described above, and unlabelled PLA2, according to the methods described in section 
4.2.
6.2.2 Effect of OG-conjugation to dextrin, PLA2 and dextrin-PLA2 on 
fluorescence output
First, the fluorescence emission spectrum for OG and the OG-labelled 
conjugates was determined in ddHzO. OG and OG-labelled conjugates were 
dissolved in ddH20  (100 ng/mL OG-eq.) and their emission spectra measured using 
excitation and emission filters selected from the and A.em wavelengths of OG 
= 488 nm and kcm = 520 nm).
6.2.3 Measurement of MCF-7 uptake and binding by flow cytometry
The general methods used for flow cytometry and the data analysis were 
described in section 2.4.6.6. In these experiments all probes were used at an OG-eq. 
concentration of 1.5 pg/mL OG-eq. in all cases. An incubation of MCF-7 cells 
without probe was used to account for cell autofluorescence. The cytotoxicity studies 
involving PLA2 were performed after an incubation period of 72 h, so it is important 
to note that all uptake studies were undertaken for a maximum of 1 h, to ensure no 
cell toxicity. Throughout results are expressed as the cell-fluorescence association 
(geometric mean) of the viable cell population, corrected for cell auto-fluorescence.
6.2.4 Detection of free OG after incubation of OG-labelled conjugates with 
cells
Since liberation of free OG in the culture medium or after cell uptake could 
potentially cause artefacts in the cell fluorescence seen (due to more rapid uptake 
compared to macromolecular conjugates), the cell culture medium was subjected to 
analysis by PD-10 chromatography in specific experiments to measure the levels of 
free OG at the end of the incubation period.
First, a disposable PD-10 desalting column containing Sephadex G25 was 
equilibrated with PBS (25 mL added in total). A sample of the culture media was 
added to the PD-10 column (0.5 mL). Fractions (0.5 mL in PBS) were then collected 
in 0.5 mL eppendorf tubes (total 45 fractions). Then, 100 p,L of each fraction was
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placed (in duplicate) into a black 96-well microtitre plate and the fluorescence 
measured using a fluorescent plate reader (A*x = 485 nm, Xem = 520 nm, gain 1000). 
The values obtained were then plotted against fraction volume and free OG content 
was expressed as percentage of total fluorescence measured in all fractions.
FPLC was also used to evaluate the stability of OG-labelled dextrin-PLA2 
conjugates after incubation with MCF-7 cells. Cell culture media containing OG- 
labelled conjugate was removed from the 6-well plate using a pipette and 
immediately added to the PD-10 column (200 pL). The method for FPLC is 
described in section 2.4.4.1.
6.2.5 Confocal microscopy
Figure 6.4 shows a schematic summary of the protocols used for the 
fluorescence microscopy experiments conducted using MCF-7 cells.
MCF-7 cells were seeded in 12-well plates containing a sterile glass coverslip in 
each well (1 x 106 cells/mL) in WRPMI + 5 % FCS and allowed to adhere for 24 h. 
The medium was then replaced with either fresh medium containing:
• BSA-Texas Red (BSA-TR) (TR eq. at 50 pg/mL),
• OG-labelled dextrin and BSA-TR (OG eq. at 50 pg/mL, TR eq. at 50 
pg/mL),
• OG-labelled dextrin-PLA2 or OG-labelled PLA2 (OG eq. at 50 pg/mL).
The cells were incubated for either 4 h (BSA-TR, OG-labelled dextrin) or 1 h
(OG-labelled dextrin-PLA2 or OG-labelled PLA2) in the presence of 200 pM 
leupeptin (to minimise lysosomal degradation by proteases). Then the medium was 
removed and the cells were washed with PBS (37 °C, 3 x 0.5 mL). After the final 
wash, fresh medium (0.5 mL) containing 200 mM leupeptin was added for the 
prescribed chase time (16 h for BSA-TR, OG-labelled dextrin and BSA-TR; 4 h for 
OG-labelled dextrin-PLA2 or OG-labelled PLA2). At the end of the chase, the 
medium was removed and the cells were washed with PBS (37 °C, 3 x 0.5 mL) prior 
to cell fixation. Control cells (not incubated with a probe) were also prepared for 
analysis to account for the cell autofluorescence. Cells were fixed in either cold 
methanol (pre-chilled to -20 °C) and incubated for 5 min at -20 °C or placed in
187
Chapter 6 Cellular Uptake o f OG-labelled Conjugates
a) MCF-7 cells incubated with BSA-TR 
^4 h pulse
Cells washed
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Figure 6.4 Schematic describing the protocols used for confocal microscopy 
experiments. Panel (a) shows the methods used to generate data in Figures 6.12b and 
6.12c, and panel (b) shows the methods used to generate data in Figures 6.12a, 6.13 and 
6.14.
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freshly prepared 2 % w/v PFA (20 min, at 25 °C).
Those cells to be immunolabelled after aldehyde fixation were subjected to 
detergent extraction with PBS containing 50 mM glycine and 0.2 % v/v Triton-X 100 
(5 min, 25 °C), however, this step was omitted when imaging OG-labelled dextrin in 
order to maintain the integrity of the limiting membrane of intracellular vesicles and 
prevent leaking of OG-labelled dextrin from vesicles. Before immunolabelling, non­
specific binding sites were blocked by incubating the cells in 2 % v/v goat serum in 
PBS (60 min, 25 °C). The following dilutions were used for the primary 
hybridisation (60 min at 25 °C): anti-EEAl (1:300), anti-LAMP-1 (1:10). The 
secondary hybridisation was performed using anti-mouse antibodies labelled with 
either Alexafluor 488 or Cy5 for 60 min at 25 °C (1:500).
Confocal microscopy was performed on a Leica SP5 system. Standard 
procedures were followed to minimise bleed from one channel to another (giving rise 
to false positives) and sample photobleaching. All images were collected using 
monochromatic CCD cameras and data was collected using dedicated software 
supplied by the manufacturers. At least three representative images were obtained for 
each sample and exported as tagged image files (TIF); typical results are shown. 
Merged image were generated using Photoshop. Examples of co-localisation 
between the endocytic probe (i.e. BSA-TR) and the compartment marker (i.e. 
antibody) are indicated using arrows.
6.3 Results
6.3.1 Synthesis and characterisation of OG-labelled conjugates
TLC performed after a 5 h reaction at 20 °C in the dark showed a fluorescent 
spot on the baseline for OG-labelled conjugates while free OG moved up the plate 
with the solvent front. These reaction conditions were ample for efficient OG 
conjugation and all subsequent batches of OG-labelled conjugates were synthesised 
using this method.
Free OG eluted from the PD-10 column after 6.5 - 20 mL whereas the OG
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conjugates eluted in the void volume (0.5 - 4 mL), while unreacted OG eluted much 
later (4.5 -  20 mL) (Figure 6.5). Figure 6.5b-d shows typical elution profiles 
obtained for OG-labelled PLA2, OG-labelled dextrin and OG-labelled dextrin-PLA2 
conjugates, before and after purification by PD-10 column. The OG-labelled PLA2 
still had 11.3 % free OG after the first pass through the PD-10 column, therefore it 
was necessary to repeat the purification step with this conjugate to achieve 0.83 % 
free OG content. All conjugates used in these experiments contained < 1.51 % free 
OG. The characteristics of the OG-labelled conjugates synthesised are summarised in 
Table 6.1. All OG-labelled conjugates had similar specific activities (3.15 -  4.96 pg 
OG/ mg OG-labelled conjugate).
The fluorescence absorption and emission spectra of OG can be seen in Figure
6.6 ( ^  = 488 nm and X.era = 520 nm). The fluorescence excitation and emission 
spectra of OG-labelled conjugates are also shown in Figure 6.6, and are not markedly 
different from those of free OG.
6.3.2 Cell uptake of OG-labelled conjugates
An increase in cell-associated fluorescence was seen for all the OG-labelled 
conjugates after 1 h at 37 °C, with the increase seen for OG-labelled PLA2 being the 
greatest (Figure 6.7). Cell-associated fluorescence was reduced in all cases at 4 °C 
compared to 37 °C (Figure 6.8). When comparing the percentage of fluorescence 
which was attributable to the internalised OG-labelled conjugates, dextrin-PLA2 
conjugate showed the highest increase in internalisation after 60 min, with 76 % of 
total cell-associated fluorescence being internalised (Figure 6.9).
6.33  Stability of OG-labelled conjugates in vitro
Prior to incubation of OG-labelled conjugates with MCF-7 cells, OG-labelled 
dextrin, OG-labelled PLA2 and OG-labelled dextrin-PLA2 conjugate contained 0.49 
%, 0.83 % and 1.51 % of free OG, respectively. After 1 h incubation with MCF-7 
cells, free OG levels were estimated as 8.41 %, 15.88 % and 9.36 %, respectively 
(Figure 6.10a-c, Table 6.2).
FPLC of OG-labelled dextrin-PLA2 conjugate containing cell culture media
190
Chapter 6 Cellular Uptake o f  OG-labelled Conjugates
60000- — Free OG
50000-
40000-
8  30000-
3  20000 -  
L L
10000-
0 10 20
Elution volume (mL)
OG-labelled dextrin
60000-
^  50000- 
zj
40000-
8
30000-
Unreacted OG (crude)
c
<DO
V)
2
§  20000- 
LL
10000-
0 2010
Elution volume (mL)
Figure 6 5  Evaluation of reaction yield and purity  of OG-labelled conjugates using 
a PD-10 column. Panel a) shows the elution profile of free OG in PBS. Panels b-d show 
the elution profile of the crude and purified (b) OG-labelled dextrin, (c) OG-labelled 
PLA2, (d) OG-labelled dextrin-PLA2 conjugate. PD-10 columns eluted with PBS. (Cont. 
overleaf)
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Table 6.1 Characteristics of OG-labelled conjugates.
Name Molar ratio 
(OG: dextrin 
or PLA2)
Labelling efficiency 
(M-g OG/mg 
conjugate)
Free OG 
(%)
Dextrin-OG 0.51 4.96 0.03
p l a 2-o g 0.11 3.37 0.83
Dextrin-PLA2-OG 0.34 (dex: OG) 3.15 1.51
1.93 (PLA2: OG)
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Figure 6.6 Fluorescence excitation and emission spectra of OG (100 ng/mL) and 
evaluation of the effect of conjugation on the fluorescence spectrum. Panel a) shows 
the fluorescence emission spectra, and panel b) shows the fluorescence excitation spectra. 
OG and OG-labelled conjugates were studied in ddHzO.
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Figure 6.7 Uptake of OG-conjugates conjugates by MCF-7 cells at 4 °C. Panels a-c 
show scatter plots for cell associated fluorescence at 4 °C after incubation (1 h) with a) 
OG-labelled dextrin, b) OG-labelled PLA2 and c) OG-labelled dextrin-PLA2 conjugate. 
Panel d) shows a histogram to compare cell associated fluorescence of OG-labelled 
conjugates, compared to control cells. Control cells (incubated only with medium) are 
shown in black.
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Figure 6.8 Uptake of OG-labelled conjugates by MCF-7 cells at 37 °C. Panels a-c 
show scatter plots for cell associated fluorescence at 37 °C after incubation (1 h) with a) 
OG-labelled dextrin b) OG-labelled PLA2 and c) OG-labelled dextrin-PLA2 conjugate. 
Panel d) shows a histogram to compare cell associated fluorescence of OG-labelled 
conjugates, compared to control cells. Control cells (incubated only with medium) are 
shown in black.
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Figure 6.9 Cell associated fluorescence of OG-labelled dextrin, OG-labelled PLA2 
and OG-labelled dextrin-PLA2 conjugate by MCF-7 cells. Panel a) shows uptake of 
OG-labelled dextrin, OG-labelled PLA2 and OG-labelled dextrin-PLA2 conjugate at 37 
°C and 4 °C, and the calculated internalisation. Panel b) shows % of cell-associated 
fluorescence that represented by internalisation (((FL^ C-FL4 C)/FL37 c) x 100). Data 
represents mean ± SD, n = 3. * indicates signigficance compared to OG-labelled dextrin 
control, where p<0.05 (ANOVA and Bonferroni post hoc test). NS defines no significant 
difference, where p>0.05, (calculated using ANOVA).
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Figure 6.10 Evaluation of cell culture medium after incubation of MCF-7 cells with 
OG-labelled conjugates (1 h, 37 °C). Panels a-c show the PD-10 column elution profile 
of (a) OG-labelled dextrin, (b) OG-labelled PLA2, and (c) OG-labelled dextrin-PLA2 
conjugate. PD-10 columns eluted with PBS. (Cont. overleaf)
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Figure 6.10 Evaluation of cell culture medium after incubation of MCF-7 cells with 
OG-labelled conjugates (1 h, 37 °C). (Cont. from overleaf)
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Table 6.2 Summary of free OG released from OG-labelled conjugates 
during a 1 h incubation with MCF-7 cells.
Name Before incubation 
(%)
After incubation 
(%)
Dextrin-OG 0.49 8.41
p l a 2-o g 11.3 (1st purification) 15.88
0.83 (2nd purification)
Dextrin-PLA2-OG 1.51 9.36
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showed the presence of a number of extra peaks following incubation with MCF-7 
cells (Figure 6.11). These peaks corresponded to the elution volumes of free PLA2, 
free OG, and some additional peaks probably corresponding to smaller breakdown 
products.
6.3.4 Confocal microscopy
In parallel experiments, OG-labelled dextrin, OG-labelled PLA2 and OG- 
labelled dextrin-PLA2 were incubated with MCF-7 cells and the subcellular 
localisation was visualised using fluorescence microscopy (N.B. all fluorescent 
images are also presented in an electronic format to aid visualisation and the CD can 
be found at the back of the thesis, in Appendix II).
When incubated with MCF-7 cells (Figure 6.12b), BSA-TR was not detectable 
within EEA1 positive early endocytic compartments. Not surprisingly, after the 16 h 
chase it was found exclusively within LAMP-1 positive LE/L compartments (Figure 
6.12c). When cells were incubated with OG-labelled dextrin, after the 16 h chase 
clear vesicular labelling was seen in the perinuclear region and no apparent surface 
binding (Figure 6.12a). Moreover, the OG-labelled dextrin conjugate was exclusively 
co-localised to the BSA-TR containing vesicles. It was thus concluded that OG- 
labelled dextrin was also solely located within these LE/L structures.
When cells were incubated with OG-labelled PLA2 (1 h pulse, 4 h chase at 37 
°C) clear plasma membrane labelling was seen. There was negligible vesicular 
labelling at this shorter incubation time (Figure 6.13). OG-labelled dextrin-PLA2 
conjugate (1 h pulse, 4 h chase at 37 °C) also showed marked labelling of the plasma 
membrane, but in this case there was a small degree of vesicular labelling (Figure 
6.14). Imaging of EEA1 and LAMP-1 positive structures in these cells showed 
marked changes in vesicle distribution (Figure 6.13 and 6.14). The staining was seen 
predominantly around the edge of those cells treated with OG-labelled PLA2 and 
OG-labelled dextrin-PLA2 conjugate. There was no co-localisation of EEA1 or 
LAMP-1 probes with OG-labelled conjugates in any instance.
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Figure 6.11 FPLC characterisation of cell culture medium after incubation of MCF- 
7 cells with OG-labelled conjugates (1 h, 37 °C). Figure shows FPLC analysis of OG- 
labelled dextrin-PLA2 conjugate. FPLC column eluted with PBS. (Cont. overleaf)
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Figure 6.12 Representative confocal images of fixed MCF-7 cells showing cellular 
localisation of BSA-TR and OG-labelled dextrin. Cells were incubated with OG- 
labelled dextrin (4 h pulse and 16 h chase at 37 °C) and co-labelled with endosomal 
(EEA1) and lysosomal (LAMP-1) markers. Cells were seeded at a density of 1 x 104 
cells/mL. Size bar =10 p,m. Arrows indicate co-localisation of probes.
203
204
a-LAMP-1
Figure 6.13 Representative confocal images of fixed MCF-7 cells showing cellular localisation of OG- 
labelled PLA2. Cells were incubated with OG-labelled PLA2 (1 h pulse and 4 h chase at 37 °C) and co-labelled 
with endosomal (EEA1) and lysosomal (LAMP-1) markers. Cells were seeded at a density of 1 x 104 cells/mL. 
Size bar = 10 pm.
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Figure 6.14 Representative confocal images of fixed MCF-7 cells showing cellular localisation of OG- 
labelled dextrin-PLA2 conjugate. Cells were incubated with OG-labelled dextrin-PLA2 conjugate (1 h pulse 
and 4 h chase at 37 °C) and co-labelled with endosomal (EEA1) and lysosomal (LAMP-1) markers. Cells were 
seeded at a density of 1 x 104 cells/mL. Size bar = 10 pm.
Chapter 6 Cellular Uptake o f OG-labelled Conjugates
6.4 Discussion
Since neither dextrin nor PLA2 have inherent fluorescence it was necessary to 
label them with a fluorescent probe to study cell uptake and intracellular localisation. 
It was hoped that these studies would give further insight into the site of action of the 
dextrin-PLA2 conjugate, identify to what extent it was taken up by cells, and also 
define its intracellular fate, compared to unconjugated PLA2 and dextrin.
Synthesis of the OG-labelled conjugates was performed by reacting OG with the 
carboxylic acid groups of succinoylated dextrin or PLA2 (glutamic acid, aspartic acid 
residues and terminal COOH). A 5 h reaction time was chosen as TLC showed 
successful conjugation at this time. The conjugates prepared contained 3-5 p,g OG/ 
mg conjugate and in all cases, purification by PD-10 column successfully removed 
free OG from reaction mixtures, producing conjugates with < 1.51 % free OG as was 
also seen in the OG-labelled conjugates synthesised here. Ideally, OG-labelled 
conjugates should contain minimal free OG. A number of other OG-labelled polymer 
conjugates have been described in the literature (Table 6.3). Despite using different 
reaction conditions to conjugate OG to architecturally different polymers, similar 
molar ratios were achieved with dextrin in these studies.
OG conjugation to the probes studied here showed no change in the fluorescent 
profile of OG. This was particularly important to verify since previous studies have 
shown that the fluorescence of doxorubicin was quenched after conjugation to 
HPMA copolymers and yields were different in conjugates containing more than one 
drug (Greco et al„ 2007).
6.4.1 Cellular uptake of dextrin-PLA2 conjugate
While low molecular weight drugs can easily enter cells by passive diffusion, 
macromolecules are usually excluded from this route. Uptake is therefore limited to 
the endocytic route. The studies presented here confirmed internalisation of OG- 
labelled dextrin, OG-labelled PLA2 and OG-labelled dextrin-PLA2 conjugate by 
MCF-7 cells. However, the pattern of cell-associated fluorescence differed among 
the conjugates. OG-labelled PLA2 showed highest cell-associated fluorescence after
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Table 63 Characteristics of some polymer-OG conjugates described in the literature.
Polymer Reaction Molar ratio Labelling FreeOG Reference
conditions (OG/polymer) efficiency (% total)
(pg OG/ 
mg polymer)
PEI 2 h,RT NS NS NS (Godbey, 1999)
G5 PAMAM dendrimer 3 h,RT,pH 8.5 4.0 68.2 NS (Yoo and Juliano, 2000)
1.75 30.1 NS (Yoo and Juliano, 2000)
0.8 13.8 NS (Yoo and Juliano, 2000)
PEI (branched) MeOH,pH 8.5, 0.80 16.4 0.6 (Seib etal 2007)
PEI (linear) 2h,RT 0.73 15.0 0.7 (Seib et al, 2007)
G2 PAMAM dendrimer 0.50 78.6 0.1 (Seib et al, 2007)
G3 PAMAM dendrimer 0.56 41.5 0.2 (Seib et al, 2007)
G4 PAMAM dendrimer 0.71 25.6 0.6 (Seib et al, 2007)
HPMA copolymer DMSO, 16 h, RT 0.91 2.5 0.6 (Richardson et al, 2008)
mPEG-NH2 NaHC03 buffer 0.04 4.2 2.9 (Richardson et al, 2008)
pH 9,4h ,R T
Hyaluronic acid ddH20 ,p H  8, 0.9 3.4 0.1 (Gilbert, 2007)
20 h, RT
Dextrin PBS buffer, pH 8 0.51 4.96 0.03 (Richardson et al, 2008)
EDC/sulfo-NHS, 
5 h,RT
NS = not stated
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1 h at both 37 °C and 4 °C, while OG-labelled dextrin and OG-labelled dextrin-PLA2 
conjugate showed much lower rates of internalisation or extracellular binding. As 
PLA2 is known to act at the cell membrane it is not surprising that there was a high 
degree of extracellular binding for OG-labelled PLA2. As the extracellular binding of 
OG-labelled dextrin-PLA2 conjugate was so low, it would seem that dextrin 
conjugation has sterically masked the enzyme and reduced membrane binding. 
However, since the conjugate showed equivalent cytotoxicity to free PLA2 after 72 h 
(Chapter 5) it is proposed that sufficient time for unmasking is required for full 
enzyme activity, and this is not achieved within the 1 h incubation used here.
- In order to standardise the flow cytometry experiments, OG concentration was 
kept the same for all conjugates (1.5 pg/mL). However, it is worth bearing in mind 
that the concentration of dextrin and PLA2 differed among the OG-labelled 
conjugates in order to keep OG concentration constant. Table 6.4 summarises the 
concentrations of OG components applied to cells for flow cytometry studies. Given 
that OG-labelled dextrin-PLA2 conjugates contained 5.2 % protein, it is not 
surprising that PLA2 concentration in this study was low. This difference could affect 
the cellular uptake and localisation of the conjugated PLA2, compared to free 
enzyme, however it was felt that it was more important to standardise the OG content 
for these studies.
It was important to know if the probe used was stable during such cell culture 
experiments designed to study trafficking of the probes to confirm that 
internalisation was of the OG-conjugate, and not simply the free probe. Here, it was 
shown that some free OG was liberated from all the probes after a 1 h incubation 
with MCF-7 cells. This could have been due to enzymatic degradation of dextrin and 
PLA2, or hydrolysis of the amide bond to OG. The amide bond formed between OG 
and dextrin and PLA2 might be expected to be biologically stable (Banks and 
Paquette, 1995) but of course both dextrin and PLA2 are potentially biodegradable. 
Seib et al (2007) also observed some OG liberation and they speculated that there 
may be a degree of reversible complexation between OG and the polymers.
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Table 6.4 Comparison of the concentrations of OG, dextrin or PLA2 
applied to cells during the flow cytometry experiments.
Name
pg/mL
OG
mM
Dextrin 
pg/mL mM
p l a 2
pg/mL mM
Dextrin-OG 1.5 0.0030 302 1.664 -
p l a 2-o g 1.5 0.0030 - - 408 0.0282
Dextrin-PLA2-OG 1.5 0.0030 451 2.485 24.8 0.0016
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All OG-labelled conjugates showed evidence of internalisation, and a higher 
uptake was seen for OG-labelled PLA2. While OG-labelled dextrin and OG-labelled 
dextrin-PLA2 conjugate showed only 8-9 % free OG release over a 1 h incubation, 
the amount of OG released from OG-labelled PLA2 was double in the same time 
frame. Still, the amount of free OG in these studies was not high and previous studies 
have shown that while cells can readily take up free fluorophore, this could be easily 
removed during normal cell washing and should not significantly affect uptake 
observations (Seib et al, 2007).
6.4.2 Cellular localisation of dextrin-PLA2 conjugate
Visualisation of the subcellular localisation of OG-labelled dextrin uptake by 
confocal microscopy showed fluorescence in vesicular compartments which was 
consistent with an endocytic uptake and correlates with the internalisation seen with 
flow cytometry. Since cells were subjected to 4 h pulse and 16 h chase for the 
microscopy studies, it is not surprising that cellular uptake of OG-labelled dextrin 
appeared higher than seen in the flow cytometry experiments which were only 
conducted for 1 h.
It is also worth mentioning the different pulse-chase times used for confocal 
microscropy experiments. 4 h pulse with 16 h chase was first used for OG-labelled 
dextrin, however there were concerns that incubating cells with PLA2 or dextrin- 
PLA2 conjugate for this length of time could kill the cells. Richardson et al (2008) 
have shown that a 1 h pulse followed by a 4 h chase is sufficient time for trafficking 
to the lysosomes, therefore cellular localisation of the OG-labelled conjugates can 
still be compared. In the MTT assay, 55 % and 90 % viability was see when MCF-7 
cells were incubated for 72 h with PLA2 (408 pg/mL) and dextrin-PLA2 conjugate 
(24.8 pg/mL), respectively.
It is often assumed that PLA2 induces cell lysis by disruption of the cell 
membrane, however recent studies have shown it to be more complicated. Normally, 
after injury to the cell membrane, rapid resealing occurs with little loss of 
intracellular contents. However, studies undertaken by Steinhardt et al (1994) 
revealed that botulinum neurotoxins A and B are capable of blocking membrane
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resealing. Given that PLA2 acts by hydrolysing phospholipids, this effect could also 
result in inhibition of membrane repair.
When cells were incubated with OG-labelled PLA2 and OG-labelled dextrin- 
PLA2 conjugate, migration of endosomal and lysosomal vesicles towards the plasma 
membrane was observed (Figure 6.13 and 6.14). Direction of secretory vesicles to 
the cell membrane is well documented as a means of repairing damage to cell 
membranes (Reddy et al, 2001). Reddy et al (2001) showed that after cells were 
subjected to wounding by scratching the cell surface with a single-edge surgical 
blade, plasma membrane repair was mediated by Ca2+ regulated vesicle trafficking to 
the membrane. The authors hypothesised that fusion of lysosomes with the plasma 
membrane was triggered by elevated intracellular Ca2+ concentrations. Further 
studies by Jaiswal et al (2002) observed that many organelles, including the 
endoplasmic reticulum, post-Golgi vesicles, early endosomes, late endosomes, and 
lysosomes, were located within 100 nm of the plasma membrane after incubation 
with Ca2+ and they suggested that this could also be implicated in repair of 
membrane damage.
Similarly, transmission electron microscopy (TEM) and scanning electron 
microscopy (SEM) have also been used to visualise the effect of PLA2 on OVCAR-3 
cell membranes (Newman et al, 1996). SEM studies demonstrated cell separation, 
membrane damage and blebbing after 3 h treatment with PLA2, while longer periods 
of exposure revealed ‘holes’ in the membrane associated with severe disruption of 
the cell membrane. TEM also showed the formation of small lipid-containing 
vesicles inside the cells, which increased in number as PLA2 exposure time was 
extended.
The evidence here supports the hypothesis that PLA2 and dextrin-PLA2 
conjugate does indeed act at the level of the cell membrane causing damage by 
hydrolysis of phospholipids. This agrees with previous studies where cells that were 
incubated in the presence of 20 mM ammonium chloride or 0.5 mM quinacrine, 
(inhibitors of receptor-mediated endocytosis), did not appear to internalise PLA2 
(Alicea, 1998). Alicea (1998) also observed release of lactase dehydrogenase (LDH) 
into the medium, an increase in concentration of free palmitic acid in cell membranes
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and a concentration-dependant increased staining with trypan blue, all of which are 
consistent with membrane damage.
Considerations for confocal microscopy interpretation
A number of technical issues can limit the usefulness of confocal microscopy. 
These include limited optical resolution, the small number of cells that can be viewed 
relative to the entire population, artefacts produced during fixation, and incorrect 
interpretation of the data (North, 2006; Pearson, 2007). In these studies, OG was 
selected as the fluorescent probe to reduce the likelihood of artefacts, since it is less 
susceptible to photobleaching and both concentration- and pH-dependent 
fluorescence quenching. Careful loading of OG also ensured that cellular uptake and 
subsequent trafficking was due solely to dextrin, PLA2 or dextrin-PLA2 conjugate, 
and not simply probe-driven effects. Here, the intracellular localisation of OG- 
labelled conjugates was observed relative to both endocytosed physiological markers 
and indirect immuno-fluorescent labelling, in an effort to reduce making incorrect 
assumptions as to the compartments occupied by OG-labelled conjugates.
6.5 Conclusions
Fluorescent probes were synthesised using OG, with free OG content of < 1.51 
% of total OG content after purification by PD-10 column and specific activity was 
similar (specific activity = 3.15 -  4.96 pg OG/ mg OG-labelled conjugate) for all 
OG-conjugates synthesised. The fluorescence characteristics of free and bound OG 
and OG-labelled conjugates were similar.
It was concluded that PLA2, and OG-labelled dextrin-PLA2 conjugate to a lesser 
extent, interact with cells extracellularly, resulting in the migration of early and late 
endosomal vesicles to the cell periphery as a means of repairing membrane damage. 
It was also noted that dextrin conjugation reduced extracellular binding of PLA2.
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Investigating Dextrin-PLA2 Conjugates as a Trigger for 
Polymer Enzyme Liposome Therapy (PELT)
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7.1 Introduction
The evaluation of dextrin-PLA2 conjugate in the preceding chapters has 
demonstrated its potential as a novel therapeutic agent against cancer in it’s own 
right. However, there is also the possibility of using dextrin-PLA2 conjugates as a 
trigger for the release of drug encapsulated within liposomes. This concept has 
previously been named ‘Polymer Enzyme Liposome Therapy’ (PELT) (Duncan et al, 
2001). The concept of PELT has been previously introduced in detail in Chapter 1 
(section 1.5.2). Previous preliminary experiments have demonstrated proof of 
concept using HPMA copolymer-PLC with Doxil® and DaunoXome® (Satchi- 
Fainaro and Duncan, unpublished). Therefore the aim of this study was to establish 
whether a dextrin-PLA2 conjugate would also be capable of accelerating the rate of 
drug release from liposomes.
7.1.1 Recent progress in controlling liposomal drug release
Despite the many advantages of clinically used liposomal anticancer drugs, i.e. 
prolonging drug circulation time, and tumour targeting by EPR (reviewed in 
Torchilin, 2005), there remain some drawbacks to their use (described more fully in 
section 1.5.2). A major limitation is the relatively slow release of encapsulated drug 
at the target site. Therefore, research has been undertaken to try and enhance the drug 
release rate. Examples of currently used liposome formulations and the novel 
methods being explored to enhance active and tumour-specific drug release are 
shown in Figure 7.1.
Antibody-PLC conjugates
One approach has been the use of antibody-PLC conjugates to try and improve 
the release of daunorubicin from DaunoXome® (Carter et al, 1998) (Figure 7 .Id). 
This two-step method uses IV administration of an anti-carcinoembryonic antigen 
(CEA)/ EGFR antibody-PLC conjugate. Time is allowed for clearance and tumour 
targeting of the immunoconjugates, before the liposome-encapsulated daunorubicin 
is administered. It is postulated that the liposomes are specifically lysed in the 
tumour interstitium by the pre-targeted PLC, resulting in localised release of 
cytotoxic drug in the tumour. Results from fluorescence studies in vitro revealed an
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Figure 7.1 Schematics of liposomal formulations in clinical use and in 
development.
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increase in free daunorubicin in the medium of HeLa cells previously treated with 
anti-EGFR antibody-PLC conjugates. This group also looked at the effect of anti- 
EGFR antibody-PLC conjugates and DaunoXome® on A431 tumour xenografts in 
mice. They found that 50 days after the two-step treatment was administered, tumour 
growth was inhibited in 5 out of 6 mice compared with no effect in the 13 control 
mice treated with DaunoXome® alone or the anti-EGFR antibody (without PLC) and 
DaunoXome® (Carter et al, 1998).
LiPlasomes
Many solid tumours appear have a high concentration of sPLA2 in the tumour 
interstitium, with sPLA2 concentrations in the region of 9 to 188 ng/mL (Cupillard et 
al, 1999). Moreover, sPLA2 concentration is said to increase with tumour grade 
(Graff et al, 2001; Jiang et al, 2002). LiPlasomes, a form of liposomal drug carrier, 
which exploit the high concentration of intratumoural PLA2, have been developed to 
capitalise on this observation (Figure 7.1c). These novel lipidic systems are based on 
PEG-coated liposomes, and they contain phospholipids specially designed to be 
hydrolysed by the sPLA2 found in cancer tissues. It is postulated that this results in a 
site-specific release of encapsulated drug. Moreover, the phospholipids used to 
encapsulate the drug are ‘permeability proenhancer lipids’ that are converted to 
‘permeability enhancers’ after enzyme hydrolysis, which can further enhance drug 
diffusion across target cell membranes (Andresen et al, 2004a).
In vitro experiments have been undertaken with Liplasomes encapsulating 
doxorubicin, which show release of drug within 2-4 h in the presence of sPLA2- 
secreting colon cancer cells. Greater cytotoxicity was seen than for free drug. Doxil® 
alone showed only slow doxorubicin release and significantly less cytotoxicity after 
6 h treatment (Andresen et al, 2004b). Further in vitro studies using HT29 cells 
compared LiPlasome-encapsulated cisplatin with a clinically tested Stealth liposomal 
formulation. In this case the LiPlasome formulation had an IC^ value of 10 pM (ten­
fold lower than for free cisplatin) while the stealth liposomal platinate had an IC50 
value that was > 1000 pM (24 h incubation) (Andresen et al, 2004c).
The in vitro experiments using LiPlasomes have mainly used a group II PLA2
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extracted from snake venom (Agkistrodon piscivorus piscivorus). It is composed of a 
121 amino acids, eight of which are lysine residues (Han et al, 1997). In contrast, the 
human group IIA sPLA2 found endogenously in tumour tissues contains 124 amino 
acids, six of which are lysine residues. Human group IIA sPLA2’s expression and 
secretion is induced by pro-inflammatory agents (e.g. IL-2, TNF and particularly IL- 
6) and is inhibited by glucocorticoids (Diez et al, 1992). Studies by Cupillard et al 
(1999) showed that mouse group IIA sPLA2s have a high affinity to the mouse M- 
type membrane receptor (1-10 nM range), but much lower affinity to receptors from 
other animal species, including human.
These observations could mean that the LiPlasome may not be degraded in the 
same way in vivo as it has in vitro due to the use of snake venom PLA2 from a 
different species to the cells. Furthermore, studies comparing the activity of bee 
venom and bovine pancreas PLA2 described in section 4.3.1 showed a significant 
difference in in vitro cytotoxicity towards MCF-7 cells, with the mammalian PLA2 
being far less toxic. This is a potential limitation for LiPlasomes, which rely on 
human, intratumoural PLA2 for activation.
7.1.2 Choice of liposomal drug formulation: DaunoXome®
DaunoXome® was selected here as the model liposomal drug formulation. 
Doxil® and Myocet® have been previously described in detail in section 1.5.2 and 
Table 7.1 lists the characteristics of some liposomal drug formulations on the market.
DaunoXome® is commonly used as a first-line chemotherapy agent for advanced 
AIDS-related Kaposi’s sarcoma (Rosenthal et al, 2002). It is usually administered IV 
over 60 min at a dose of 40 mg/m2, with doses repeated every two weeks. 
DaunoXome® contains daunorubicin citrate (Figure 7.2) encapsulated in small 
unilamellar vesicles (SUV) dispersed in an aqueous medium containing sucrose, 
glycine and calcium chloride dihydrate (2 mg/mL, pH 4.9-6.0). DaunoXome® was 
selected since the liposomes are not PEGylated (unlike Doxil®). The PEG coat could 
sterically hinder access of the dextrin-PLA2 conjugate, decreasing phospholipid 
hydrolysis. Furthermore, studies on the body distribution of Doxil® suggests that 
drug clearance occurs in two phases, with a relatively short first phase (tm
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Table 7.1 Examples of liposomal drugs currently on the market.
Product name Indication 
Drug
Phospholipids 
(Drug/lipid ratio)
Liposome
type
Particle
diameter
Membrane incorporated drug
Abelcet® Invasive fungal infections in 
Amphotericin B immuno-compromised patients
DMPC: DMPG 7:3 
(1:1 molar ratio)
MLV < 5 pm
AmBisome® Visceral leishmaniasis 
Amphotericin B Cryptococcal meningitis in HIV- 
infected patients 
Aspergillus, Candida and/or 
Cryptococcus infections
HSPC 213 mg; DSPG 84 mg; 
cholesterol 52 mg; 
a-tocopherol 0.64 mg 
(1:6 w/w ratio)
SUV < 100 nm
Visudyne™ Age-related macular 
Verteporfin degeneration (AMD) 
Encapsulated drug
DMPC: EPG 
(1:7.5-15)
SUV < 100 nm
DaunoXome® Advanced HIV-related Kaposi’s 
Daunorubicin Sarcoma
DSPC: cholesterol 2:1 
(18.7:1 w/w ratio)
SUV ~45 nm
Doxil® Ovarian Cancer 
Doxorubicin
mPEG-DSPE: HSPE: 
cholesterol 1: 3: 1 
(1:6 w/w ratio)
LUV 100 nm
Myocet® Advanced HIV-related Kaposi’s 
Doxorubicin Sarcoma, Ovarian cancer, 
Advanced breast Cancer
EPC: cholesterol 1:1 
(1:4 molar ratio)
OLV 180 nm
DMPC- dimyristoyl phosphatidylcholine; DMPG- dimyristoyl phosphatidylglycerol; HSPC- hydrogenated soy phosphatidylcholine; DSPG- 
distearoyl phosphatidylglycerol; EPG- egg phosphatidylglycerol; mPEG-DSPE- N-(carbonyl-methoxypolyethylene glycol 2000)-1,2- 
distearoyl-sn-glycero-3-phosphoethanolamine sodium salt; EPC- egg phosphatidylcholine; MLV- multilamellar vesicle; SUV- small 
unilamellar vesicle ; LUV- large unilamellar vesicle ; OLV-Oligolamellar vesicle
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» 5 h) and a prolonged second phase (t1/2= 45 h) (Janknegt, 1996). This biphasic drug 
clearance is not seen with DaunoXome®, which has a t1/2 of ~ 5 h (Bellott et al, 
2001), and so it was decided that DaunoXome® would give a simpler drug release 
profile for these initial proof of concept studies than a PEGylated formulation.
When administered as free drug, daunorubicin has a t1/2 of 0.77 h. Its use is 
associated with severe acute toxicities including myelosuppression, alopecia, 
necrosis of tissue following extravasation and cumulative dose-limiting 
cardiotoxicity (maximum tolerated cumulative dose (MTD) = 550 mg/m2) (reviewed 
in Hortobagyi, 1997). Moreover, since daunorubicin is inherently fluorescent, 
monitoring drug release from the liposomes can be undertaken simply using a 
fluorescent platereader. Daunorubicin produces a three-peak fluorescence emission 
spectra (520 -  700 nm) corresponding to its triple helical complexes. It is well 
known that the shape of the fluorescence spectrum of daunorubicin is markedly 
changed by factors such as hydrophobicity of the solvent and intercalating with DNA 
(Goldman et al, 1978; Laigle et al, 1996).
7.1.3 PLA2 as a trigger for PELT
Although proof of concept studies for PELT used PLC to rupture liposomes, it 
was interesting to determine whether PLA2 could also be used. A number of studies 
have shown that sPLA2 can degrade liposomes (including bee venom PLA2) 
(Ghomashchi et al, 1998; Jorgensen et al, 1999a) and also it was shown here that 
dextrin-PLA2 conjugate retained activity in the cytotoxicity assays and the egg yolk 
emulsion assay (Chapters 4 and 5). An additional benefit of using a dextrin-PLA2 
conjugate as a component of PELT would be the option to combine its individual 
activity at the cell surface with improved liposomal action (Figure 7.1e).
Moreover, while PLC and HPMA copolymer have a similar molecular weight (~ 
30,000 g/mol) (HPMA copolymer was used as a polymer carrier for PLC (Satchi- 
Fanairo and Duncan, unpublished)) the dextrin used here (MW ~ 51,000 g/mol) is 
approximately 3 times larger than PLA2. This should allow greater protein masking 
as well as a better pharmacokinetic profile able to promote better tumour targeting by 
the EPR effect. As dextrin-PLA2 conjugate can be activated by a-amylase (the
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PUMPT concept (Chapter 4) this might enhance the slow unveiling of PLA2 to be 
able to release liposomally-entrapped drug.
7.1.4 Aims of these studies
To summarise, the aims of this study were:
• To evaluate the ability of free PLA2 and the dextrin-PLA2 conjugate to 
trigger the release of daunorubicin from DaunoXome®.
• To assess the effect of incubation of DaunoXome® with free PLA2 and 
dextrin-PLA2 conjugate on liposome size by photon correlation 
spectroscopy (PCS).
• To test the cytotoxicity of daunorubicin and DaunoXome® incubated 
with free PLA2 and the dextrin-PLA2 conjugate in MCF-7 cells.
7.2 Methods
Succinoylated dextrin was prepared as described in section 3.2.2. EFdex5 (20.9 
mol % succinoylation) was used for these studies. Dextrin-PLA2 conjugates were 
synthesised and characterised according to methods described in Chapter 4. 
DexPLA7 (MW ~ 195,000 g/mol; PLA2 content 9.4 wt. %) was used in these studies.
7.2.1 Fluorescence properties of free daunorubicin and DaunoXome®- effect of 
Triton X-100
First, the fluorescence emission spectrum of DaunoXome® was determined in 
PBS (pH 7.6) and a Triton X-100 solution (1 % v/v) (to solubilise liposomes and 
release daunorubicin). DaunoXome® was diluted in PBS (20 pg/mL), placed in a 
polystyrene cuvette (3 mL), and the emission was measured in the interval 500-700 
nm with the excitation wavelength set at Xex = 485 nm. For comparison, 
DaunoXome®, diluted in Triton X-100 solution (20 pg/mL in 1 % v/v Triton X-100 
solution), was monitored for fluorescence in the same way.
The effect of Triton X-100 concentration on the fluorescence of free 
daunorubicin was studied in various concentrations of Triton X-100. A stock solution 
of Triton X-100 was prepared in ddH2Q (1 % v/v) and serial dilutions were made to
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produce a range of concentrations (0 - 1 % v/v). A stock solution of daunorubicin (1 
mg/mL) was then diluted using Triton X-100 solutions to a final concentration of 20 
pg/mL. Daunorubicin + Triton X-100 solutions (3 mL) were transferred to a 
polystyrene cuvette and their fluorescence emission was measured in the interval 
500-700 nm and the excitation wavelength was set at Xex = 485 nm.
7.2.2 Stability testing of liposomes
PCS was used to measure mean diameter and polydispersity of DaunoXome® 
following incubation with dextrin-PLA2 conjugate, PLA2, Triton X-100 and in PBS. 
DaunoXome® (2 mg/mL) was diluted fresh on the day of experiment to 1:100 in PBS 
(pH 7.6) and stored at 4 °C prior to use. Dextrin-PLA2 conjugate and PLA2 were 
dissolved in PBS (pH 7.6, 100 pg/mL) and equilibrated at 37 °C. DaunoXome® 
solution (1 mL) was added to a polystyrene cuvette and allowed to equilibrate to 37 
°C in the PCS machine (30 min). Dextrin-PLA2 conjugate, PLA2 or Triton X-100 (2 
%) solution (1 mL) was added immediately before initiating the first measurement. 
The stability of the liposomes was followed for 3 h at 37 °C (n = 3). Data is presented 
as mean liposome diameter over 3 h.
7.2.3 Daunorubicin release from DaunoXome® in the presence of PLA2 and 
dextrin-PLA2 conjugate
DaunoXome® (2 mg/mL) was diluted fresh on the day of experiment (1:100) in 
PBS (pH 7.6) and was always stored at 4 °C between experiments on the day of use. 
Then PLA2 or dextrin-PLA2 conjugate (100 pg/mL PLA2 eq.; final experiment 
concentration of 50 pg/mL) (100 pL) was added to each well of a black 96-well 
microfluor plate and the plate was incubated at 37 °C for 30 min prior to starting the 
experiment to preserve enzyme activity. Triton X-100 (2 % v/v; final experiment 
concentration of 1 % v/v) was used to give 100 % drug release value while PBS was 
used as a negative control.
A countdown of 60 min was started upon addition of 100 pL of DaunoXome® 
solution to the first column (6 replicates) and the plate incubated at 37 °C to ensure 
PLA2 activity was preserved. Subsequently, DaunoXome® solution was added at 50, 
40, 30, 20, 10, 5 and 0 min time points. Fluorescence was measured using a
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fluorescent plate reader ((Xex = 485 nm and = 520 nm) and results presented as 
percentage of 100 % drug release by Triton X-100 (corrected for background 
fluorescence of intact DaunoXome®).
7.2.4 Unmasking of dextrin-PLA2 conjugates by incubation with a-amylase
To study the effects of a-amylase on the ability of the dextrin-PLA2 conjugates 
to release daunorubicin from DaunoXome®, dextrin-PLA2 conjugates (0.5 mg/mL) 
were first incubated with a-amylase (2 mg/mL, 200 SU/mL) for 16 h at 37 °C in Tris 
buffer (1.5 mL, pH 8.2). The release of daunorubicin from DaunoXome® was then 
followed as described in section 7.2.3.
7.2.5 Cytotoxicity assessment in MCF-7 cells
For determination of cytotoxicity against MCF-7 treatments were tested by MTT 
assay (section 2.4.7.5) using media supplemented as detailed in below.
To compare the cytotoxicity of daunorubicin and DaunoXome®, complete media 
was supplemented with a range of concentrations of daunorubicin or DaunoXome®.
To study the effect of PLA2 or dextrin-PLA2 conjugate on the cytotoxicity of 
daunorubicin or DaunoXome®, complete media was used. A PLA2 or dextrin-PLA2 
conjugate concentration of 50 p-g/mL PLA2 eq. was used and the daunorubicin or 
DaunoXome® concentration varied.
7.3 Results
7.3.1 Fluorescence properties of free daunorubicin and DaunoXome®- effect of 
Triton X-100
The fluorescence emission spectra of daunorubicin exhibited peaks at 560, 590 
and 620 nm. When the liposomes were incubated with Triton X-100, fluorescence 
was noticeably increased. The fluorescence of DaunoXome® in PBS was ~ 12-13 
times lower than when they were incubated in the presence of Triton X-100 (Figure 
7.3).
Overall, the general shape of the fluorescence emission spectrum of free 
daunorubicin was unchanged by the addition of Triton X-100, up to 1 % v/v and
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Figure 7.3 Fluorescence emission spectra of DaunoXome® before and after release 
of entrapped daunorubicin using Triton X-100. DaunoXome® (20 pg/mL) was 
suspended in PBS or Triton X-100 (1 % v/v) solution.
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there was no obvious fluorescence quenching (Figure 7.4).
7.3.2 Stability testing of DaunoXome®
DaunoXome® showed a classical unimodal distribution of size (Figure 7.5a). 
The mean diameter was 49.8 nm and this remained the same over a 3 h incubation 
period (Figure 7.5b). When Triton X-100 was added the vesicle diameter dropped 
rapidly to < 20 nm within 1 min. In contrast, when DaunoXome® was incubated with 
free PLA2 the liposomes appeared to get larger over time, reaching a maximum 
diameter of ~ 120 nm after 3 h. When liposomes were incubated with the dextrin- 
PLA2 conjugate, the mean diameter remained unchanged over the course of the 3 h 
experiment. However, when the dextrin-PLA2 conjugate was unmasked using a- 
amylase, a slight increase in size of the liposomes was seen (~ 60 nm).
7.3.3 Daunorubicin release from DaunoXome®
When DaunoXome® was incubated with various concentrations of native PLA2 
complete release of daunorubicin was achieved after 1 h incubation with 50 and 100 
pg/mL PLA2 (Figure 7.6). Incubation of DaunoXome® with 25 pg/mL achieved only 
partial drug release, which appeared to plateau at ~ 60 %. As expected, Triton X-100 
caused immediate release of 100 % daunorubicin, while PBS caused < 5 % 
daunorubicin release during the 1 h incubation.
A concentration of 50 pg/mL PLA2 eq. was subsequently selected for assessing 
the drug release from DaunoXome® by the dextrin-PLA2 conjugate. Dextrin 
conjugation reduced daunorubicin release by PLA2 to ~ 20 % of the free PLA2 level 
(Figure 7.7) Addition of a-amylase led to a faster initial rate of drug release, 
however free daunorubicin detected after 1 h was statistically equal to that of masked 
dextrin-PLA2 conjugate.
7.3.4 Cytotoxicity of DaunoXome® in MCF-7 cells
First, the cytotoxiticity of free daunorubicin towards MCF-7 cells was compared 
to that of DaunoXome® (Figure 7.8). The results showed very similar effects on cell 
viability, such that free drug had an IC^ of 125.0 ± 35 pg/mL, and DaunoXome® had 
an IQ q value of 83.6 ± 10.7 pg/mL. These results were not significantly different.
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Figure 7.4 Fluorescence emission spectra of Daunorubicin in varying 
concentrations of Triton X-100. Daunorubicin (20 pig/mL) was suspended in Triton X- 
100 (0-1 % v/v) solution.
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Figure 7.5 M easurements of liposome diameter for stability testing of DaunoXome® 
+/- PLA2 and dextrin-PLA2 conjugate (50 pg/mL PLA2 eq.) over 3 h. Panel (a) shows 
a typical unimodal calibration curve of DaunoXome® in PBS. Panel (b) shows variation 
over time of DaunoXome® diameter. Data represents diameter (nm) ± SD, (n = 6; except 
DaunoXome® n =3). Where error bars are invisible they are within size of data points. * 
indicates significance compared to PBS control, where p<0.05 (ANOVA and Bonferroni 
post hoc test).
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Figure 7.6 Release of daunorubicin from DaunoXome® in the presence of different 
P L A 2 concentrations over 60 min. DaunoXome® in the absence of enzyme is included 
as a control. Triton X-100 (1 % v/v) was used for 100 % drug release. Data represents % 
fluorescence compared to Triton X-100 (1 % v/v) solution ± SEM, (n = 6). Where error 
bars are invisible they are within size of data points.
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Figure 7.7 Release of daunorubicin from DaunoXome® in the presence of PLA2, 
dextrin-PLA2, unmasked dextrin-PLA2 conjugate (50 pg/mL PLA2 eq.) over 60 min.
DaunoXome® in the absence of enzyme is included as a control. Triton X-100 (1 % v/v) 
was used for 100 % drug release. Data represents % fluorescence compared to Triton X- 
100 (1 % v/v) solution ± SEM, (n = 6). Where error bars are invisible they are within 
size of data points. * indicates significance compared to PLA2 control, where p<0.05 
(ANOVA and Bonferroni post hoc test). + indicates significance compared to dextrin- 
PLA2 control, where p<0.05 (ANOVA and Bonferroni post hoc test).
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Next, the cell viability of MCF-7 cells incubated with free daunorubicin (Figure 
7.9) or DaunoXome® (Figure 7.10) +/- PLA2 or dextrin-PLA2 conjugate was 
assessed. The IQo values obtained are summarised in Table 7.2. When free 
daunorubicin was combined with PLA2, it was found to be as cytotoxic as the 
daunorubicin + dextrin-PLA2 conjugate combination (IC50 values = 10.0 pg/mL and 
16.7 pg/mL, respectively). However, when DaunoXome® was combined with the 
dextrin-PLA2 conjugate it was more cytotoxic than DaunoXome® with free PLA2 
(IQo values = 33.6 pg/mL compared to 4.3 pg/mL, respectively).
7.4 Discussion
Since Triton X-100 was to be used to achieve complete drug release, it was first 
considered important to (i) confirm that encapsulation of daunorubicin in 
DaunoXome® quenched its fluorescence, and (ii) that Triton X-100 would not greatly 
alter the spectral shape or fluorescence output of daunorubicin. As expected, 
encapsulation decreased the fluorescence output of daunorubicin. However, addition 
of Triton X-100 to the DaunoXome® solution greatly increased the fluorescence, and 
the intensity and shape of the fluorescence spectrum was the same as that of free 
daunorubicin.
The results here showed that PLA2 caused a surprising increase in liposome 
diameter, which is likely to be accompanied by a striking change in vesicle volume. 
The liposomes in the absence of PLA2, however, were stable for 3 h, suggesting that 
the morphological changes must be attributable to hydrolysis of phospholipids. It 
was expected that lysophospholipids and fatty acid hydrolysis products would desorb 
as monomers, micelles or smaller vesicles (Speijer et al, 1996). It has been reported 
that higher membrane curvature allows tighter packing of the wedge-shaped 
lysophospholipids in the outer monolayer (Haydon and Taylor, 1963). It is, therefore, 
surprising that incubation of DaunoXome® with PLA2, and to a lesser extent, 
unmasked dextrin-PLA2 conjugate, induced growth of liposomes, rather than 
shrinkage. However, this trend has also been reported when liposomes were 
incubated with PLC (Basanez et al, 1997). Initially, vesicle aggregation was seen by 
TEM, followed by PLC-induced vesicle fusion, and ultimately, the formation of
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Figure 7.8 Cell viability of MCF-7 cells incubated with daunorubicin and 
DaunoXome® for 72 h. Graph compares the effect of daunorubicin and DaunoXome® 
concentration on cell viability. Data represents % normal growth of control cells ± SEM, 
(n =18). Where error bars are invisible they are within size of data points. NS defines no 
significant difference (p>0.05), calculated using paired students t-test.
Table 7.2 IC50 values of daunorubicin and DaunoXome® +/- PLA2 and dextrin- 
PLA2 conjugate following cell viability assessment using the MTT assay (72 h).
IC50 (ng/mL)
Drug Drug Drug
+ p l a 2
% change Drug 
+ dextrin-PLA2
% change
Daunorubicin 125.0 ±35 10.0 ±2.5 1 92 16.7 ±3.3 I 87
DaunoXome® 83.6 ±10.7 33.6 ±4.3 I 60 4.3 ± 0.7 I 95
Data represents % normal growth of control cells ± SEM, (n = 18).
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Figure 7.9 Cell viability of MCF-7 cells incubated with daunorubicin +/- PLA2 and 
dextrin-PLA2 conjugate (50 jxg/mL PLA2 eq.) for 72 h. Graph shows effect of 
daunorubicin concentration on cell viability. Data represents % normal growth of control 
cells ± SEM, (n = 6; except daunorubicin n =18). Where error bars are invisible they are 
within size of data points. * indicates significance compared to daunorubicin control, 
where p<0.05 (ANOVA and Bonferroni p os t hoc test). NS defines no significant 
difference (p>0.05) from daunorubicin + PLA2 control (ANOVA and Bonferroni pos t 
hoc test).
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Figure 7.10 Cell viability of MCF-7 cells incubated with DaunoXome® +/- PLA2 and 
dextrin-PLA2 conjugate (50 pg/mL PLA2 eq.) for 72 h. Graph shows effect of 
DaunoXome® concentration on cell viability. Data represents % normal growth of 
control cells ± SEM, (n = 6; except DaunoXome® n =18). Where error bars are invisible 
they are within size of data points. * indicates significance compared to DaunoXome® 
control, where p<0.05 (ANOVA and Bonferroni post hoc test). + indicates significance 
compared to DaunoXome® + PLA2 control, where p<0.05 (ANOVA and Bonferroni post 
hoc test).
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large spherical vesicles.
Studies have also described the action of PLA2 on phospholipid vesicles 
(Lehtonen and Kinnunon, 1995; Wilschut et al, 1979). Here, they hypothesised that 
accumulation of lysophospholipids and fatty acids can alter the permeability of the 
membrane, rendering them more prone to osmolytic swelling. This osmotic 
stretching of the lipid bilayer can further modulate its susceptibility to PLA2 activity. 
It therefore seems likely that osmolytic swelling is the reason behind the liposome 
growth seen with DaunoXome®, and to a lesser extent, unmasked dextrin-PLA2 
conjugate.
Although dextrin-PLA2 conjugate did not have the osmolytic effect of free 
PLA2, it was encouraging to see that unmasked dextrin-PLA2 conjugate showed 
some swelling of liposomes over time, suggesting that activity of PLA2 had been 
reinstated (16 %) following dextrin degradation. This data confirms the previous 
findings that dextrin-PLA2 conjugate is a suitable model for PUMPT, even as a 
component of PELT.
It was shown that PLA2 rapidly released daunorubicin from DaunoXome® 
(Figure 7.7). Although the daunorubicin release triggered by dextrin-PLA2 conjugate 
was not as rapid, it was still reassuring to see a slow increase in free drug over the 1 
h incubation. Since it has been previously shown that PLA2 requires Ca2+ as a 
cofactor for maximal activity, it is likely that this activity would increase in 
physiological conditions, where Ca2+ is present. It would have been interesting here 
to undertake these experiments in PBS +/- Ca2+, but this was not done.
It was apparent that a-amylase treated dextrin-PLA2 conjugate was able to 
release drug from DaunoXome® faster than the masked conjugates. Again, 
physiological conditions, where a-amylase is present, would be expected to trigger 
this unmasking of the dextrin-PLA2 conjugate.
When Carter et al (1998) incubated DaunoXome® with PLC for 1 h, they 
observed maximal release of daunorubicin at 1 nM enzyme. However, the authors 
did not report the drug release from liposomes using their anti-CEA antibody-PLC 
conjugate, so it is difficult to assess whether conjugation of the antibody reduced the
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ability of PLC to burst liposomes. They did, however, report a 16-18 fold increase in 
free daunorubicin in tissue medium following 1 h pre-treatment of HeLa cells with 
anti-CEA antibody-PLC conjugate and 3 h treatment with DaunoXome®, compared 
to free PLC with DaunoXome®. In the experiments reported here, maximal drug 
release after 1 h was achieved using 50 pg/mL (3.16 pM) PLA2. This is much higher 
than the concentration of PLC required for 100 % daunorubicin release. The superior 
ability of PLC to release encapsulated drug was also seen by Satchi-Fainaro and 
Duncan (unpublished), and supports the theory that PLC may be more active towards 
DaunoXome® than PLA2. Since DaunoXome® contains PC and both PLC and PLA2 
are reported to preferentially hydrolyse PC, they should both hydrolyse 
DaunoXome® readily. However, DaunoXome® also contain cholesterol (2 PC: 1 
cholesterol), which has been shown to enhance PLC’s activity (Ruiz-Arguello et al, 
1998). This enhancement could further explain the higher activity seen with PLC 
conjugates.
Drug release studies by Satchi-Fainaro and Duncan (unpublished) used the same 
fluorescence methods as in these experiments. However, they showed complete 
release of daunorubicin from DaunoXome® during incubation with HPMA 
copolymer-PLC conjugate. Perhaps since PLC and PLA2 have different phospholipid 
specificities (PI and PC compared to PC, PE and SM, respectively), the composition 
of liposomes could also influence the rate of drug release from the vesicles.
7.4.1 Cytotoxicity of DaunoXome®
The IC50 values obtained in previous cytotoxicity studies investigating 
DaunoXome® in a number of tumour cell lines are summarised in Table 7.3 for 
comparison with those obtained for MCF-7 in these studies. In all cases, 
DaunoXome® appeared to be more cytotoxic to the cells than free daunorubicin, 
though there was a broad variation between IQo values. In these studies, the 
cytotoxicity of free and liposomal daunorubicin was not significantly different, 
although DaunoXome® had an IQo value of 84 ± 10.7 ng/mL, while free 
daunorubicin had an IC50 value of 125 ± 35 ng/mL.
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Table 7 3 IC50 values reported in the literature of daunorubicin and liposomal daunorubicin towards 
various cell lines.
Cell line Tumour origin
IC5.
Daunorubicin
(ng/mL)
DaunoXome Reference
KSC-10 AIDS-related Kaposi’s sarcoma 78 7.2 (Masood et al, 1996)
Colo-320 DM Human colorectal adenocarcinoma 333 64 (Masood et al, 1996)
P1798 Murine lymphosarcoma 43 12.8 (Masood et al, 1996)
ME180 Human ovarian carcinoma 30 11 (Masood et al, 1996)
K562 Human chronic myeloid leukaemia 5000 10000 (Liu et al, 2002)
CEM Human T-lymphoblastic leukaemia 53 77 (Liu et al, 2002)
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Jorgensen et al (1999a, 1999b) have also studied PLA2-triggered drug release 
from liposomes, although they used PEG-covered liposomes, while the liposomes 
used these studies were uncoated. In fact, the authors reported that sPLA2 was unable 
to hydrolyse DaunoXome® or Doxil® due to their high cholesterol content and 
inability to activate PLA2 by electrostatic attractions. They concluded that PLA2 is 
more active towards PEGylated liposomes and that the enzyme activity increased 
with increasing degree of PEGylation (Jorgensen et al, 1999b). This effect is 
believed to be attributed to an electrostatic interaction between the cationic PLA2 and 
the anionic phosphate head groups of the lipopolymers (reviewed in Jorgensen et al, 
2002). This observation does not correlate with the results obtained in these studies, 
where PLA2 induced 100 % daunorubicin release from non-PEGylated liposomes at 
50 p,g/mL after 1 h.
If, as Davidsen et al (2003) suggested, the phospholipid hydrolysis products, 
lysophospholipids and free fatty acids, enhance drug permeation across the target 
membrane and destabilise the liposomal carriers, then cytotoxicity of DaunoXome® 
with PLA2 or the dextrin-PLA2 conjugate would be expected to be higher than for 
free drug. However, this was not the case in these studies, where there was little 
difference seen between free drug and the liposomal formulation with PLA2 or 
dextrin-PLA2 conjugate. Similarly, Wilschut et al (1979) also noted that, despite 
PLA2 hydrolysis of 60 % of the outer membrane phospholipids, the liposomes still 
maintained barrier properties. The authors suggested that, although 
lysophospholipids and fatty aids are known to have a destabilising effect on 
membranes, this could be controlled so long as the membrane curvature was high 
and hydrolysis products were located only in one half of the bilayer.
Clostridium novyi-NT has previously been used to enhance the release and 
efficacy of liposomal doxorubicin (Cheong et al, 2006). Since C. novyi-NT is 
haemolytic and can selectively infect and kill tumours by exploiting their hypoxic 
environment (Barbe et al, 2006; Ryan et al, 2006), it was hypothesised that these 
properties could be utilised to improve tumour-selective drug release from 
liposomes. In these studies, mice bearing large, established tumours were treated 
with C. novyi-NT and a single dose of Doxil®. This combination led to complete
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tumour regression in 100 % of mice and 65 % of the mice were still alive after 90 
days. Interestingly, when mice were treated with free doxorubicin and C. novyi-NT, 
100 % died within 2 weeks, showing the importance of liposomal encapsulation for 
limiting systemic toxicity. The authors concluded that an enzyme, liposomase, was 
responsible for liposome disruption and associated enhancement of intratumoural 
release of liposomal doxorubicin. However, based the findings of the studies 
reported here, and the work of Carter et al (1998) using PLC, it is possible that the 
enzyme responsible for the lipolytic affects was actually PLC, since this enzyme is 
secreted from C. novyi-NT (Bettegowda et al, 2006). Nevertheless, this supports the 
potential of enzyme-triggered intratumoural liposomal drug release.
7.5 Conclusions
Having shown that a dextrin-PLA2 conjugate has potential as a novel treatment 
of breast cancer, these studies have also proven its applicability as a means of 
triggering drug release from liposomes. It has been shown that the PUMPT concept 
demonstrated previously, is also applicable to PELT, and unmasked dextrin-PLA2 
has higher activity towards liposomes than the masked enzyme. This work showed 
that it possible to trigger the release of liposomally encapsulated drug using PLA2 
and dextrin-PLA2 conjugate, and that these conjugates were able to enhance 
cytotoxicity towards MCF-7 cells. Morphological changes were observed in 
liposomes incubated with PLA2 and unmasked dextrin-PLA2 conjugate, suggestive of 
osmolytic swelling of the vesicles.
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8.1 General comments: Dextrin-PLA2 conjugate as an anticancer agent
Previous clinical studies demonstrated the exciting anticancer potential of PLA2 
(Costa et al, 1998; Cura et al, 2002). The first aim of this thesis was to ascertain 
whether PLA2 conjugates could be synthesised that would display reduced 
cytotoxicity and anticancer activity in cell lines (e.g. breast cancer) with high 
expression of EGFR. From Chapter 3 to 6, the research has evolved from synthesis 
and characterisation of dextrin-PLA2 to mechanistic studies.
8.1.1 Recent developments in the field: polymer-protein conjugates and other 
breast cancer treatments
It is important to consider how the field of nanomedicine and cancer therapy has 
evolved since the commencement of these studies in 2004. Although recent statistics 
show that two thirds of women newly diagnosed with breast cancer are likely to 
survive for over 20 years (Cancer Research UK), the incidence and mortality rates of 
advanced metastatic breast cancer remain high, and the disease is still a major health 
priority. Consequently, the National Institute for Health and Clinical Excellence 
(NICE) plans to publish clinical guidelines for early and advanced breast cancer 
treatment in January 2009, giving evidence-based recommendations for good 
practice.
Breast cancer treatment has advanced dramatically since the introduction of 
radical mastectomy in 1882 (Figure 8.1). Chemotherapy has evolved from nitrogen 
mustards, discovered in the 1940s during World War Two (reviewed in Benderly, 
2002), to tamoxifen, an endocrine agent initially developed as a contraceptive 
(reviewed in Jordan, 2008). More recently, treatments with improved specificity 
have become the main focus of research. Cancer therapy using proteins and peptides 
such as L-lysine-a-oxidase (Kusakabe et al, 1980) and phosphoglycerate kinase (Lay 
et al, 2000), and the development of a number of molecular targeted compounds 
such as trastuzumab and bevacizumab, have demonstrated the ongoing research in 
the field of novel breast cancer therapies. Enhanced tumour specificity has also been 
demonstrated by new polymer-protein conjugates entering clinical trials for cancer 
(reviewed in Pasut et al, 2008). For example, PEG-methioninase acts to deplete
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Figure 8.1 Milestones in the areas relating to these studies.
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methionine stores in tumour cells, which are often auxotrophic for this protein. 
Conjugation of methioninase to PEG (3-7 molecules of PEG per protein) increased 
its half-life 36-fold and reduced anti-methioninase antibodies 100-1000-fold after 
repeated administration, compared to those elicited by the native enzyme (Yang et al, 
2004). All of these conjugates, however, contain PEG, a non-biodegradable polymer, 
despite the well-known limitations associated with it (section 1.2.1). PEGylation 
chemistry is frequently being reviewed and improved (Brocchini et al, 2007; Fontana 
et al, 2007), and therefore remains a key area in the developing field of 
nanomedicine.
In parallel, a study of PubMed citations since 1975 in the field of phospholipase 
in cancer revealed rising interest in this area (Figure 8.2). However, after a peak 
around 1995, publications appear to have decreased- possibly owing to toxicity 
issues and drug delivery problems (Cura et al, 2002; Freitas and Frezard, 1997). This 
trend highlights once more the importance of developing novel methods for delivery 
of therapeutic proteins for cancer treatment.
8.1.2 Current status o f crotoxin
Given that the rationale for dextrin-PLA2 conjugate stemmed, in part, from the 
PLA2, crotoxin (reviewed in section 1.1) (Cura et al, 2002), it is important to review 
the most recent developments in this product.
Consideration has been made to using drug delivery systems to reduce 
crotoxin’s toxicity. As mentioned previously (section 1.3), PLA2 has been conjugated 
to PEG (Bianco et al, 2002). Liposomal formulations encapsulating crotoxin have 
also been described (Freitas and Frezard, 1997; Magalhaes et al, 2001). Here, Freitas 
and Frezard (1997) encapsulated crotoxin into liposomes made from SM and 
cholesterol. No toxicity was seen when mice were administered (IV) liposomal 
crotoxin at a dose of up to 91 times as high as its LD^. Magalhaes et al (2001) 
investigated the stability of liposomes having different membrane compositions 
(non-phospholipid amphiphile, polyoxyethylene 2-cetyI ether, dicetyl phosphate and 
cholesterol). All liposome formulations retained >75 % encapsulated crotoxin after 1
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Figure 8.2 Results published in Pubmed database during the period 1975-2007.
Panels a-c represent the number of publications cited in PubMed since 1975, where the 
search terms were: a) phospholipase, b) PLA2, and c) PLA2 + cancer.
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week incubation at 37 °C. As expected, toxicity in mice was dependant on the 
membrane composition, such that liposomes composed of PLA2-resistant 
phospholipids were less toxic. These studies demonstrate the interest in utilising 
novel drug delivery techniques for delivery of PLA2.
Major advances with crotoxin have also been made by Celtic Biotech, who are 
developing it for the treatment of cancer, pain and viral infections (e.g. HIV) (Celtic 
Biotech Ltd., 2005). Recent publications have described mechanistic studies of the 
cytotoxic effects of crotoxin in human breast cancer cells (Yan et al, 2006; Yan et al, 
2007), but interest is also growing in its analgesic properties (Zhang et al, 2006; Zhu 
et al, 2007). The pain relieving properties of crotoxin were discovered when it was 
noticed that patients receiving crotoxin required less analgesic medications (Giorgi et 
al, 1993). Zhang et al (2006) have since discovered that the analgesic effects are 
mediated through an action on the central nervous system, but do not involve the 
muscarinic and opioid receptors, which are responsible for the analgesic effects of 
neostigmine and morphine, respectively. More recently, Zhu et al (2007) showed that 
crotoxtin mediates its analgesic effects, at least in part, by the central serotonergic 
system, like amitriptyline.
Since PLA2 from other snake and bee venoms has also shown analgesic activity 
(Chen and Robinson, 1990; Pu et al, 1995), it is possible that PLA2 from bee venom 
could also have this effect, adding a further therapeutic opportunity to a dextrin- 
PLA2 conjugate. However, while studies have shown that bee venom does have 
analgesic properties, it is the water-soluble fraction (<10,000 g/mol) that is 
responsible for this effect (Kwon et al, 2005).
8.1.3 Critical evaluation o f the present study
The choice of dextrin as polymeric carrier for PLA2 was appropriate for the 
reasons outlined in sections 1.3.1 and 4.1.2. Moreover, as outlined by Duncan et al 
(2008), an ideal conjugate for PUMPT should be capable of fully masking the 
enzyme’s activity after polymer conjugation, but be capable of reinstating maximal 
activity after unmasking by polymer degradation. While the range of masked- 
unmasked activity described in the literature for dextrin conjugates is varied (see
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Table 4.4), the dextrin-PLA2 conjugates synthesised here demonstrated 80 % greater 
activity of the conjugate after unmasking by a-amylase. Furthermore, while the 
development of novel polymer-protein conjugates containing non-biodegradable 
polymers (e.g. PEG) is limited by their molecular weight and slow clearance from 
the body after longer-term clinical use, dextrin’s biodegradability means that 
conjugates above the renal threshold (40,000 g/mol) can still be of clinical value.
Selection of bee venom PLA2 was made after comparison with bovine PLA2, 
since these were the only two commercially and readily available PLA2s. However, 
with the growing success of crotoxin, it would be interesting to synthesise and 
characterise a dextrin-crotoxin conjugate for comparison to the bee venom PLA2 
conjugates.
To fully assess the clinical efficacy of dextrin-PLA2 conjugates as anti-cancer 
agents the most important experiments relate to in vivo assessment of 
pharmacokinetics and anti-tumour activity. Since these kinds of experiments have 
been used to test the PDEPT combinations in mice bearing subcutaneous B16F10 
melanoma (Satchi et al, 2001; Satchi-Fainaro et al, 2003), as well as a number of 
other anti-cancer polymer conjugates (Ulbrich et al, 2003), these experiments would 
be relatively easy to perform. Although in vitro model systems are useful for 
evaluating cytotoxicity, it is important to note that this technique represents a gross 
simplification of the in vivo scenario. Data obtained from in vitro studies can only 
give a possible indication of what could happen in vivo, since it lacks the complexity 
of the multicomponent physiological processes of a living model. Nevertheless, in 
vitro studies were still considered to be essential for investigating the potential of 
dextrin-PLA2 conjugates as novel anti-cancer agents.
8.1.4 Options for future development o f dextrin-PLA2 conjugates
The results presented in this thesis underline the possibilities of a polymer- 
phospholipase conjugate. However, some questions remain unanswered. Therefore, 
first, the most important outstanding experiments in developing dextrin-PLA2 as a 
novel anti-cancer agent are described, and then a broader perspective of future 
research areas that could be explored is given.
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In future studies, it would be interesting to study the physicochemical 
characteristics of the dextrin-PLA2 conjugates. The size and shape of the conjugates, 
with respect to their composition, protein loading and following unmasking, could be 
investigated using small-angle neutron scattering (SANS). This technique has 
previously been used to study the size, conformation and solution behaviour of 
unconjugated polymers (poly(amidoamine) (Khayat et al, 2006)), micelle 
components (DSPE-PEG(2000)-CCK8 peptide (Tesauro et al, 2007)) and polymer- 
drug conjugates (HPMA copolymer-doxorubicin (Paul et al, 2007)). SANS would be 
a valuable tool to determine conformation-activity relationships for dextrin-PLA2 
conjugates under physiologically relevant conditions.
Circular dichroism (CD) spectroscopy would also be a valuable tool for studying 
the effect of dextrin-conjugation on the folding of PLA2 . This technique uses 
differential absorption of left- and right-handed polarised light to determine the 
structure of macromolecules. PEG-GCSF conjugate has been analysed using CD 
spectroscopy, which showed that the secondary structure of GCSF was not altered by 
site-specific conjugation to PEG (Paul et al, 2007). CD spectroscopy would be useful 
to assess the conformational changes of PLA2 when conjugated to dextrin, but also 
after unmasking of the conjugate by incubation with a-amylase.
Considering the results obtained in these studies from a broader point of view, as 
well as the recent developments of polymer conjugates described in the literature, 
there are a number of potential avenues for extending these studies. Figure 8.3 
(panels a-b) shows a schematic representation of some future possibilities for 
dextrin-PLA2 conjugates as novel anticancer agents. First, since dextrin-PLA2 and 
doxorubicin showed enhanced cytotoxicity in MCF-7 cells (Figure 5.10) and recent 
studies have shown enhanced activity of HPMA copolymer-aminoglutethimide 
(AGM)-doxorubicin, compared to HPMA copolymer-doxorubicin with HPMA 
copolymer-AGM (Greco et al, 2005), it would be interesting to investigate dextrin- 
PLA2-doxorubicin conjugates.
Secondly, a targeting agent, such as EGF, could be added to the dextrin-PLA2 
conjugate to enhance tumour specificity, since EGFR is commonly overexpressed on 
cancer cells. However, while a number of tumour-targeting methods have been
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Polymer-PLA2-targeting groupPolymer-PLA2-drug
PELT: polymer-PLA2, liposome 
encapsulating two drugs
PELT: polymer-PLA2-enzyme, 
liposome encapsulated drug bearing 
enzymatically degradable linker
f)
PELT: polymer-PLA2, PEGylated 
liposome encapsulated drug
PELT: polymer-PLA2-targeting 
group, targeted liposome 
encausulating drug
Figure 8.3 Schematic representation of the future possibilities for the use of dextrin- 
PLA2 conjugates as novel anticancer treatments. Where P = PLA2, D = drug (e.g. 
doxorubicin), T = targeting residue (e.g. EGF), E = enzyme (e.g. P-lactamase), and TR = 
target receptor (e.g. EGFR).
Biodegradable 
linker (e.g. 
cephalosporin)
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described (e.g. antibodies, peptides, and folate) (reviewed in Duncan, 2005), only 
PK2 (HPMA copolymer-doxorubicin-galactosamine) has been evaluated clinically.
8.2 General comments: Dextrin-PLA2 conjugate as a trigger for PELT
Previous studies have demonstrated the possibility of using HPMA copolymer- 
Gly-Gly-PLC as a trigger for drug release from liposomes. Therefore, Chapter 7 of 
this thesis aimed to provide proof of concept data for the use of dextrin-PLA2 
conjugate as a trigger for PELT.
8.2.1 Current status o f LiPlasome development
Given that the rationale for using dextrin-PLA2 conjugate as a trigger for PELT 
stemmed, in part, from LiPlasome (reviewed in section 7.1.1) (Jorgensen et al, 
2002), the recent developments in this product are interesting to review.
Since the initial studies provided proof of principle for LiPlasome, ongoing 
research has investigated further the expression and activity of sPLA2 in tumour 
tissue (Tribler et al, 2007). Further studies have explored the molecular basis of 
phospholipid hydrolysis (Linderoth et al, 2008; Peters et al, 2007) and optimised 
phospholipid functionalisation and structure for PLA2 degradation (Linderoth et al, 
2007). At the end of 2007, LiPlasome Pharma reported successful completion of its 
preclinical studies, which demonstrated proof of principle of tumour-activation and 
integrated prodrug and drug delivery platform (LiPlasome Pharma A/S, 2008). 
Therefore, Phase I studies of LiPlasome encapsulating doxorubicin, cisplatin 
(LiPlaCis) and methotrexate (LiPloxa), as well as novel prodrug lipids that are 
specifically converted to active anticancer lipids by tumoural PLA2, are due to 
commence early in 2008.
8.2.2 Critical evaluation o f the present study
The data presented here were only preliminary to demonstrate proof of concept, 
and further investigations are necessary for optimisation of the concept.
Initial proof of concept studies for the PELT concept used HPMA copolymer-
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Gly-Gly-PLC (Satchi-Fainaro and Duncan, unpublished). These non-biodegradable 
conjugates contained ~ 60 wt. % PLC, compared to 5-9 wt. % PLA2 in dextrin-PLA2 
conjugates. These differences make it difficult to compare the efficiency of HPMA 
copolymer-PLC conjugate and dextrin-PLA2 conjugate to trigger drug release from 
liposomes. The value of using a biodegradable polymer has already been reviewed in 
sections 1.3.1 and 4.1.2. It is unknown whether the biodegradability of dextrin 
improves the ability of PLA2 to trigger drug release from liposomes, so it would be 
interesting to compare dextrin-PLA2 conjugates with HPMA copolymer- or PEG- 
PLA2 conjugates. The benefits of these polymers have been outlined in sections 1.2.1 
and 1.3.1.
Although these studies used the commercially available formulation, 
DaunoXome®, improved activity and selectivity could be achieved by designing the 
liposome specifically for the PELT concept. Literature shows that PLA2 
preferentially hydrolyses PC, SM and PE (Diez et al, 1994; Monteggia et al, 2000), 
and has a preference for curved, tightly packed membranes (Best et al, 2002). The 
hydrolytic activity of the dextrin-PLA2 conjugate could be assessed using 
phospholipid monolayers in Langmuir troughs. These systems allow the preparation 
of stable model membranes in different molecular environments while 
simultaneously assessing their influence on the rate of phospholipid hydrolysis. 
Grainger et al (1990) have used this method to study phospholipid hydrolysis by 
PLA2. By studying the activity of dextrin-PLA2 towards a variety of phospholipid 
monolayers, it would be possible to select the best composition for the drug-loaded 
liposomes.
These studies also reported morphological changes in DaunoXome® during 
incubation with PLA2. TEM would be a valuable tool to further investigate the 
effects of dextrin-PLA2 conjugate to the liposomal surface. This technique would 
also elucidate the mechanism of action of dextrin-PLA2.
8.2.3 Options for future development o f PELT
Since PELT is part of a whole new field of two-step processes and combination 
therapies using polymers as carriers Figure 8.3 (panels c-f) also shows several 
polymer combinations based on this model for development in the future.
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Briefly, panel (c) represents a liposome encapsulating two different drugs to act 
synergistically on cancer cells. Panel (d) describes a drug-loaded liposome bearing 
an anti-cancer drug conjugated to the surface via an enzymatically degradable linker. 
This model uses a polymer-PLA2-enzyme conjugate to simultaneously trigger drug 
liberation from inside liposome and release the drug bound to the liposome surface 
after enzymatic cleavage of the degradable linker. Panel (e) represents the PELT 
concept using PEGylated liposomes, since some literature has suggested that PLA2 is 
more active on these surfaces (reviewed in section 7.4.3). Finally, panel (f) 
demonstrates polymer-PLA2 bearing a targeting residue which co-localises with 
drug-loaded liposomes labelled with the corresponding target receptor. This concept 
has the potential to increase specificity, though relies heavily on the efficacy of the 
EPR effect.
8.3 Contribution of this thesis to nanotechnological medicine
The work undertaken in this thesis has demonstrated two ways in which dextrin- 
PLA2 conjugates can be used as anticancer agents.
These studies have shown the ability to mask and unmask enzyme activity by 
triggered degradation of dextrin (Ferguson et al, 2006a; Ferguson et al, 2006b). The 
underlying mechanism of dextrin-PLA2’s anticancer activity with respect to EGFR 
has been demonstrated (Ferguson and Duncan, 2008; Ferguson et al, 2007) and its 
intracellular fate followed (Richardson et al, 2008). Results from the PELT studies 
have proven that dextrin-PLA2 conjugates are suitable triggers for drug release from 
liposomes (Ferguson and Duncan, 2008).
In conclusion, bioresponsive conjugates of PLA2 have shown exciting anticancer 
activity. Not only has its inherent anti cancer activity been demonstrated, but also 
dextrin-PLA2’s ability to trigger drug release from liposomes in the PELT model 
offers an additional opportunity for research.
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